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Protein arginine methylation is a posttranslational modification catalyzed by the 
family of proteins known as the protein arginine methyltransferases (PRMTs). Thousands 
of methylated arginines have been found in mammalian cells. Many targets of arginine 
regulation are involved in important cellular processes like transcription, RNA transport 
and processing, translation, cellular signaling, and DNA repair. Since PRMT dysregulation 
has been linked to a variety of disease states, understanding how the activity of the PRMTs 
is regulated is of paramount importance. PRMT1 is the predominant PRMT, responsible 
for about 85% of all arginine methylation in cells, but very little is known about how 
PRMT1 is regulated.  Although a few methods to regulate PRMT1 activity have been 
reported, the details of interaction and regulatory mechanisms remain largely unknown.  
To better understand how PRMT1 is able to bind its substrates and how PRMT1 
activity is regulated, we followed a mechanistic and structural biology approach to better 
iv 
understand how PRMT1 interacts with its substrates and protein regulators. In this study 
the regulation of Hmt1 methyltransferase activity by the Air1 and Air2 proteins was 
analyzed and only one was determined to affect Hmt1 activity. The posttranslational 
phosphorylation of Hmt1 had also been reported to affect Hmt1 activity in vivo and our 
preliminary studies suggest that additional factors may help influence the regulatory effect 
of phosphorylation. Lastly, we report a new method of PRMT regulation through the 
reversible oxidation of key PRMT1 cysteine residues. We are also able to show that this 
regulation occurs in cells and affects several PRMT isoforms.  
 




Protein Arginine Methyltransferase 1 Interactions and Regulation 
Yalemi Morales 
Protein arginine methyltransferases, or PRMTs, are enzymes that can add one or 
two methyl groups to certain arginine residues in target proteins. The modification of the 
target protein, or substrate, changes the substrate just enough to affect its function. This 
typically occurs by allowing the target protein to interact with new proteins or molecules, 
or by preventing interactions that occur with the unmodified target protein. In mammalian 
cells, there are thousands of arginines that can be methylated and many of those are found 
in proteins involved in critical cellular processes like RNA transport and processing, 
transcription, and translation. Therefore, it is important to understand how the PRMTs 
select which arginine substrates to methylate, and how this activity is regulated. 
The work presented in this dissertation includes several lines of investigation that 
together aimed to describe how PRMT1, the predominant PRMT in mammalian cells, 
interacts with substrates and can be regulated. The visualization of PRMT1 interactions 
with target proteins was sought out through protein crystallography, but could not be 
achieved within the scope of this study. The regulation of the yeast PRMT1 (Hmt1) protein 
by the Air1 and Air2 proteins was analyzed and only one was determined to affect the rate 
of methyl groups transferred. The modification of the yeast PRMT1 through 
phosphorylation was also investigated and preliminary results suggest that additional 
factors are likely involved in the regulatory effect of phosphorylation. Lastly, a new method 
of PRMT1 regulation through reversible oxidation was reported and was confirmed to be 
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 Posttranslational modification of proteins allows organisms to expand upon the 
limits of the proteome by influencing protein localization, protein-protein or protein-
nucleic acid interactions, and protein stability. Protein arginine methylation is a type of 
posttranslational modification that has been implicated in a many fundamental biological 
pathways such as RNA transport and processing, DNA repair, transcriptional regulation, 
and signal transduction (reviewed in (1-4)).  The family of enzymes responsible for the 
catalysis of protein arginine methylation is the protein arginine methyltransferases 
(PRMTs). Due to the significant role PRMTs play in many cellular pathways, 
dysregulation of PRMT expression and/or activity has been linked to several human 
diseases including cardiovascular disease (5-7), stroke (8,9), asthma (10), viral 
pathogenesis (11-13), multiple sclerosis (14), and carcinogenesis (15-17).  
 Unlike other posttranslational modifications such as phosphorylation and even 
lysine methylation which can be reversed by phosphatases or lysine demethylases, no 
enzyme has yet been found to reverse the posttranslational methylation of arginine 
residues. The seemingly irreversible nature of this modification underscores the 
importance of proper regulation over the activity of the protein arginine methyltransferases. 
Yet, although much progress has been made in understanding the pathways in which the 
PRMTs are involved, surprisingly little is known about how the PRMTs select and interact 
with substrates, or how their activity is regulated.  
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 The goal of this dissertation is to understand how PRMT1, the predominant protein 
arginine methyltransferase, functions by characterizing the molecular details of substrate 
interactions, and to determine how the methyltransferase activity of PRMT1 is regulated.  
 In Chapter 3, I used structural biology techniques in an attempt to observe the 
interactions of PRMT1 with a substrate. A previously solved structure of PRMT1 was co-
crystallized with a substrate containing three methylatable arginines (18). This structure 
contained clear density only for the active site arginine, while only broken tracks of 
backbone density were observed for the other residues in the substrate peptide. The poor 
resolution observed for the peptide in this structure was hypothesized to be due to crystal 
heterogeneity resulting from the three possible methylatable arginines each binding the 
active site on different PRMT1 molecules. In order to limit the binding modes, only peptide 
substrates containing a single arginine were used in my crystallization attempts. 
Furthermore, since the initial structure was able to depict the residues coordinating the 
binding of the substrate arginine, a peptide substrate containing a monomethylated arginine 
was chosen for our attempts in order to decipher how the MMA substrate is coordinated in 
the PRMT1 active site for the second catalytic step. Unfortunately, we have been unable 
to solve a structure with clear electron density for any bound substrate. To overcome this 
problem, a new strategy of co-crystallizing PRMT1 with a protein substrate was put in 
place . The yeast PRMT1, Hmt1, and a truncated Npl3 protein substrate were chosen for 
this approach. The structure of Hmt1 had been previously solved by X-ray crystallography 
(19) and Npl3 is the best characterized Hmt1 substrate. The Npl3 protein was truncated to 
remove a flexible N-terminal region that is not required for Hmt1 interaction in order to 
improve the favorability of crystallization. Crystals have been obtained containing both 
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Hmt1 and the substrate Npl3 construct; however, these crystals have failed to provide X-
ray diffraction patterns of sufficient quality to solve a structure. Further optimization of 
crystallization conditions is recommended in order to improve diffraction resolution and 
produce a structure capable of revealing the molecular details of how PRMT1 interacts 
with substrate proteins.  
 Beginning in Chapter 4, my work shifts towards characterizing the regulation of 
PRMT1. In this chapter, I worked in collaboration with the Johnson lab to investigate the 
previously reported regulation of Hmt1 by the Air1 and Air2 proteins (20). The Air1/2 
proteins are part of the TRAMP (Trf4/Mtr4/Air1 or Trf5/Mtr4/Air2) nuclear RNA 
surveillance complex studied in the Johnson lab. However, the Air (arginine 
methyltransferase-interacting RING finger) proteins were both initially identified and 
named after their ability to interact with Hmt1 substrates in a yeast two hybrid study. In 
this initial report, Air1 was shown to inhibit Hmt1 methylation both in vivo and in vitro. A 
large degree of sequence similarity between Air1 and Air2, in combination with a knockout 
screen indicating the two might be functionally redundant led to the conclusion that both 
may be Hmt1 regulators. Investigations using C-terminally truncated constructs of both 
Air1 and Air2 quickly showed that while Air1 is indeed an Hmt1 inhibitor, Air2 was unable 
to inhibit Hmt1 methylation of any of the substrates tested. To further probe the Hmt1 
inhibition by Air1, several constructs of Air1 were created to map both the regions of 
interaction with Hmt1, as well as the minimal region required for inhibition. We were able 
to determine that a ~60 amino acid region of Air1 containing the fourth and fifth zinc 
knuckle motifs of the protein are enough to inhibit methyltransferase activity. Further work 
should be done to finalize the minimal Air1 construct required for Hmt1 inhibition and 
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characterize the method of inhibition. Additionally, since discovering that Air2 does not 
seem to inhibit Hmt1, but is still able to form a stable complex, we have attempted to solve 
the crystal structure of the complex and provide the first insights on how the PRMTs 
interact with other proteins. Crystals containing both proteins have been optimized and 
have produced diffraction data suitable to ~3.2 Å. This structure has not yet been solved, 
but molecular replacement using a previously solved Hmt1 structure has produced initial 
electron density maps in which the structure of the complex will be built. Similar efforts to 
crystallize and solve the structure of an Air1/Hmt1 complex are recommended.  
 In Chapter 5, I attempt to validate results indicating that Hmt1 activity and 
oligomeric state could be regulated by posttranslational phosphorylation on the N-terminus 
of Hmt1 (21). This report indicated that in vivo phosphorylation of Hmt1 at Ser9 results in 
an increase in the methylation of Npl3. However, because in vitro studies were not 
performed, it is unclear if phosphorylation affected the intrinsic activity of Hmt1 or if this 
PTM resulted in recruitment of another factor that modulated the methyltransferase 
activity. Since this report elegantly demonstrated that the phosphorylation effects could be 
mimicked using a glutamate substitution at position 9, I set out to characterize the 
mechanism by which phosphorylation affects Hmt1 activity. Hmt1 S9E (phosphorylation 
mimic) and S9A (unable to be phosphorylated) constructs were expressed, purified, and 
their activities measured in order to corroborate the in vivo published results. However, 
despite the use of several different solubility tags and a variety of substrates, it was 
impossible to validate the previous results with our in vitro methylation assay. This 
discrepancy hints at the possibility that the published results were a result of recruitment 
of an unknown factor, rather than solely due to the phosphorylation event. 
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 In Chapter 6, I followed the discovery of Dr. Shanying Gui and Damon Nitzel, 
previous students in the Hevel lab, who had observed that PRMT1 activity changes as a 
function of the redox state and that this effect is cysteine-dependent. I was able to further 
characterize that PRMT1 activity decreases in a hydrogen peroxide (H2O2) concentration-
dependent manner and is reversible within physiologically relevant levels of H2O2. 
Additionally, I was able to identify the cysteine residues necessary for this redox effect to 
occur and determine that the two critical cysteines are oxidized to sulfenic acid. 
Furthermore, I then looked at cysteine conservation among the PRMT isoforms and found 
that PRMT3, PRMT6, and PRMT7 are also under redox control. This work not only reveals 
the details of a novel PRMT1 regulatory mechanism, but also indicates that redox 
regulation is a conserved feature of several members of the PRMT family.  
 Chapter 7 includes preliminary results from several ongoing projects and discusses 
possible future directions. Follow up work on the redox regulation of PRMT1 is discussed. 
Ex-vivo assays show that oxidation of PRMT1 in cells results in increased sulfenic acid 
formation and diminished PRMT1 activity, indicating that the redox regulation described 
in vitro is likely also occurring in vivo. In addition, a detailed comparison between PRMT1 
and PRMT6 suggests that while redox regulation is conserved, the mechanism through 
which oxidation impairs enzymatic activity may be different among the two isoforms. 
Constructs created to validate this hypothesis will be discussed, as well as avenues for 
future investigation. Lastly, preliminary data seems to indicate that the redox state of 
PRMT1 may influence product specificity. A summary of the initial data and suggestions 
for future work will be discussed.    
6 
 In summary, this dissertation provides new insights into regulatory mechanisms 
poised to control PRMT methyltransferase activity in cells. The investigation/validation of 
previously reported regulators along with the discovery of a new PRMT regulatory 
mechanism provide a strong foundation for future avenues of investigation.  
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Cellular methylation requires the presence of a methyl group donor such as S-
adenosyl-L-methionine (AdoMet/SAM) (Figure 2-1-A) or tetrahydrofolate (THF) and a 
methyl acceptor. AdoMet is the second most commonly used enzyme cofactor after 
adenosine triphosphate (ATP) (1). Methionine and ATP are used by methionine 
adenosyltransferase to synthesize AdoMet, which can be used by AdoMet-dependent 
methyltransferases (MTases) as a methyl group donor, leaving the product S-adenosyl-L-
homocysteine (AdoHcy/SAH). AdoMet is the preferred methyl group donor in biological 
systems likely due to the favorable energetics of the methyl transfer reaction which releases 
-17 kcal/mol, more than twice the energy released during ATP hydrolysis (1). AdoMet-
dependent methyltransferases are remarkably diverse enzymes, utilizing any of five 
different structural folds to bind AdoMet and catalyze the transfer of a methyl group to 
substrates ranging from small molecules, to nucleic acids, to proteins (2). At the atomic 
level, the targets for MTases can be carbon, oxygen, nitrogen, sulfur, or even halides (1,3). 
The diversity in methyl group acceptors means that MTases have evolved a wide variety 
of mechanisms to activate the catalytic nucleophile. However, despite the many differences 
among the AdoMet-dependent MTases, all are thought to proceed in an SN2-like 
mechanism and transfer the methyl group from AdoMet to the substrate with an inversion 
of symmetry (Figure 2-1-B) (3).  
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FIGURE 2-1. Structure of AdoMet and SN2 mechanism of AdoMet-dependent 
methyltransferases. (A) Structure of S-adenosyl-L-methionine (AdoMet) which includes 
the adenosine moiety and the methionine moiety. (B) In this general SN2 reaction 
mechanism, a general base (:B) deprotonates the target atom (X=N, O, S, or C) prior, 
during, or after methyl transfer. A transition state forms from the nucleophilic attack of the 
target atom onto the methyl group carbon of AdoMet, resulting in the methyl group transfer 
from AdoMet to the target atom.  
 
Protein Arginine Methylation 
Protein arginine methylation is a type of posttranslational modification (PTM) 
which enables organisms to expand the limits of their genomes and enlarge the 
functionality of proteins. The AdoMet-dependent methylation of arginine residues does not 
alter the positive charge of the amino acid, but it does increase the hydrophobicity and 
steric bulk, thereby affecting how modified proteins interact with other proteins or nucleic 
acids. Arginine methylated proteins are involved in a wide array of cellular processes, 
11 
including transcription (4), translation (5), RNA transport and metabolism (6,7), and DNA 
damage repair (8).  
 This widespread PTM is catalyzed by nine known mammalian protein arginine 
methyltransferases (PRMTs), as well as homologs present in yeast, protozoa, plants, 
nematodes, and fish, but not in bacteria (2).  The PRMTs are classified based on their 
product formation as either type I, type II, type III, or type IV enzymes (Figure 2-2). Types 
I, II, and III PRMTs methylate the terminal () guanidino nitrogen atoms of arginine 
residues in protein substrates, resulting in a modified monomethylarginine (MMA) residue. 
While PRMT7, the only known type III PRMT can only make MMA, type I and II enzymes 
are capable of catalyzing the addition of a second methyl group. Type I PRMTs (PRMT1, 
2, 3, 4, 6, 8) can add a second methyl group to the same nitrogen atom, making asymmetric 
dimethylarginine (ADMA). Type II PRMTs (PRMT5, 9) can also add a second methyl 
group to the unmodified terminal nitrogen atom, making symmetric dimethylarginine 
(SDMA). Type IV PRMTs, which have thus far been identified only in yeast, catalyze the 
monomethylation of the internal () guanidino nitrogen atom (Figure 2-2). Correct product 
formation is critical given that different products can have different biological 
consequences (9,10). Yet, very little is currently known regarding how product specificity 
is regulated for the PRMTs.    
 
Protein Arginine Methyltransferase Family 
Each of the nine members of the mammalian PRMT family contain four conserved 
amino acid sequence motifs (I, post-I, II, and III) characteristic of the class I seven β-strand  
12 
 
FIGURE 2-2. Reactions catalyzed by the PRMTs. The four types of PRMTs are 
classified based on the products formed. All catalyze the transfer of a methyl group from 
AdoMet to a substrate arginine residue making -MMA, MMA, ADMA, or SDMA.  
 
AdoMet-dependent methyltransferases (2,11), as well as a highly conserved THW loop 
(Figure 2-3). Although the PRMTs vary widely in length, a 310 amino acid conserved core 
(gray in Figure 2-3) is present in all isoforms. Most isoforms also have extended N-terminal 
additions (blue and green in Figure 2-3) that are unique to each isoforms and may be 
responsible for altering substrate recognition (12), dictating protein-protein interactions 
(13), specifying cellular localization (14), or even regulating methyltransferase activity 
(15), thus facilitating the unique function of each PRMT isoform.  
PRMT1 is the predominant type I PRMT in mammalian cells, catalyzing 85% of 
cellular protein arginine methylation (16). PRMT1 has been found to localize in both the 
cytoplasm and the nucleus and is ubiquitously expressed in all tissues (17,18). Seven 
PRMT1 splice variants have been found in humans that display distinct activity, substrate 
specificity, and subcellular localization (12). PRMT2 is also a ubiquitously expressed type 
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FIGURE 2-3. Schematic comparison of the nine mammalian PRMT isoforms. The 
catalytic core is colored in gray with each conserved motif (I, post-I, II, III, and THW loop) 
highlighted in dark blue, or light blue if not strictly conserved. Various N-terminal modules 
are also shown in green. PRMT2 has an SH3 domain, PRMT3 has a zinc finger domain 
(ZnF), PRMT5 has a TIM barrel motif, PRMT8 has a myristoylation site (Myr), and 
PRMT9 has a tetratricopeptide repeat (Tri-TPR).  
 
I PRMT (19). PRMT2 contains an N-terminal SH3 domain which is essential for 
interactions with proline-rich proteins (20). PRMT2 functions as a coactivator for the 
estrogen receptor (21,22) and has been shown to directly interact with and stimulate the 
activity of PRMT1 in cells (23). PRMT3 is an exclusively cytoplasmic type I PRMT 
isoform which contains an N-terminal zinc finger domain shown to play a role in PRMT3 
substrate recognition (24,25).  PRMT3 is found mostly in association with ribosomes, 
where it methylates the S2 protein of the small ribosomal subunit (13,26). The type I 
PRMT4 (also commonly called CARM1) is a transcriptional coactivator that can function 
synergistically with PRMT1 and histone acetyltransferases (27). PRMT4 has also been 
found to methylate mRNA stabilizing proteins and splicing factors, indicative of a role in  
coupling transcription and RNA processing (28). PRMT5 is the predominant type II PRMT 
and can be found as part of several different protein complexes (29). In the cytoplasm, 
PRMT5 is part of the “methylosome” complex where its activity is implicated in snRNP 
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biogenesis through the methylation of Sm proteins (30). In the nucleus, PRMT5 can 
complex with chromatin remodeling proteins which are able to enhance PRMT5 activity 
towards selected targets (31). PRMT6 is a primarily nuclear type I PRMT (32). PRMT6 
has been implicated in viral immunity since methylation by PRMT6 negatively regulates 
the activity of the HIV transactivator protein Tat, thereby acting as a restriction factor for 
viral replication (33).  PRMT7 is the only known type III PRMT, capable of catalyzing 
only MMA formation (34). PRMT7 contains a duplicated core catalytic domain, both of 
which are required for activity (35). PRMT8 is a type I PRMT found primarily in the human 
brain (14). It is uniquely found to be localized at the plasma membrane through N-terminal 
myristoylation (14). PRMT8 has been found to associate with PRMT1 and to self-regulate 
through automethylation on its N-terminal region (36). PRMT9 has been recently 
determined to have type II PRMT activity (37). PRMT9 also contains a duplicated catalytic 
core, along with an N-terminal tetratricopeptide repeat, although the functional importance 
of these domains for PRMT9 activity is unknown (38).  
 
PRMT Structure and Substrate Binding  
The crystal structures of many of the PRMT isoforms have been solved (39-50), 
revealing a striking structural conservation of the PRMT catalytic core. The monomeric 
structure of all PRMTs can be divided into three conserved parts (Figure 2-4): an AdoMet 
binding domain (green), a β barrel domain (gray), and a dimerization arm (blue). The 
AdoMet binding domain adopts a typical Rossmann fold conserved in other class I 
AdoMet-dependent methyltransferases (51), while the β barrel domain is unique to the 
PRMT family and is thought to participate in substrate binding (39,41). The dimerization 
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arm is inserted into the β barrel domain and although the length and sequence composition 
varies among the PRMT isoforms, a highly similar helical fold is observed in all PRMT 
crystal structures. The conservation of the dimeric interface coincides with the formation 
of head-to-tail homodimers observed in all PRMT structures (43) (human,  mouse, and  C. 
elegans PRMT7 are the exception since they contain a duplicated core which mimics the 
dimeric structure (48)). Dimerization appears required for methyltransferase activity, as 
experiments in PRMT1, PRMT3, and A. thaliana PRMT10 (AtPRMT10) have shown that 




FIGURE 2-4. Structural overview of a PRMT monomer. The structure of rat PRMT1 
(PDB: 1OR8) is used to illustrate the general fold of all PRMT isoforms. The AdoMet 
binding domain adopts a typical Rossmann fold (green) to bind the AdoMet cofactor 
(green) and is capped by N-terminal helices (helix αY is shown in orange, while αX is not 
present in this structure). The substrate arginine residue is colored in pink, while the β 
barrel domain is in gray and the dimerization arm is in blue. 
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 AdoMet binding by PRMTs is coordinated primarily through the conserved motifs 
found in the typical Rossmann fold of class I AdoMet-dependent methyltransferases. Motif 
I (VLD/EVGxGxG) forms the base of the AdoMet binding site. The carboxylate of the 
acidic residues within the post-I motif (L/V/IxG/AxD/E) form hydrogen bonds with the 
hydroxyl groups of the ribose moiety of AdoMet. While motif II (F/I/VDI/L/K) stabilizes 
motif I through the formation of a parallel B sheet, and motif III (LR/Kxxg) forms a parallel 
B sheet with motif II. The THW loop is close to the active site cavity and helps stabilize 
the N-terminal helix, which is important for arginine substrate recognition. In addition to 
these conserved motifs, the AdoMet binding pocket is completed by a conserved structural 
element composed of two helical segments, helices αX and αY, than fold onto the bound 
cofactor and provides a physical division between the cofactor binding site and the arginine 
binding site (see helix αY, orange in Figure 2-4). Most of the available PRMT crystal 
structures are missing most or all of the αX helix, suggesting that dynamics may be 
involved in cofactor binding and release. In support of this theory, the mouse PRMT6 
crystal structure was recently published in both oxidized and reduced states (49), capturing 
the αX helix in an unfolded, inactive state when oxidized, and a properly folded active state 
when reduced, and thus providing direct evidence of the protein dynamics involved in 
cofactor binding.  
 The active site of all PRMTs contains a pair of conserved glutamate residues (E144 
and E153 in rat PRMT1). These residues commonly referred to as the “double-E loop”, 
hydrogen bond with the positively charged guanidino nitrogen of the target arginine residue 
and thereby create the correct orientation for catalysis (magenta in Figure 2-5) (41).  
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 The active site of type I PRMTs also contain a pair of conserved methionine 
residues (M48 and M155 in rat PRMT1) which are positioned very close to the guanidino 
group of the target arginine residue and have been found to affect the type and degree of 
methylation (blue in Figure 2-5). Mutation of both methionines in rat PRMT1 was found 
to affect the MMA/ADMA ratios (52). Mutation of M48 of rat PRMT1 to the 
correspondingly conserved phenylalanine residue in the type II PRMT5 led to the 
transformation of rPRMT1 into a mixed type I/type II enzyme (53). The equivalent 
mutation in PRMT5 (F379 in C. elegans PRMT5 to methionine) also transformed this type 
II enzyme into a mixed type II/type I PRMT (44). This result is intriguing since the 
equivalent position on the other type II PRMT, PRMT9, is a methionine; indicating that 
other unidentified factors collaborate to confer the product specificity of the PRMTs. 
Current work in the Hevel lab is also investigating the role of residues in the type III 
PRMT7 in conferring this isoform its strict type III activity.   
While much has been revealed on the details of AdoMet binding and the PRMT 
catalytic mechanism (reviewed in (54)), the structures of PRMTs with peptide substrates 
bound have only revealed pieces of information on how PRMTs recognize and bind their 
substrates. Recently, the Trypanosoma brucei PRMT7 (TbPRMT7) and human PRMT5 
(hPRMT5) structures were both solved in the presence of a histone H4 peptide, providing 
the first clear images of how these PRMTs interact with the H4 substrate. In the PRMT5 
structure, the substrate arginine is presented/projected into the active site at the tip of a 
sharp β-turn in the peptide substrate (55)(Figure 2-6-A), and in the PRMT7 structure, the 




FIGURE 2-5. Zoomed in view of PRMT1 active site (PDB: 1OR8). Double-E-loop 
glutamates (E144 and E153) are in magenta; two methionines involved in product 
specificity (M48 and M155) are in blue. Substrate arginine (pink) and AdoHcy (green) are 
also shown. Note that E153 in this structure points away from the active site arginine 
(inactive conformation) due to the low pH of the crystallization conditions.  
 
However, both the type II hPRMT5 and the type III TbPRMT7 recognize the substrate 
primarily through peptide backbone interactions. Because of the wide array of substrates 
and substrate sequences methylated by these enzymes, structures with additional substrates 
will be needed in order to determine if the observed binding modes (turns in the backbone 
bracketing the arginine) are inherent for these PRMTs, or rather are substrate-specific, a 
possibility suggested by PRMT1 studies.  
The structure of rat PRMT1 (rPRMT1) was solved with a substrate peptide 
containing three arginines (R3; GGRGGFGGRGGFGGRGGFG) (39). Heterogeneity 
likely caused by the three different methylatable arginines each binding the active site of 
different molecules resulted in clear electron density only for an arginine residue in the 
active site, while the rest of the substrate peptide side chains could not be observed. 
However, patches of electron density revealed three possible peptide binding grooves 
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(39)(Figure 2-6-C), suggesting that different PRMT1 substrates might interact with 
PRMT1 using different binding modes.   In support of this theory, biochemical 
manipulation of a residue on one of these grooves altered the pattern of PRMT1 
methylation on hypomethylated cell extracts, inhibiting methylation of some proteins while 
leaving methylation of others unchanged (56). Interestingly, the PRMT4 structure also 
revealed multiple potential binding grooves on the surface of this isoform (42).  
Similar to what was observed in the hPRMT5 and TbPRMT7 structures, binding of 
the R3 peptide to rPRMT1 seems to occur mainly through backbone interactions.  This 
observation is also supported by substrate profiling studies which have shown little to no 
consensus sequence for substrate recognition by PRMT1 (57,58), (although there is a 
prevalence of ‘RGG’, ‘RXR’, and ‘RG’ sequences observed in vivo). The presence of 
glycine around the targeted arginine builds conformational flexibility into the region of 
methylation that may be a requirement of specific binding modes.  Alternatively, the 
prevalence of glycine could reflect the physical contortions that substrates must commit to 
in order to access an active site situated in the rim of the dimeric structure.  
Although the PRMTs seem somewhat promiscuous, small changes in the sequences 
of protein substrates can have profound effects on methyltransferase activity. For example, 
a single amino acid change in the helicase eIF4A1 (a PRMT1 protein substrate) from 
‘RGG’ to ‘RSG’ (to mimic the sequence found in eIF4A3, which is not normally a PRMT1 
substrate) abolished methylation by PRMT1 (57). Surprisingly, when the same RGG  
RSG change was made in a peptide substrate methylation was retained, suggesting that 
other interactions distant from the target arginine are important in influencing the substrate  
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FIGURE 2-6. PRMT substrate binding modes. Surface representations of (A) hPRMT5 
(4GQB, residues 331-636) and (B) TbPRMT7 (4M38, residues 82-374) binding to a 
histone H4 peptide fragment (red) and AdoMet analog or AdoHcy (green). In both, active 
site glutamates are shown in purple to provide orientation, while the backbone of the H4 
peptide fragment (SGRGKRRK in (A) and SRGK in (B)) is in red with only the arginine 
side chain shown for clarity. In (A), the H4 peptide forms a sharp β-turn to present the 
arginine into the hPRMT5 active site. In (B), the H4 peptide forms a wide turn on the 
surface of the TbPRMT7 active site. (C) Surface representation of a rPRMT1 monomer 
(PDB ID: 1OR8). Gray core with blue dimerization arm and orange helix αY. Active site 
glutamates are shown in purple. The active site arginine is shown in red, along with the 
three peptide binding grooves. 
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specificity (57).  This idea is supported by a study showing that mutation of positively 
charged or polar residues distal from the arginine within peptide substrates of PRMT1 to 
non-charged residues led to decreased catalytic efficiency of the PRMT1 enzyme (59). 
Although the field has made advances in understanding facets of substrate 
recognition and binding (particularly for PRMT1), the current studies also show that 
recognition and binding are complex and emphasize the need for a structure of a PRMT 
with a protein substrate bound, a goal that was attempted as described in chapter 3. 
However, even upon determination of such a structure, we may find that different classes 
of protein substrates bind the PRMT isoforms using a set of binding modes instead of a 
single binding site. 
 
PRMT Mechanism  
The kinetic mechanisms of the type I PRMT1 and PRMT6, as well as the type II 
PRMT5 have all shown a rapid equilibrium sequential random mechanism in which either 
one of the two substrates can bind in a random fashion (60,61). Methyl transfer seems to 
be the rate limiting step (62), and subsequent product release also occurs in a random 
fashion. However, an investigation of the PRMT2 mechanism found ordered substrate 
binding and product release with AdoMet binding first and AdoHcy release occurring last 
(63).  
 The determination that different methyl marks on substrates can lead to opposing 
biological consequences, highlights the importance of understanding the factors that may 
influence the distributive or processive methylation of type I and type II PRMTs. Although 
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all type I and type II PRMTs have the potential to be processive and synthesize a 
dimethylated product without releasing the monomethylated product, only PRMT1, 
PRMT6, and PRMT5 have been carefully examined. Interestingly, our lab has found 
PRMT1 activity is semi-processive, with the degree of processivity varying depending on 
the substrate tested (64). The type II PRMT5 enzyme works through a distributive 
mechanism, where the dimethylated product only appears after the monomethylated 
product exceeds the unmodified substrate (65). Since proper control over the processivity 
of these enzymes is essential for biological wellness, it is striking how little is known about 
what factors may PRMT enzyme processivity. A careful investigation of how regulators 
affect PRMT activity may lead to identification of factors that affect processivity as well.    
 
PRMT Regulators 
Protein regulators— A variety of PRMT-binding proteins have been reported to 
regulate methyltransferase activity by inhibiting, activating, or even changing the PRMT 
substrate specificity (see Table 2-1). Several proteins have been reported to inhibit the 
activity of PRMTs (Table 2-1). In one example, hCAF1 inhibited PRMT1 methylation of 
Sam68 and histone H4, but not hnRNPA1 (66). The hCAF1 protein is part of the 
mammalian CCR4-NOT complex which is involved in the regulation of transcription and 
RNA metabolism in yeast and mammalian cells.  Interestingly, multiple components of the 
yeast CCR4-NOT complex have also been shown to associate with the PRMT1 homolog, 
Hmt1 (67). Since many PRMT1 substrates are RNA-binding proteins involved in various 
aspects of RNA processing and transport, PRMT1 regulation by hCAF1 and association 
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with the CCR4-NOT complex suggests these proteins are involved in crosstalk between 
transcription and RNA processing. The exact mechanism of regulation and substrates 
involved remain unknown and will prove to be a strong avenue for future investigations.  
The PRMT5-MEP50 complex is a prime example of protein-induced activation 
since binding by the MEP50 protein is necessary for PRMT5 activity in mammalian cells 
(30,68).  Current evidence points to a mechanism in which MEP50 binding is required for 
the PRMT5-MEP50 complex to simultaneously engage the protein substrate and orient the 
target arginine to the catalytic site (55,68). Other binding proteins can function as 
modulators of the PRMT5-MEP50 complex enhancing activity towards specific substrates 
(see Table 2-1). One well-characterized example is the SWI/SNF chromatin remodeling 
complex which can bind PRMT5-MEP50 and enhance methyltransferase activity toward 
histone substrates. Thus, the components present at a specific time in complex with PRMT5 
and MEP50 function to fine-tune PRMT5 methylation activity and preferred targets 
depending on the precise cellular needs. While many regulatory complexes have been well 
described for PRMT5, the high number of PRMT-interacting proteins (69-71) may suggest 
that similar multi-protein regulatory mechanisms have yet to be identified for the other 
PRMTs.  
Posttranslational modifications— Automethylation activity has been reported for 
several PRMTs; the functional significance of these modifications remains under 
investigation, but thus far seem specific to particular PRMT isoforms. PRMT6 
automethylation on its N-terminal region (R29, R35, R37 of human PRMT6) contributes  
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Table 2-1. PRMT protein regulators 
PRMT 
Isoform 
Protein regulator Effect of interaction 
PRMT1 hCAF1 Inhibition towards certain substrates (66) 
Btg1  Stimulates activity towards selected 
substrates (72) 
Tis1/Btg2 Stimulates activity towards selected 
substrates (72) 
orphan nuclear receptor 
TR3 (NR4A1) 
Inhibition of PRMT1 activity (73) 
PP2Ac Inhibition of PRMT1 activity (74) 
PRMT2 Enhances PRMT1 activity (23) 
Air1 Inhibition of Hmt1 (yeast PRMT1) 
activity (75) 
PRMT3 DAL-1/4.1B Inhibition of PRMT3 activity (76) 
PRMT4 NUMAC Targets CARM1 to nucleosomal H3 in 
vivo (77) 
PRMT5 MEP50 Required for PRMT5 activity in 
mammalian cells (30) 
COPR5 Changes balance of activity from H3R8 
toward H4R3 in vivo (78) 
hSWI/SNF complex 
(BRG and BRM) 
Enhances PRMT5 activity towards 
histones (31) 
RIOK1 Regulates PRMT5 substrate specificity 
(79) 
pICLN Regulates PRMT5 substrate specificity 
(79) 
CDK4 Enhances PRMT5 activity and triggers 
neoplastic growth in vitro (80) 
Exon junction complex 
(RNA binding protein 
Y14) 
Increased activity of MEP50:PRMT5 
towards Sm proteins of the small nuclear 
ribonucleoprotein core (81) 
DAL-1/4.1B Mediates PRMT5 methylation in a 
substrate-specific manner (82) 
PRMT6 HMGA1 Increased MIF methylation by PRMT6 in 
vitro (83)  
PRMT7 CTCFL Enhanced PRMT7* activity (84)* 
* The reported CTCFL regulation of PRMT7 needs to be re-evaluated. PRMT7 is now 
known to be a type III PRMT, and is therefore unable to catalyze SDMA formation. In 
the report by Jelinic et al. CTCFL was shown to increase SDMA formation in vivo on 
Histone H4R3 (84), which neither indicates, nor discounts PRMT7 activity enhancement 
since it did not directly measure PRMT7 activity.  
25 
to PRMT6 protein stability and regulates its anti-HIV-1 activity (85). PRMT4 
automethylation occurs on its C-terminal end at R551 of the mouse sequence, which 
exhibits strict conservation in vertebrates.  Preventing automethylation impaired both 
PRMT4-activated transcription and pre-mRNA splicing (86). PRMT8 automethylation 
occurs in cis at N-terminal arginines R58 and R73 of the human sequence and is 
independent of PRMT8 G2 myristoylation. Preventing PRMT8 automethylation increased 
the turnover rate and decreased KM of AdoMet, but not of peptide substrates (36), 
indicating that automethylation regulates PRMT8 activity by decreasing the affinity of the 
enzyme for AdoMet (87).   PRMT1, PRMT3, and PRMT7 automethylation has also been 
reported, but neither the location of the methylated arginines nor functional significance 
have yet been uncovered (52,88-90). While there are reports showing that PRMT4 
automethylation is regulated at the level of alternative splicing (91), the significance and 
regulation of automethylation on other PRMT isoforms remains to be determined.  
Phosphorylation has also been reported to regulate several PRMTs. A constitutively 
active JAK2 mutant found in leukemia phosphorylates PRMT5 at three conserved tyrosines 
(Tyr297, Tyr304, and Tyr307 of the human PRMT5 sequence) on the N-terminal domain, 
diminishing PRMT5 activity, likely by disrupting the substrate binding pocket, resulting in 
decreased PRMT5 activity and contributing to the myeloproliferative phenotype 
(55,92,93). Two distinct mechanisms for phosphor-inhibition of PRMT4 function have 
been reported. An initial report indicated that phosphorylation in the PRMT4 dimerization 
arm (Ser229 mouse/rat, Ser228 human) severely impacted dimer formation and led to 
reduced AdoMet binding and methyltransferase activity (94). A second report has revealed 
that PRMT4 phosphorylation of Ser217 (Ser216 human PRMT4) abolished AdoMet 
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binding and methyltransferase activity in vitro, while promoting cytoplasmic localization 
and abrogating its coactivator function in vivo. The side chain hydroxyl group of Ser217 
forms a hydrogen bond with the backbone carbonyl of Tyr154 which is believed to close 
the AdoMet cavity (95), phosphorylation likely disrupts this interaction and as a result the 
enzyme no longer binds AdoMet. This data led Feng et al. to propose a model in which 
Ser217 phosphorylation serves as a molecular switch to control PRMT4 activity during the 
cell cycle (95). Interestingly, Ser217 and Tyr154 are strictly conserved among type I 
PRMTs, suggesting the possibility for a conserved regulatory mechanism. Reports have 
also indicated that PRMT1 may be phosphorylated, although they differ on the site and 
effect of phosphorylation. Rust et al. found that PRMT1 phosphorylation on Tyr291 (in a 
region conserved for type I PRMTs called the THW loop) alters both substrate specificity 
and protein-protein interactions (96). Messier et al. reported yeast PRMT1 (Hmt1) 
phosphorylation on Ser9 activates Hmt1 activity in vivo (97). Hmt1 Ser9 is conserved in 
rat and human PRMT1 (Ser21) and it will be interesting to determine whether 
phosphorylation at this residue is conserved and can regulate function in higher eukaryotes.  
Regulation by modification or masking of substrate arginines— Posttranslational 
modifications adjacent to arginine methylation sites have also been shown to regulate 
PRMT activity by masking or blocking methylation. Histone tails are heavily modified in 
order to regulate transcription and are a perfect example of the interplay different PTMs 
can have in regulating other modifications. In one example, PRMT5 methylation of histone 
H3R8 leads to a decrease in transcription; however this methylation can be blocked by 
H3K9 acetylation (98).  In turn, the H3R8me2a or H3R8me2s marks can block methylation 
of H3K9 (99). In another example, H3R2 methylation by PRMT6 is inhibited, but not 
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completely blocked by the H3K4me3 mark (100) and H3K4 methylation is also blocked 
by prior H3R2 methylation (101). In a striking example, acetylation of H4K5 shifts H4R3 
from being a primarily PRMT1 substrate to a preferred PRMT5 substrate, shifting the 
balance from ADMA to SDMA and thus leading to suppressed transcription (102). The 
interplay between histone tails modifications thus regulates PRMTs by varying the 
substrate accessibility or preference, and may also regulate product specificity. Examples 
of this substrate masking effect are now also beginning to emerge for non-histone 
substrates. It was recently shown that PRMT6 methylation of the androgen receptor occurs 
at AKT consensus site motifs and is mutually exclusive with serine phosphorylation by 
AKT (103,104). Phosphorylation of the C-terminal tail of RNA Polymerase II  at Ser2 or 
Ser5 has also been reported to block Arg1810 methylation by PRMT4, resulting in 
misexpression of a variety of small nuclear RNAs and small nucleolar RNAs (105). Since 
many PRMT non-histone substrates are also heavily modified (hnRNPk, Npl3, Sam68, 
PABPN1, etc.), it is not difficult to imagine that similar masking of substrate arginines will 
continue to emerge and be found to play a regulatory role in many PRMT-regulated 
signaling pathways. 
Another indirect path of regulating protein arginine methylation is through the 
activity of protein arginine deiminase (PAD4), which removes an amino group from the 
guanidino side chain of arginine, converting a previous arginine substrate into a non-
substrate citrulline (106,107)(for a recent in-depth review of protein arginine deiminases 
see Fuhrmann et al. (54)). Although PAD4 was initially believed to also convert MMA 
(but not DMA) to citrulline (107), later work by Raijmakers et al. showed that 
monomethylarginine is a poor substrate for PAD4 (108). PAD4 was the first enzyme shown 
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to antagonize histone methylation and it has subsequently been shown to also deiminate at 
least one site on p300, preventing PRMT4 methylation (109). Other examples of 
antagonistic effects of citrullination at methylation sites in non-histone proteins are 
continually emerging (110,111).  It will be interesting to see how many of the PRMT 
substrates can become citrullinated, what regulates PAD4 activity and substrate selection, 
and whether this is truly an irreversibly process or one that can be reversed by a yet 
undiscovered aminotransferase.  
Impact of oligomeric state on PRMT activity— As previously discussed, the 
PRMT field has widely accepted that PRMTs must form at least a dimer in order to be 
catalytically active (39,40,43). This concept has been supported by dimer observations in 
all known PRMT crystal structures (39,41-43,45-48,50), as well as by biochemical 
characterizations indicating loss of activity when the dimerization arm is removed or 
mutated (39-41,43). Most dimer molecular interactions occur between the dimerization 
arm of one monomer and the outer surface (αY, αZ, αA, and αB) of the AdoMet binding 
domain of the other monomer (Figure 2-7).  Although the dimerization arm sequences for 
different PRMTs vary widely in length and amino acid composition, in each case 
hydrophobic interactions make up the majority of the dimer interface, complemented by a 
small network of hydrogen bonds (note that the residues on the surface of the AdoMet 
binding domain are highly conserved among PRMTs). 
Cheng et al. calculated the atomic position fluctuations (APFs) of AtPRMT10 Cα 
atoms in monomeric and dimeric states. The αY-αZ region, which both forms direct 
contacts with AdoMet and contributes to the conserved substrate binding groove I, and the 
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dimerization arm region displayed significantly reduced APFs in the dimeric form. These 
reduced fluctuations are a result of direct involvement in forming the dimer interface and 
suggest that stabilization of this region by dimerization likely improves the binding of 
AdoMet and substrate proteins (43). This stabilizing effect of dimerization is consistent 
with the report that the PRMT4 dimerization arm phosphorylation mimic S229E exhibits 
decreased AdoMet binding and methyltransferase activity (94). To date, the only data 
suggesting any PRMT may exist as a monomer was presented by Tang et al. in the initial 
characterization of PRMT3, where PRMT3 isolated from mammalian cell extracts 
migrated as a monomer over gel filtration, although no activity was shown for this 
monomeric PRMT3 (24). Herrmann et al. corroborated the presence of PRMT3 monomers 
using glycerol gradient experiments and additionally observed that PRMT6 behaved as a 
monomer in fluorescence correlation spectroscopy experiments (18). However, it should 
be noted that there is no evidence to suggest methyltransferase activity can be obtained 
from a PRMT monomer.  FRET experiments yielding KD of dimerization for PRMT1 and 
PRMT6 homodimers indicate that the strength of dimer formation varies among the 
PRMTs and can be impacted by the presence of AdoMet (112). Together, the data thus far 
indicates that dimerization is conserved throughout the PRMTs and serves to stabilize 
cofactor binding and orient the active site for catalysis.   
In addition to dimers, several PRMTs have been detected as high molecular weight 
oligomers in solution both in vivo and in vitro (18,39,40,62,113). Feng et al. introduced the 
idea that changing the oligomeric state of PRMT1 affects methyltransferase activity (62). 
In these studies, crosslinking data showed an increase in oligomerization with increasing 
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FIGURE 2-7. PRMT dimer interacting regions. rPRMT1 (IOR8) dimer interactions 
occur through the dimerization arm (blue, residues 188-216) of one monomer and the outer 
surface of the AdoMet binding domain (helices αY, αZ, αA, and αB shown in lime) of the 
second monomer.  
 
protein concentration correlated to an increase in the turnover rate per PRMT1 monomer 
reaching a plateau around 0.5µM PRMT1 (62). Recently, the oligomeric state of PRMT1 
was also shown to change as a function of the redox state (114). However, while this work 
showed that reduced PRMT1 is more active and forms a lower molecular weight oligomer 
than oxidized PRMT1, a clear explanation for this effect could not be discerned. Future 
work should address the factors driving the formation of PRMT1 high molecular weight 
aggregates and exactly how these affect methyltransferase activity.  
Redox control of PRMT activity— A novel redox-based PRMT regulatory 
mechanism was also recently discovered and published as described in chapter 6. We were 
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able to show that rPRMT1, hPRMT3, hPRMT6, and TbPRMT7 all display a reversible 
increase in methyltransferase activity in the presence of reductant (PRMT8 is also believed 
to be under redox control, but was not tested) (114). Further biochemical characterization 
revealed that two PRMT1 cysteine residues (C101 and C208 of rat PRMT1) can become 
reversibly oxidized to sulfenic acid. Preventing oxidation at these two sites abolished the 
typical increase in methyltransferase activity in the presence of reductant, indicating that 
these two cysteine residues allow rPRMT1 activity to be regulated by the redox 
environment. Sequence alignment shows that one of these two cysteines (Cys208 in 
rPRMT1) is conserved in all but one (TbPRMT7) of the PRMTs shown to be redox 
regulated. Only PRMT8 shows conservation of both cysteine residues, while the type III 
TbPRMT7 contains only three cysteines, none of which are conserved in the other PRMTs. 
These variations in cysteine conservation imply that while redox regulation may be a 
conserved trait for several PRMT family members, the mechanism of redox control likely 
varies among them.   
The biological implications of redox regulation remain to be determined. However, 
it is impossible not to speculate on the potential involvement of PRMT1 in the cellular 
oxidative stress response. In one example, Lafleur et al. suggests that PRMT1 may be 
important for the cellular hypoxic response (115). PRMT1 acts as a repressor of both HIF-
1 and HIF-2 which are essential mediators for the adaptive transcriptional response to low 
oxygen conditions (115). It will be interesting to determine if during hypoxia and HIF 
activation, PRMT1 activity is decreased by increased oxidative stress resulting in a 
decrease on PRMT1-dependent HIF repression to maintain elevated HIF-1α levels. 
Although Lafleur et al. did not observe this phenomenon under their hypoxic conditions, 
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it was suggested that this feedback regulation may only be observed under longer periods 
of hypoxic exposure (115). The impact of this newly discovered redox regulatory 
mechanism on several PRMT family members will surely be the focus of much 
investigation in years to come.  
 
Biological Importance of PRMTs   
The continued development of techniques for detecting PRMT substrates has 
allowed the identification of thousands of in vivo arginine methylation sites in proteins 
involved in a plethora of biological pathways (2,5,69,89,116-118). However, in order to 
truly understand the impact of the PRMTs, the effects of methylation on the substrate 
protein structure and on its molecular interactions must be related to the corresponding 
cellular function of the substrate protein. This level of understanding often requires the 
creative application of a combination of in vivo and in vitro techniques. A brief 
representation of the many ways PRMTs are involved in critical biological pathways, with 
particular focus on PRMT1, is presented below.  
Transcription—The PRMTs have a well-established involvement in the regulation 
of gene transcription (119). PRMTs have been shown to form numerous interactions with 
transcription factors and transcriptional coactivators in addition to their ability to directly 
methylate histones and RNA polymerase II (28). PRMT1 and PRMT4/CARM1 can 
cooperatively enhance gene expression and are generally considered transcriptional 
activators (120), while PRMT5-dependent SDMA formation is generally associated with 
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transcriptional repression (65,121). Additionally, methyltransferase activity in yeast has 
also been found to regulate transcription elongation and termination (122) 
Cell signaling— Posttranslational modifications drive cellular signaling by altering 
protein function through the promotion or prevention of specific protein-protein 
interactions. PRMT1 binds the type I interferon α/β (INF α/β) receptor and PRMT1 
knockdown interfere with the biological function of this receptor (123). Knockdown of 
PRMT1 expression similarly was shown to attenuate the signaling cascade from the insulin 
receptor (IR) (124), indicating that PRMT1 methylation is a positive regulator of IR 
function and subsequent glucose uptake.  
mRNA transport and splicing—  Many of the known PRMT substrates are RNA-
binding proteins (RBPs) that contain GAR (glycine-arginine rich) or PGM (proline-
glycine-methionine) motifs, which are some of the preferred sites of PRMT1 and CARM1 
methylation, respectively (28,125). In many RBP binding sites, arginine residues are key 
amino acids for RNA-protein interactions (126). Arginine methylation has been found to 
both negatively (methylation can block hydrogen bonding) and positively (increased 
arginine hydrophobicity when methylated may facilitate stacking with RNA bases) 
regulate protein-RNA interactions (127). In yeast, the PRMT1 homolog Hmt1 methylates 
mRNA export factor Npl3 (128), an activity which is required for the mRNA shutting 
function of Npl3 (129). Hmt1 also methylates Snp1, a U1 small nuclear RNP (snRNP)–
specific protein (130). The deletion of HMT1 was found to deregulate the recruitment of 
U1 snRNP and its associated components to intron-containing genes (130), therefore 
implicating arginine methylation in the promoting target specificity in splicing.  
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DNA damage repair— The loss of PRMT1 has been linked to genome instability 
(131). PRMT1 is known to methylate and regulate the exonuclease activity of MRE11, a 
key enzyme in DNA double-strand break repair and overall genome stability (132). 
Importantly, arginine methylation seems to be required for MRE11 localization to the site 
of DNA damage (133). The p53-binding protein 1 (53BP1), which is important for the 
early events of detection, signaling, and repair of DNA double-strand breaks is also 
methylated by PRMT1 (134), and methyltransferase activity was also found to be required 
for 53BP1 localization to DNA damage sites (135).  
 
Protein Arginine Methylation and Diseases 
Cardiovascular disease— All type I PRMTs have the ability to make ADMA, but 
the predominant arginine methyltransferase, PRMT1, is responsible for most of the ADMA 
formation in cells (16). Altered levels of free ADMA, which is generated by the proteolysis 
of asymmetrically dimethylated proteins, have been found in a variety of disease states 
(136) Recently, plasma ADMA levels have been used as a biomarker for prognosis after a 
cardiac event (137,138). ADMA is a competitive inhibitor of nitric oxide synthase (NOS) 
(139), which is responsible for the production of nitric oxide, a potent vasodilator. 
Therefore, the inhibition of NOS by ADMA has major consequences on the cardiovascular 
system (139,140). Elevated expression of PRMT1, the primary generator of ADMA in 
cells, has been found in coronary heart disease (141), implicating the dysregulation of 
PRMT1 activity with cardiovascular disease (142) as well as other pathophysiological 
conditions such as kidney failure (143,144) and chronic pulmonary disease (145,146).  
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Cancer— The role of PRMTs in cancer has been extensively reviewed recently 
(147). Overexpression or aberrant splicing of PRMT1 has been reported in leukemia 
(148,149), as well as breast (150-153), prostate (154,155), colon (156,157), and lung cancer 
(158). In Mixed Lineage Leukemia (MLL), PRMT1 was shown to be an essential 
component of an MLL oncogenic transcriptional complex which unitizes both histone 
acetylation and arginine methylation (H4R3) activities to enhance the expression of critical 
MLL targets (148). The essential role of PRMT1 in this oncogenic complex has made it as 
a prominent therapeutic target (159).  
Viral pathogenesis— Arginine methylation has been shown to regulate the viral 
replication of both the human immunodeficiency virus (HIV-1) and the hepatitis delta virus 
(HDV). The HIV-1 transactivator protein (Tat) is methylated by PRMT6, which negatively 
regulates its transactivation activity (160). Correspondingly, knocking down PRMT6 
increased HIV-1 production and viral infectiousness (160), indicating that arginine 
methylation offers some protection against HIV infection (33). In contrast, PRMT1 
methylation of the small hepatitis delta antigen (sHDAg) appears to enhance its nuclear 
transport and therefore facilitate viral replication (161), suggesting that blocking 
methylation may offer protection against some viruses (162).  
 
CONCLUSIONS 
 Protein arginine methylation is critical for organismal well-being. The vast array of 
PRMT substrates implicates this posttranslational modification in important cellular 
pathways. Not surprisingly, the dysregulation of PRMT activity has been implicated in a 
number of high-profile human diseases like cardiovascular disease, cancer, and viral 
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pathogenesis. Yet, despite the important role of the PRMTs, how these proteins are 
regulated remains mostly unclear. We have aimed to understand how PRMT1, the 
predominant PRMT in cells, interacts with its substrates and is regulated. This dissertation 
provides increased understanding of both existing and novel PRMT1 regulatory 
mechanisms, which will contribute to the PRMT research field, and provide a foundation 
for an advanced understanding of PRMT roles in vivo.  
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INVESTIGATING PRMT1: SUBSTRATE INTERACTIONS 
 
ABSTRACT 
Protein arginine methyltransferases (PRMTs) catalyze the methylation of terminal 
guanidino nitrogens of arginine residues in their protein substrates. PRMTs play a pivotal 
role in biology, yet much of the basic biochemistry for this class of enzymes remains 
unexplored. In particular, the molecular basis for substrate recognition by the PRMTs is 
poorly understood. The only current crystal structure of a PRMT1 with a substrate bound 
has very weak electron density around the substrate peptide side chains and therefore 
provides no information about what interactions are important for binding parts of the 
substrate besides the target arginine. Additionally, it remains unclear how a 
monomethylated peptide binds and is dimethylated by PRMT1. Herein, we aimed to co-
crystallize PRMT1 with a monomethylated peptide substrate in order to understand how a 
monomethylated arginine is coordinated by the PRMT1 active site, and to learn how 
PRMT1 interacts with other parts of the peptide substrate. Many peptide containing crystals 
were screened, but no electron density for substrates was observed. A new strategy to use 
a protein substrate rather than a peptide also resulted in successful crystallization.  Thus, 
detection of electron density of a suitable resolution has not been attained. Further trials 





 Protein arginine methyltransferases (PRMTs) catalyze the transfer for methyl 
groups from the cofactor S-adenosyl-L-methionine (SAM or AdoMet) to the terminal 
guanidinium group of arginine residues in substrate proteins. Development, 
carcinogenesis, heart disease, and viral pathogenesis are among the processes influenced 
by the PRMT family of enzymes (1). Nine human PRMT isoforms (PRMT1-PRMT9) have 
been identified with homologues present in yeast, protozoa, C. elegans, Drosophila 
melanogaster, Trypanosoma brucei, plants, and fish, among others (2). PRMTs catalyze 
the methylation of arginine residues resulting in the formation of monomethylarginine 
(MMA), asymmetric dimethylarginine (ADMA), or symmetric dimethylarginine (SDMA) 
(Fig. 3-1). PRMTs can be classified into three distinct categories based on produt 
formation: type I PRMTs monomethylate and asymmetrically dimethylate arginyl residues 
(PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6, and PRMT8), type II PRMTs 
monomethylate and symmetrically dimethylate arginyl residues (PRMT5, and PRMT9), 
while type III PRMTs can only monomethylate arginine residues (PRMT7). PRMT 
methylation can alter protein-protein, protein-DNA, and protein-RNA interactions (2). 
PRMTs also regulate many cellular processes such as transcription, DNA repair, RNA 
processing and export, and cell differentiation (2,3). Intriguingly, MMA, ADMA, and 
SDMA can have opposing biological consequences (4,5).    
Protein structures have been solved for many of the PRMTs from a variety of 
organisms and with a variety of cofactors. These structures include those of PRMT1 (6), 
PRMT3 (7), PRMT4/CARM1 (8), PRMT5 (9), PRMT6 (10), PRMT7 (11), and the plant  
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FIGURE 3-1. Reactions catalyzed by the mammalian protein arginine 
methyltransferases. PRMTs catalyze the transfer of a methyl group from AdoMet to a 
substrate arginine residue to form MMA, ADMA, or SDMA. Type I PRMTs (PRMT1, 2, 
3, 4, 6, 8) can make MMA and ADMA. Type II PRMTs (PRMT5 and 9) can make MMA 
and SDMA. PRMT7, the only type III PRMT can only make MMA.  
 
PRMT10 (12). These structures have provided a wealth of information regarding 
oligomerization, active site residues, and product specificity. PRMT1 is responsible for 
about 85% of arginine methylation in humans (13) and as the predominant PRMT in vivo, 
it is of particular interest. The rat PRMT1 homolog differs from human PRMT1 at only 
one residue (rH161 = hY161) and has high expression levels and activity, therefore making 
it an ideal model with which to study PRMT1. The crystal structure of rat PRMT1 was 
solved in 2003 with AdoHcy and R3, a 19 amino acid peptide substrate derived from 
fibrillarin (GGRGGFGGRGGFGGRGGFG) (6). Because the peptide in this structure 
contains three potential methylation target arginines, it can be described as a slippery 
substrate; that is, one in which several parts of the substrate can be in the active site at any 
given time (Figure 3-2-A and B). The structure of the PRMT1-AdoHcy-R3 complex 
yielded electron densities revealing the location of bound peptide ligands. However, the 
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densities were broken into three separate peptide fragment binding sites and, except for the 
arginine in the active site, the side chain densities were not sufficiently resolved to allow 
clear identification of the amino acids (6). The three disconnected densities were suggested 
to represent a mixture of binding modes of the R3 peptide (Figure 3-2-C). The solved 
structure has been very valuable in identifying active site residues involved in binding and 
processing of the target arginine. However, it is still unclear how the monomethylated 
peptide binds and is dimethylated. Furthermore, because electron density was not observed 
for the peptide substrate side chains, little is known about what protein interactions are 
important with other parts of the substrate. Additionally, the observation of three different 
binding modes generated the possibility that various substrates may bind PRMT1 utilizing 
different binding grooves. 
In order to better understand how PRMT1 binds its substrates, we set out to 
crystallize PRMT1 with a peptide containing only one monomethylated arginine. The 
target peptide chosen has two advantages: 1) it is not “slippery” and therefore should result 
in better electron density allowing visualization of the interactions between PRMT1 and 
the other parts of the substrate and 2) it would be the first monomethylated substrate 
crystallized with PRMT1, thus providing a better understanding of how a monomethylated 
species binds PRMT1 and is coordinated for a second catalytic step. Given that MMA and 
ADMA can produce different biological outcomes (5), knowing how PRMT1 is able to 
orient a monomethyl substrate is of great significance.  
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FIGURE 3-2. Structure of rat PRMT1 bound to R3 peptide (PDB: 1OR8). (A) PRMT1 
(gray) was crystallized in the presence of AdoHcy (blue) and the R3 peptide substrate 
(blue). While most of the peptide backbone was observed, electron density was not 
observed for any of the peptide side chains, except for the active site arginine. (B) 
Representation of the three methylatable arginines in the R3 peptide each bound in the 
PRMT1 active site. (C) Surface representation of the PRMT1 monomer highlighting the 
three peptide binding grooves (green) where peptide backbone electron density was found.  
 
Another goal of this work was to obtain a crystal structure containing PRMT1 and 
a full protein substrate. PRMT1 functions as a ring-like dimer arranged in head to tail 
fashion with a central cavity. This arrangement results in two active sites located on 
opposing ends of the central cavity. The substrate binding surface of PRMT1 is expected 
to be acidic because most PRMT1 substrates contain multiple positively charged arginines. 
The surface charge distribution of the dimer shows that acidic residues are enriched on the 
inner surface of the dimer ring and on the outer surface of the β barrel motif. While arginine 
substrates are commonly located on flexible loop regions of substrate proteins, how 
arginines in substrate proteins arrange into the PRMT1 dimer central cavity remains 
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unknown. In order to determine how a protein substrate is bound and methylated by 
PRMT1, we set out to choose a suitable protein substrate and solve a crystal structure of 
the proteins in complex.  
 For both goals, I have optimized purification protocols, created optimal constructs, 
and found various initial crystallization conditions. Further work should be done in order 
to optimize these conditions and obtain larger, better diffracting crystals.  
 
EXPERIMENTAL PROCEDURES 
Materials— AdoHcy was purchased from Sigma. All the peptides were 
synthesized by the Keck Institute and purified to ≥ 95%. The Natrix, Index, and Salt 
crystallization screens were purchased from Hampton Research, and the JCSG Core Suite 
screen was purchased from Qiagen.  
Expression and Purification of S14-PRMT1— S14-PRMT1 (rat PRMT1v1 with 
first 13 residues removed) was expressed with a His6 tag in E. coli BL21 cells at OD600 of 
0.4 with 0.5 mM IPTG for 18 hours at 22° C. The cells (~24 g) were lysed by sonication 
in lysis/wash buffer containing 50 mM sodium phosphate pH 7.5 and 20 mM imidazole at 
a 1 to 4 cell mass to buffer ratio. The soluble fraction was separated by centrifugation and 
allowed to incubate with 16 ml Ni-NTA Agarose (Qiagen) resin for 3 hours at 4° C. The 
Nickel resin was washed of impurities six times with four times the column volume using 
50 mM sodium phosphate pH 7.5 and 70 mM imidazole (this was later corrected to 20 mM 
imidazole and two additional washes were added with 70 mM imidazole buffer to increase 
overall purification yield). The protein was eluted five times with one column volume of 
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50 mM sodium phosphate pH 7.5 and 250 mM imidazole. The protein was dialyzed 
overnight into 50 mM sodium phosphate pH 7.5 buffer and then loaded at a rate of 1 ml/min 
onto a HiTrap MonoQ (GE) column. The MonoQ column was run using a salt gradient 
with buffer A: 50 mM sodium phosphate pH 7.5 and buffer B: 50 mM  sodium phosphate 
pH 7.5, 1 M NaCl. The gradient was run at 1 ml/min with step 1) 100% buffer A for 5 ml, 
step 2) increase to 20% buffer B over 15 ml, step 3) hold 20% buffer B for 5ml, step 4) 
increase to 40% buffer B over 15 ml, step 5) hold 40% buffer B for 5ml, step 6) increase 
to 100% buffer B over 20 ml, and step 7) hold 100% buffer B for 10 ml. Fractions 
containing protein (typically around 35% buffer B) were slowly concentrated to less than 
1ml total volume using a 30 kDa cutoff centrifugal filter concentrator (Amicon). The 
protein was then loaded onto a 24 ml Superdex 200 gel filtration column equilibrated with 
50 mM sodium phosphate, 300 mM NaCl pH 7.5, and run at 0.6 ml/min while collecting 
2.5 ml fractions. Pure S14-PRMT1 was then buffer exchanged into 20 mM Tris pH 8.0, 
250 mM NaCl, 1 mM EDTA, 0.1% β-mercaptoethanol, 5% glycerol and concentrated to 
≥ 20 mg/ml prior to using for crystallization. AdoHcy was added to a final concentration 
of 600 µM (concentration used for crystallization in paper) after the S14-PRMT1 was 
concentrated to ~20 mg/ml and prior to setting up crystallization trials. This step was 
slightly problematic due to the low solubility of AdoHcy in water. AdoHcy was made up 
in 1 M hydrochloric acid at a concentration of 120 mM and a small volume of this stock 
solution was added to the protein to a final concentration of 600 µM AdoHcy. Because 
proteins tend to be less stable when very concentrated, the acidic addition often caused 
some of the protein to precipitate and become inviable for crystallization. If this occurred, 
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the solution was spun down and the soluble portion transferred to a new tube to use for 
crystal trials.  
Expression and Purification of Hmt1 Constructs— E. coli BL21 cells expressing 
His6-tagged Hmt1 were grown in Luria Broth media at 37° C to OD600 reached 0.6, 
followed by induction with 0.5 mM IPTG at 22° C for 20 hours. Cell pellets were 
resuspended in two times cell volume lysis buffer (50 mM sodium phosphate pH 7.5, 100 
mM NaCl, 20 mM imidazole, or 5 mM imidazole when purifying tagless constructs) and 
lysed using sonication. The cell lysate was clarified via centrifugation and incubated with 
Nickel resin (GoldBio) in a 1:1 cell mass: resin ratio for 1-2 hours at 4° C. The resin was 
washed eight times with eight column volumes of lysis buffer, followed by three washes 
with eight column volumes of wash buffer (50 mM sodium phosphate pH 7.5, 100 mM 
NaCl, 70 mM imidazole). The protein was then eluted off the resin five times with two 
column volumes of elution buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 250 
mM imidazole). Elutions were pooled and dialyzed into 50 mM Hepes pH 7.5, 10% 
glycerol. The protein was then concentrated to ≥15 mg/ml and used immediately for 
crystallization trials.    
Expression and Purification of Truncated Npl3 Proteins— His6-tagged full 
length Npl3 was received from Ann McBride (pAM436). The pAM436 plasmid was 
generated by inserting an N-terminally His6-tagged Npl3 into the pET24b+ vector using 
NdeI and SacI restriction sites. The His6-TEV-T7 (HTT7) Npl3 constructs were all created 
in the Hevel lab as follows. An ultramer was synthesized by GenScript containing a 5’ 
NdeI site followed by a 3 amino acid spacer, then a His6 tag which was also followed by a 
9 amino acid spacer prior to sequence for a TEV cleavage site. A NcoI site was next and 
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then a T7 affinity tag followed by a BamHI site. The ultramer then contained codon 
optimized Cterm Npl3 sequence (aa 284-414) and ended with a 3’ KpnI site. This construct 
was received in a pUC57 vector. Because the 3’ restriction site in the ordered sequence 
was mistakenly coding for a KpnI restriction site, instead of the desired SacI site, the entire 
sequence was PCR amplified using forward primers containing the 5’ NdeI site and reverse 
primers matching the end of the Cterm Npl3 sequence and coding for a 3’ SacI site. This 
PCR product was then ligated into a pAM436 plasmid that had been double digested with 
NdeI and SacI to remove all tags and Npl3 sequence. The resulting plasmid had a pET24b+ 
backbone and contained coding sequence for a His6 tag, a TEV cleavage site, and a T7 tag; 
all flanked by NdeI and BamHI sites; this is referred to as the “HTT7” vector. Between the 
BamHI sites and the SacI site was the Cterm Npl3 codon optimized construct, which could 
be exchanged for any other sequence using the flanking restriction sites. These BamHI and 
SacI sites were then used to insert all other Npl3 constructs, into the “HTT7” plasmid.  
E. coli BL21 NiCo21 (DE3) cells expressing His-TEV-T7 tagged Cterm Npl3 
(residues 284-414) protein were grown in Luria Broth media at 37° C until OD600 reached 
0.6, followed by induction with 0.5 mM IPTG at 22° C for 20 hours. Cell pellets were 
resuspended in two times cell volume lysis buffer (50 mM sodium phosphate pH 7.5, 500 
mM NaCl, 20 mM imidazole) and lysed using sonication. The cell lysate was clarified via 
centrifugation and incubated with Nickel resin (GoldBio) in a 2:1 cell mass to resin ratio 
for 1-2 hours at 4° C. The resin was washed eight times with eight column volumes of lysis 
buffer, followed by three washes with eight column volumes of wash buffer (50 mM 
sodium phosphate pH 7.5, 100 mM NaCl, 70 mM imidazole). The protein was then eluted 
off the resin five times with two column volumes of elution buffer (50 mM sodium 
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phosphate pH 7.5, 100 mM NaCl, 500 mM imidazole). Elutions were pooled, filtered and 
further purified using MonoQ and Heparin columns (GE) in tandem. Fractions containing 
Npl3 were pooled and dialyzed into 50 mM Hepes pH 7.5, 10% glycerol. The protein was 
then concentrated to ≥ 1 mg/ml, beaded in liquid nitrogen, and stored at -80° C.   Note that 
all Npl3 constructs were expressed and purified as above.  
Expression and co-purification of Hmt1 and Npl3 protein— E. coli BL21 cells 
expressing tagless Hmt1 were grown in Luria Broth media at 37° C to OD600 reached 0.6, 
followed by induction with 0.5 mM IPTG at 22° C for 20 hours. E. coli BL21 NiCo21 
(DE3) cells expressing His-TEV-T7 tagged Cterm Npl3 (residues 284-414) protein were 
grown in Luria Broth media at 37° C to OD600 reached 0.6, followed by induction with 0.5 
mM IPTG at 22° C for 20 hours. Seven grams of each cell pellet were weighed out and 
combined into 30 ml of lysis buffer (50 mM Hepes pH 7.5, 0.5 M NaCl, 20 mM imidazole) 
and lysed by sonication. The combined cell lysates was incubated with GoldBio Nickel-
charged resin for 1 hour at 4° C. The Nickel resin was then washed twelve times with 5 
column volumes of lysis buffer to remove any Hmt1 not complexed with HTT7 Cterm 
Npl3, as well as any nonspecific nucleic acids bound to the proteins. The resin was then 
washed twice with 5 column volumes of 50 mM Hepes pH 7.5, 0.1 M NaCl, 20 mM 
imidazole wash buffer, prior to eluting the protein complex six times with two column 
volumes of 50 mM Hepes pH 7.5, 0.1 M NaCl, 250 mM imidazole. The protein-complex 
containing elutions were pooled and dialyzed overnight into 50 mM Hepes pH 7.5 buffer 
to remove excess salt and imidazole. The proteins were then concentrated using a 30 kDa 
cutoff spin concentrator (Millipore) to ≥ 15 mg/ml and used for crystallization attempts. 
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Protein Interaction Determination— Initial attempts to map the interacting 
regions of Npl3 with Hmt1 using binding to T7 resin were unsuccessful due to strong 
nonspecific binding by Hmt1 to the T7 resin even in the absence of Npl3. Ultimately, 
protein interactions were probed by mixing lysates and co-purifying tagless Hmt1 with 
various HTT7-tagged Npl3 constructs over Nickel affinity resin. Positive interactions 
resulted in protein co-purification, while negative interactions resulted in most of the Hmt1 
being present in the unbound fraction. Note that although tagless Hmt1 could also form 
nonspecific interactions with the Nickel resin, the amount of resin and protein present still 
allowed for clear distinction between true binding vs nonspecific binding. This was not the 
case when using T7 resin due to the small amount of both resin and protein used for these 
studies which required visualization by Western blotting in order to determine the presence 
of protein.  
 
RESULTS  
S14-PRMT1: Peptide Substrate Crystallization and Optimization— Initial 
attempts to solve a PRMT1 substrate bound structure were modeled closely after the 
published rat PRMT1 (rPRMT1) structure (6). The rPRMT1/R3 crystals were grown in 
mother liquor containing 100 mM Tris pH 9.0 and 1.6 M ammonium phosphate monobasic 
(final pH ~4.7). The concentration of peptide used, when present, was 1 mM and the protein 
was 20 mg/ml and contained 600 µM AdoHcy (6). Our initial crystallization trials were set 
up on a 24 well sitting drop vapor diffusion hand tray in mother liquor containing 100 mM 
Tris pH 9.0 and varying the final ammonium phosphate monobasic concentration from 1.3 
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M to 1.8 M in 0.1 M increments. Using protein concentrated to 20 mg/ml or greater, drops 
were set up containing either 1.5 µl protein: 1.5 µl mother liquor, 2 µL protein: 1 µl mother 
liquor, or 1 µl protein: 2 µl mother liquor and the trays were placed in a 4° C crystallization 
chamber. Initial results indicated that using 2 µl: 1 µl protein to well solution ratio resulted 
in precipitation of the protein and not crystal formation. Small, needle shaped crystals were 
obtained when using a 1.5 µl: 1.5 µl protein to well solution ratio in the presence of 1.5 M 
to 1.8 M ammonium phosphate monobasic. Therefore, future crystallization conditions 
were based around these initial results. Many large batches of cells were grown, purified, 
and used in crystal trials. A summary of the most promising conditions that yielded crystals 
is depicted in Figure 3-3.   
While conditions were optimized for production of crystals in the absence of 
peptide, any time monomethylated peptide was present in the crystallization attempts, 
either no crystals, or crystals of very small size formed. At this point, we turned to wider 
screening for any conditions that would yield crystals in the presence of peptide. Purified 
protein was taken to the lab of Dr. Chris Hill at the University of Utah where a Phenix 
crystallization robot was used to set up many conditions at once using much lower volumes 
of protein, effectively allowing us to screen hundreds of conditions using the same amount 
of protein needed to set up one 24 well hand tray. Two new conditions were obtained from 
this effort that yielded crystals in the presence of JMH1W-CH3 peptide 
(KGGFGGR(CH3)GGFGGKW) (0.2 M magnesium acetate, 0.1 M sodium cacodylate pH 
6.5, 30% (v/v) 2-methyl-2,4-pentanediol) (0.1 M bicine pH 9.0, 2% (v/v) 1,4 dioxane, 10% 
w/v PEG 20,000). Sitting drop vapor diffusion hand trays were then set up around these 
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FIGURE 3-3. Summary of initial S14-PRMT1 crystallization conditions. The initial 
conditions found to produce S14-PRMT1 crystals are described in detail, along with the 
concentration of protein and substrates present and the shape of the resulting crystals. 
 
conditions, but unfortunately these crystals were salt, rather than protein crystals. We 
turned once again to trying to optimize the published crystallization conditions to grow 
crystals in the presence of peptide. Eventually, crystals containing S14-PRMT1- AdoHcy- 
eIF4A1-CH3 (YIHRIGR(CH3)GGR) were grown that produced good quality diffraction 
pattern when sent to the Stanford Synchrotron Radiation Lightsource. The structure was 
solved by molecular replacement using the existing PRMT1 structure (PDB: 1OR8) as a 
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search model. Unfortunately, although some density was present in the active site where 




FIGURE 3-4. Diffraction pattern and electron density of PRMT1 crystal containing 
the eIF4A1-CH3 peptide. A crystal of S14-PRMT1-AdoHcy-eIF4A1-CH3 is shown along 
with two frames of a typical diffraction pattern that was used to solve the structure. 
However, there was not enough density visible in the active site to build the peptide 
substrate.  
 
 Given the lack of success in attaining a PRMT1 structure with a peptide substrate 
bound, a strategic decision was made to focus on attaining a structure with a protein 
substrate bound instead. The use of protein substrates is advantageous since these are the 
substrates PRMT1 methylates in vivo. Additionally, the length of a protein substrate is 
much greater than that of any peptide and a structure would yield a clearer picture of how 
substrate interactions far away from the PRMT1 active site contribute to determining 
whether a specific arginine-containing motif is a PRMT1 substrate. This is significant since 
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previous work in the Hevel lab showed that a single amino acid change in the helicase 
eIF4A1 (a PRMT1 protein substrate) from ‘RGG’ to ‘RSG’ (to mimic the sequence found 
in eIF4A3, which is not normally a PRMT1 substrate) abolished methylation by PRMT1. 
However, when the same RGG to RSG change was made in a peptide substrate methylation 
was retained, suggesting that sequences distant from the site of methylation are important 
in influencing the PRMT1 substrate specificity (14). For these reasons, all efforts were 
aimed at obtaining a structure of PRMT1 in complex with a protein substrate.  
Hmt1: Protein Substrate Interaction Analysis— As previously mentioned, two 
PRMT1 crystals structures have thus far been solved, one from rat PRMT1, and one from 
yeast PRMT1, also called Hmt1 (heterogeneous nuclear ribonucleoprotein 
methyltransferase). Hmt1 is the major arginine methyltransferase in Saccharomyces 
cerevisiae and is the only known type I PRMT in this organism. Surprisingly, while 
mammalian PRMT1 is essential for survival, yeast HMT1 is not essential for normal yeast 
growth unless the HMT1 knockouts are combined with mutations in the Npl3 protein (15). 
Npl3 is a major Hmt1 substrate that functions to shuttle mRNA between the nucleus and 
the cytoplasm (15). Functionally, inactivation of Hmt1 decreases the nuclear export of its 
major known substrates, Hrp1 and Npl3 (15), implicating arginine methylation in the 
regulation of mRNA and ribonucleoprotein (mRNP) export.  
Npl3 is a heterogeneous nuclear ribonucleoprotein that contains a C-terminal 
domain rich in arginine and serine residues that are essential for its role in RNA transport. 
Methylation directly affects Npl3 export by weakening contacts with nuclear proteins (16). 
Efficient export does not require methylation, but unmethylated arginine residues lead to 
nuclear retention of hnRNPs and previous data has also shown that the C-terminal domain 
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of Npl3 alone (Cterm) can partially rescue RNA transport in Npl3-deficient cells (16). 
Given the importance of arginine methylation by Hmt1 on Npl3, these two proteins were 
chosen for our guided attempts at crystallization of Hmt1 in complex with a protein 
substrate.  
The Npl3 protein is composed of a long, unstructured N-terminus, two RNA 
recognition motifs (RRMs), and a long arginine and serine (RS) rich C-terminal domain. 
While the RRM motifs have a conserved secondary structure (which has been solved by 
NMR (17)), the rest of the protein is predicted to be largely unstructured. Interestingly, the 
long C-terminal domain of Npl3 contains 15 RGG, 3RG, and 2RxR peptides (starting at 
R284 in Figure 3-5), all of which are potential methylation sites. Importantly, the RS-rich 
C-terminal domain of Npl3 alone has been shown to rescue growth of an Δnpl3 strain, 
highlighting its importance for Npl3 function (18).  Mass spectrometry studies have 
identified 16 arginine residues that are dimethylated in vivo, and one additional methylation 
site (16) (Figure 3-5). It was also noted that Npl3 function was greatly affected by lysine 
substitution at methylation sites. Notably, lysine substitutions in the four RGG tripeptides 
at the N-terminus of the RS domain had a greater influence on Npl3 function than mutating 
RGGs closer to the C-terminal end (16). The optimal Hmt1 co-crystallization partner 
should: 1) form a stable complex with Hmt1 and be easily purified, 2) provide enough 
steric bulk to limit binding modes in the crystal, and 3) form quality diffracting crystals. 
With all of this in mind, we set out to create the best possible construct of Npl3 to co-





FIGURE 3-5. Npl3 sequence and arginine methylation sites. The sequence of the Npl3 
protein is shown, the two RNA recognition motifs (RRMs) are colored in light blue, while 
the long C-terminal tail is colored in dark blue. Arginines found exclusively dimethylated 
are marked with a filled circle, while those found monomethylated and dimethylated are 
marked with open circles.  
 
Npl3 Construct Design— Hmt1 constructs were designed both with a His6-tag and 
without any affinity tags in order to study the interaction between Hmt1 and truncated parts 
of Npl3. The design of Npl3 constructs required either the absence or presence of a His6-
tag, which could be cleaved in order to quickly assess Hmt1: Npl3 interaction. All Npl3 
constructs were generated containing an N-terminal His6-tag, followed by a TEV cleavage 
site and a T7 short affinity tag, which is collectively referred to as an HTT7 tag. This design 
allowed us to take advantage of the His6-tag for quick purification, or to cleave the His6-
tag and study Npl3 interaction with Hmt1 via pull-down studies binding Npl3 to a T7 resin. 
Attempts to study the interaction between Hmt1 and Npl3 bound to T7 resin was 
unsuccessful due to the ability of Hmt1 to bind to the T7 resin in a nonspecific fashion 
(data not shown). Subsequent interaction studies were done by binding HTT7-Npl3 
(various constructs) to Nickel resin and determining whether tagless Hmt1 could be co-
purified.   
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FIGURE 3-6. Npl3 constructs designed. Npl3 constructs were designed with an N-
terminal His6-TEV-T7 tag for purification and interaction studies.  Constructs were 
designed to isolate each domain in Npl3 and to test the minimal region and number or 
arginines required for arginine methylation to occur. 
 
While it is known that the Npl3 methylation sites are contained within the C-
terminal tail, it was unknown whether additional regions of the Npl3 protein were required 
for Hmt1 recognition. Therefore, constructs were created containing only RRM1, only 
RRM2, RRM1 and 2, the C-terminal domain only (Cterm), or RRM2 with various lengths 
of C-terminal domain (see Figure 3-6 and table 3-1) in order to minimize the possible 
binding modes while maintaining steric bulk for crystallization.  
The Npl3 constructs were tested for their ability to co-purify tagless Hmt1, and to 
be methylated. Although all constructs presented in Table 3-1 were created, many remain 
to be tested. Ultimately, while work continued to produce an optimal, minimal construct 
which could be methylated and stably bind Hmt1, the Cterm Npl3 construct was used in 
efforts to solve a structure of Hmt1 and a substrate protein complex.  
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Table 3-1. Npl3 construct interaction with Hmt1   
Npl3 construct Residues Able to pull down Hmt1? Methylated? 
Full Length Npl3 1 - 414 yes yes 
RRM1 Npl3 121 - 194 no no 
RRM2 Npl3 199 - 273 no no 
RRM1 and 2 Npl3 121 - 273 no no 
Cterm Npl3 284 - 414 yes yes 
R284 Npl3 1 - 284 no no 
RRM2Rgg286 Npl3 199 - 286 no no 
R290 Npl3 1 - 290 no N/A 
RRM2 Rggf297 Npl3 199 - 297 N/A N/A 
RRM2 Rggf301 Npl3 199 - 301 N/A N/A 
RRM2 Rggf305 Npl3 199 - 305 N/A N/A 
RRM2 Rggf310 Npl3 199 - 310 N/A N/A 
RRM2 Rggf317 Npl3 199 - 317 N/A N/A 
 
Hmt1: Protein Substrate Crystallization and Optimization— For crystallization 
attempts, HTT7 Cterm Npl3 (R284 - 414) and excess tagless Hmt1 cells were mixed and 
purified in tandem. The His6-tag on the Npl3 construct was used to bind to Nickel resin 
and any tagless Hmt1 not in complex with Npl3 was removed during the Nickel resin 
washing steps, assuring that only stable complex was purified. Additionally, because it is 
known that both Npl3 and Hmt1 bind nucleic acids, the lysis and initial wash buffers 
contained 500 mM NaCl in order to break up any weak nucleic acid interactions. After the 
Nickel purification step, the complex was dialyzed to remove excess imidazole and 
subsequently concentrated prior to setting up crystallization trials. The concentration step 
used a 30 kDa cutoff concentrator in order to assure protein complex formation; since the 
Cterm Npl3 construct has a molecular weight of about 15 kDa, any protein not in complex 
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with Hmt1 should flow through the concentrator membrane, assuring that only the larger 
molecular weight complex was used for crystallization.  
Crystallization attempts were first tried at a complex concentration of 16.3 mg/ml 
or 26.86 mg/ml. Crystallization conditions were screened using commercially available 
kits (Natrix, Index, Salt [Hampton Research], and JCSG Core Suites [Qiagen]) by the 
sitting drop vapor diffusion method in 96-well three drop plates, and employing a Gryphon 
crystallization robot (Art Robbins Instruments) with 100 nl protein solution + 300 nl 
mother liquor drops, 200 nl protein solution + 200 nl mother liquor drops, and 300 nl 
protein solution + 100 nl mother liquor drops. The plates were placed in a 4° C 
crystallization chamber and monitored periodically. Initial crystal hits were followed up by 
hand with larger volume crystallization trays using the hanging drop vapor diffusion 
method. A representative summary of the crystal hits found is shown in Figure 3-7.  
As shown in Figure 3-7, most conditions yielding crystals preferentially 
crystallized one protein or the other and only one condition contained both Hmt1 and Cterm 
Npl3. Additionally, these initial crystal hits diffracted poorly with the best crystals reaching 
only about 15 Å resolution. Further optimization of these crystallization conditions, with 
special focus on the condition yielding the protein complex should be able to improve the  
crystal diffraction.  
 
DISCUSSION 
 While much biochemical work has been done to probe the parameters 
guiding PRMT1 substrate specificity (14,19,20), the field has been largely constrained by  
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FIGURE 3-7. Summary of Hmt1 and Cterm Npl3 crystallization conditions. The 
conditions found to produce Hmt1, Cterm Npl3, or Hmt1-Cterm Npl3 complex crystals are 
described. Crystal shapes and the proteins present in each crystal are also shown. 
 
the absence of a crystal structure clearly detailing the molecular interactions between 
PRMT1and its substrates. The work reported here aimed to fill this knowledge gap by first 
attempting to solve a structure of PRMT1 in complex with a peptide substrate, and later 
with a protein substrate.  
 The basic strategy outlined by the only available structure of PRMT1 with a 
substrate (PDB ID: 1OR8) was modified in an attempt to solve a similar structure with a 
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monomethylated peptide substrate. Although unsuccessful in attaining additional 
information about substrate binding, the work summarized in this chapter has helped in 
solving the structure of a PRMT1 variant (21), and should serve as a guide for future 
attempts at solving a seemingly elusive substrate bound PRMT1 structure. In hindsight, the 
use of phosphate buffer in purifying the rat PRMT1 protein was likely responsible for the 
many salt crystals obtained during the initial screening phase and should be avoided for 
any future crystallization attempts. Hepes buffers were used in the second phase of this 
work (Hmt1/Npl3) and there was a steep decline in the number of salt crystals obtained 
from initial crystallization screens. Since this work was done we have also learned that 
PRMT1 is under redox control and is susceptible to oxidation in air (22). Any future 
PRMT1 crystallization attempts should maintain reductant in all steps of purification in 
order to minimize protein heterogeneity.  
 The choice of substrate for co-crystallization is also critical in obtaining a complex 
with clear substrate density. A peptide substrate containing a single methylatable arginine 
should be targeted to avoid the shifting observed with the R3 substrate, and the sequence 
and KD of the peptide also need to be considered when choosing the optimal crystallization 
partner, Work by Osborne et al. using variants of the H4-21 peptide (Ac-
SGRGKGGKGLGKGGAKEHRKV) showed that C-terminal basic residues are important 
for substrate recognition (20). For this reason, it will be important to maintain a positive 
patch in the peptide sequence for PRMT1. The dissociation constant (KD) of most peptide 
substrates have been reported in the low micromolar rage and may limit the success of 
solving a structure of PRMT1 in complex with a peptide. For example, the KD determined 
by Dr. Gui in our lab for the eIF4A1-CH3 peptide which could not be observed in the 
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previously mentioned structure is 2.61 ± 0.20 µM, while the KD for the H4-21 peptide is 
0.080 ± 0.018 µM (data generated by Dr. Laurel Gui in Hevel lab), indicating this peptide 
is much better suited for co-crystallization. In fact, and as will be discussed later, structures 
of other PRMT isoforms have been solved recently with the H4-21 peptide bound. While 
the H4-21 peptide associates strongly with PRMT1, the KD of the monomethylated version 
is 1.33 ± 0.12 µM, making it a less suitable substrate for co-crystallization. Although a KD 
for a protein substrate has not been reported, a variety of substrate proteins are able to 
precipitate with PRMT1, indicating that PRMT1 forms stronger interaction with protein 
substrates; making the use of a protein substrate likely a more successful strategy for co-
crystallization attempts.  
The structures of human PRMT5 (hPRMT5) and Trypanosoma brucei PRMT7 
(TbPRMT7) containing portions of histone H4 substrate peptide have been published. 
Although the substrate bound structure of these type II and type III, PRMTs have helped 
identify how the histone H4 peptide substrate is bound by each of these isoforms, progress 
has not been made in deciphering the PRMT1 substrate binding mechanism. However, the 
differences and similarities in binding modes between the hPRMT5 and TbPRMT7 
structures may help indicate what features may be specific to each isoform, or conserved 
among the PRMTs. The substrate arginine is projected into the active site of hPRMT5 at 
the tip of a sharp β-turn in the peptide substrate In contrast, the peptide substrate TbPRMT7 
forms a wide turn on the surface of the active site (9,23). These differences seem to indicate 
that hPRMT5 requires flexibility in the substrate sequence immediately surrounding the 
target arginine in order to form a sharp β-turn, whereas no such constraints seem necessary 
for TbPRMT7 substrates to bind into the active site. However, these generalizations are 
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speculative since only one substrate bound structure has emerged for each isoform and 
different binding modes may likely exist for different substrates, a possibility suggested by 
the current PRMT1 substrate bound structure (6). The R3 
(GGRGGFGGRGGFGGRGGFG) peptide substrate co-crystallized with rat PRMT1 was 
mapped onto the PRMT1 core as patches of backbone density along three possible peptide 
binding grooves with only an arginine residue clearly identifiable in the active site. The 
presence of the three binding grooves led to the theory that different PRMT1 substrates 
might interact with PRMT1 using different binding modes through different binding 
grooves. In support of this theory, biochemical manipulation of a residue on one of these 
grooves resulted in an altered pattern of PRMT1 methylation on hypomethylated cell 
extracts, inhibiting the methylation of some proteins while leaving the methylation of 
others unchanged (24).  
 Similar to what was observed in the hPRMT5 and TbPRMT7 structures, binding of 
the R3 peptide to rPRMT1 seems to occur mainly through backbone interactions.  This 
observation is also supported by substrate profiling studies which have shown little to no 
consensus sequence for substrate recognition by PRMT1 (14,19), (although there is a 
prevalence of ‘RGG’, ‘RXR’, and ‘RG’ sequences observed in vivo). The presence of 
glycine around the targeted arginine builds conformational flexibility into the region of 
methylation that may be a requirement of specific binding modes.  Alternatively, the 
prevalence of glycine could reflect the physical contortions that substrates must commit to 
in order to access an active site situated in the rim of the dimeric structure. Additional 
PRMT structures with various substrates are critical to be able to answer many of these 
questions and should be the focus of future work.  
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  This chapter has summarized crystallization efforts aimed at determining the 
molecular details of how PRMT1 is able to interact with substrates. Although a structure 
was not achieved, this work was able to narrow down several crystallization conditions that 
can serve as a road map for future crystallization attempts. The recently obtained structures 
of hPRMT7 and TbPRMT7 bound to H4 peptide substrates highlight the need for substrate 
bound PRMT structures.   
 
REFERENCES 
1. Pawlak, M. R., Scherer, C. A., Chen, J., Roshon, M. J., and Ruley, H. E. (2000) 
Arginine N-methyltransferase 1 is required for early postimplantation mouse 
development, but cells deficient in the enzyme are viable. Molecular and cellular 
biology 20, 4859-4869 
 
2. Bedford, M. T., and Richard, S. (2005) Arginine methylation an emerging regulator 
of protein function. Mol. Cell 18, 263-272 
 
3. Bedford, M. T., and Clarke, S. G. (2009) Protein arginine methylation in mammals: 
who, what, and why. Mol. Cell 33, 1-13 
 
4. Jung, C. S., Oldfield, E. H., Harvey-White, J., Espey, M. G., Zimmermann, M., 
Seifert, V., and Pluta, R. M. (2007) Association of an endogenous inhibitor of nitric 
oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid 
hemorrhage. J. Neurosurg. 107, 945-950 
 
5. Kirmizis, A., Santos-Rosa, H., Penkett, C. J., Singer, M. A., Green, R. D., and 
Kouzarides, T. (2009) Distinct transcriptional outputs associated with mono- and 
dimethylated histone H3 arginine 2. Nat. Struct. Mol. Biol. 16, 449-451 
 
6. Zhang, X., and Cheng, X. (2003) Structure of the predominant protein arginine 
methyltransferase PRMT1 and analysis of its binding to substrate peptides. 
Structure 11, 509-520 
 
7. Zhang, X., Zhou, L., and Cheng, X. (2000) Crystal structure of the conserved core 
of protein arginine methyltransferase PRMT3. EMBO J. 19, 3509-3519 
 
77 
8. Troffer-Charlier, N., Cura, V., Hassenboehler, P., Moras, D., and Cavarelli, J. 
(2007) Functional insights from structures of coactivator-associated arginine 
methyltransferase 1 domains. EMBO J. 26, 4391-4401 
 
9. Antonysamy, S., Bonday, Z., Campbell, R. M., Doyle, B., Druzina, Z., Gheyi, T., 
Han, B., Jungheim, L. N., Qian, Y., Rauch, C., Russell, M., Sauder, J. M., 
Wasserman, S. R., Weichert, K., Willard, F. S., Zhang, A., and Emtage, S. (2012) 
Crystal structure of the human PRMT5:MEP50 complex. Proceedings of the 
National Academy of Sciences 109, 17960-17965 
 
10. Wang, C., Zhu, Y., Chen, J., Li, X., Peng, J., Chen, J., Zou, Y., Zhang, Z., Jin, H., 
Yang, P., Wu, J., Niu, L., Gong, Q., Teng, M., and Shi, Y. (2014) Crystal structure 
of arginine methyltransferase 6 from Trypanosoma brucei. PLoS One 9, e87267 
 
11. Hasegawa, M., Toma-Fukai, S., Kim, J. D., Fukamizu, A., and Shimizu, T. (2014) 
Protein arginine methyltransferase 7 has a novel homodimer-like structure formed 
by tandem repeats. FEBS Lett. 588, 1942-1948 
 
12. Cheng, Y., Frazier, M., Lu, F., Cao, X., and Redinbo, M. R. (2011) Crystal structure 
of the plant epigenetic protein arginine methyltransferase 10. J. Mol. Biol. 414, 106-
122 
 
13. Tang, J., Frankel, A., Cook, R. J., Kim, S., Paik, W. K., Williams, K. R., Clarke, 
S., and Herschman, H. R. (2000) PRMT1 is the predominant type I protein arginine 
methyltransferase in mammalian cells. J. Biol. Chem. 275, 7723-7730 
 
14. Wooderchak, W. L., Zang, T., Zhou, Z. S., Acuna, M., Tahara, S. M., and Hevel, J. 
M. (2008) Substrate profiling of PRMT1 reveals amino acid sequences that extend 
beyond the "RGG" paradigm. Biochemistry 47, 9456-9466 
 
15. Shen, E. C., Henry, M. F., Weiss, V. H., Valentini, S. R., Silver, P. A., and Lee, M. 
S. (1998) Arginine methylation facilitates the nuclear export of hnRNP proteins. 
Genes Dev. 12, 679-691 
 
16. McBride, A. E., Cook, J. T., Stemmler, E. A., Rutledge, K. L., McGrath, K. A., and 
Rubens, J. A. (2005) Arginine methylation of yeast mRNA-binding protein Npl3 
directly affects its function, nuclear export, and intranuclear protein interactions. J. 
Biol. Chem. 280, 30888-30898 
 
17. Deka, P., Bucheli, M. E., Moore, C., Buratowski, S., and Varani, G. (2008) 
Structure of the yeast SR protein Npl3 and Interaction with mRNA 3'-end 
processing signals. J. Mol. Biol. 375, 136-150 
 
78 
18. McBride, A. E., Conboy, A. K., Brown, S. P., Ariyachet, C., and Rutledge, K. L. 
(2009) Specific sequences within arginine-glycine-rich domains affect mRNA-
binding protein function. Nucleic Acids Res. 37, 4322-4330 
 
19. Bicker, K. L., Obianyo, O., Rust, H. L., and Thompson, P. R. (2011) A 
combinatorial approach to characterize the substrate specificity of protein arginine 
methyltransferase 1. Mol. Biosyst. 7, 48-51 
 
20. Osborne, T. C., Obianyo, O., Zhang, X., Cheng, X., and Thompson, P. R. (2007) 
Protein arginine methyltransferase 1: positively charged residues in substrate 
peptides distal to the site of methylation are important for substrate binding and 
catalysis. Biochemistry 46, 13370-13381 
 
21. Gui, S., Wooderchak, W. L., Daly, M. P., Porter, P. J., Johnson, S. J., and Hevel, J. 
M. (2011) Investigation of the molecular origins of protein-arginine 
methyltransferase I (PRMT1) product specificity reveals a role for two conserved 
methionine residues. The Journal of Biological Chemistry 286, 29118-29126 
 
22. Morales, Y., Nitzel, D. V., Price, O. M., Gui, S., Li, J., Qu, J., and Hevel, J. M. 
(2015) Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. 
J. Biol. Chem. 290, 14915-14926 
 
23. Wang, C., Zhu, Y., Caceres, T. B., Liu, L., Peng, J., Wang, J., Chen, J., Chen, X., 
Zhang, Z., Zuo, X., Gong, Q., Teng, M., Hevel, J. M., Wu, J., and Shi, Y. (2014) 
Structural determinants for the strict monomethylation activity by trypanosoma 
brucei protein arginine methyltransferase 7. Structure 22, 756-768 
 
24. Lee, D. Y., Ianculescu, I., Purcell, D., Zhang, X., Cheng, X., and Stallcup, M. R. 
(2007) Surface-scanning mutational analysis of protein arginine methyltransferase 
1: roles of specific amino acids in methyltransferase substrate specificity, 





HMT1 REGULATION BY THE AIR1/2 PROTEINS 
 
ABSTRACT 
PRMTs are crucial enzymes that affect a multitude of biological processes and 
pathways by posttranslationally methylating protein arginine residues. However, despite 
the knowledge that dysregulation of PRMTs leads to disease, very little is currently known 
about how the PRMT proteins are regulated. Evidence suggests the Air1/2 proteins may 
regulate Hmt1 (yeast PRMT1) activity, but the mechanism of regulation is unknown.  Here 
we provide the first data to show that while Air1 is a regulator of Hmt1 activity, the Air2 
protein does not have a significant effect on methyltransferase activity. We have 
determined that a ~60 amino acid region of the Air1 protein is sufficient for the inhibition 
of Hmt1 activity. Interestingly, this same region of Air1 is necessary for interactions with 
Trf4, a member of the nuclear RNA surveillance TRAMP complex. We also present 
conditions used to generate a crystal containing an Air2-Hmt1 complex that has produced 
3.2 Å quality data that will be used to solve the structure of this complex. This could be the 
first structure showing how a protein interacts with any of the PRMTs and could lead to 
insights on how Air2 binds and interacts with Hmt1. 





 Protein arginine methyltransferase (PRMT) activity has emerged as an important 
player in numerous essential biological processes (1,2). Several disease states have been 
linked to dysregulation of arginine methyltransferase activity (3-10), marking PRMTs an 
important potential drug targets (11). However, before significant progress can be made in 
this area, the general knowledge of the regulation of PRMTs needs to be dramatically 
increased. In fact, despite the large number of pathways known to be affected by arginine 
methylation, very little is currently known about how arginine methyltransferase activity 
is affected by protein regulators.  
 Nine PRMT isoforms have been described in humans, and four have been described 
in Saccharomyces cerevisiae (Rmt2, Hsl7, Sfm1, and Hmt1)(12). Each of the yeast PRMTs 
exhibits unique product specificity (Figure 4-1). Rmt2 is a type IV PRMT that methylates 
the -nitrogen of arginine, an activity currently observed only in yeast (13). Hsl7 is a type 
II PRMT capable of forming monomethylarginine (MMA) and symmetric 
dimethylarginine (sDMA) (14). Sfm1 is a SPOUT methyltransferase family member 
tentatively classified as a type III PRMT, since only MMA formation has been observed 
(15). Hmt1, the predominant S. cerevisiae arginine methyltransferase, is a type I PRMT 
capable of both MMA and asymmetric dimethylarginine (aDMA) formation. Hmt1, like 
its human homolog PRMT1, is responsible for most PRMT activity in S. cerevisiae, 
accounting for about 66% of all MMA and 89% of all ADMA formed in vivo (16,17). 
While the number of identified Hmt1 substrates continues to grow (18), the best 
characterized substrates are RNA binding proteins such as Npl3 and Hrp1. Although the 
full effect of methylation on such proteins is still unclear, Hmt1 activity has been shown to 
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facilitate the export of mRNA-shuttling proteins from the nucleus, thus implicating Hmt1 
methylation in nucleocytoplasmic RNA transport (19). Given that Hmt1 is the only known 
type I PRMT in S. cerevisiae and seems to function as the work horse of yeast arginine 
methylation, Hmt1 serves as a good model on which to study how other proteins are able 
to regulate PRMT activity. In all organisms, only a handful of proteins have been reported 
to modulate PRMT1 activity (1). In S. cerevisiae, the Air1 protein is the only protein to 
have a proven role in regulating yeast arginine methylation (20).  
 
 
FIGURE 4-1. Reactions catalyzed by yeast protein arginine methyltransferases. Four 
types of PRMTs are present in yeast and are classified by the products formed. The type I 
PRMT, Hmt1 can form MMA and aDMA. The type II Hsl7 can form MMA and sDMA. 
The Sfm1 protein has only been found to catalyze MMA formation and is classified as a 
type III. The type IV Rmt2 catalyzes the monomethylation of the -nitrogen of arginine, 
making -MMA.  
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Air1 and Air2, or Arginine methyltransferase-interacting RING finger proteins 1 
and 2, were discovered in 2000 by Inoue et al. in a study aimed at finding Hmt1-interacting 
proteins in S. cerevisiae (20). This report went on to show that Air1 can inhibit Hmt1 
methylation of the Npl3 protein, both in vivo and in vitro (20). Although not specifically 
tested, the high degree of similarity between Air1 and Air2, along with functional overlap 
suggested from single and double knockout experiments in which severe growth defect 
was observed only when both proteins were absent, led to the suggestion that Air1 and Air2 
may both regulate Hmt1 activity (20). Even though this discovery occurred over a decade 
ago, the interaction has not been explored further until now.  
 The primary function of the Air1/2 proteins is within the TRAMP 
(Trf5(4)/Air1(2)/Mtr4 polyadenylation) complex. The TRAMP complex is an essential 
exosome cofactor that is able to recognize a wide variety of RNA substrates including 
aberrant forms of tRNAs, rRNA processing intermediates, snoRNAs, and cryptic unstable 
transcripts (21-24). The TRAMP complex recognizes a particular RNA substrate and adds 
a short poly-adenylate tail to the 3’ end of the RNA, stimulating it for degradation by the 
nuclear exosome (Figure 4-2) (23,25).  
The nuclear exosome is conserved in eukaryotes from yeast to humans, and 
homologs of TRAMP components are found in many organisms as well, including humans 
(26,27). In the TRAMP complex, Mtr4 is a helicase which unwinds substrate RNA 
secondary structure before delivery to the exosome. Trf5 and Trf4 are RNA specific 
poly(A) polymerases that add short (4-5) poly(A) tails to the 3’ end of the RNA substrate 
which targets the RNA for degradation; either one can be found as part of the TRAMP 
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FIGURE 4-2. The TRAMP complex is an essential nuclear exosome cofactor. The 
TRAMP complex is composed of Trf4/5, Air1/2, and the Mtr4 helicase. TRAMP adds short 
poly(A) tails to the 3’ end of substrate RNA, which targets the RNA for degradation by the 
exosome.  
 
complex. The homologs Air1 and Air2 are putative RNA binding proteins with 45% 
sequence similarity, each composed of a core (68% sequence identity in core) containing 
five zinc knuckle motifs (C-X2-C-X4-H-X4-C) flanked by extended N- and C-terminal 
sequences which are predicted to be largely unstructured (Figure 4-3). The zinc knuckle 
(also commonly called zinc finger) motifs are typically found to fold into reverse turns, 
coordinating a zinc ion using one histidine and three cysteine residues, and are known for 
their ability to bind RNA (28,29), although these motifs have been shown to bind DNA 
and proteins as well (30-32). Either Air1 or Air2 can be found as part of the TRAMP 
complex, suggesting they may be functionally redundant in this complex. One of the most 
intriguing questions regarding the TRAMP complex is how it is capable of identifying a 
84 
vast number of RNA targets which have no obvious sequence or secondary structure in 
common. The Trf4/5 proteins lack a recognizable RNA binding motif, suggesting that it is 
the Air1/2 proteins that provide RNA binding function, likely through the use of the zinc 
knuckle motifs. Recently, a crystal structure of the catalytic core of Trf4 and a fragment of 
Air2 (zinc knuckles 4 and 5) showed that these two zinc knuckles serve in the interaction 
of Air2 with Trf4 (32). This study was also able to demonstrate that in vitro, zinc knuckle 
one of Air2 enhances polyadenylation of some tRNAs by Trf4. This is the only report that 
has shown any part of Air2 being involved in substrate discrimination. Presumably, Air1 
would interact with Trf5 in a very similar manner. While the role Air1/2 play in substrate 
recognition as part of the TRAMP complex is still not fully understood, the regulation of 
Hmt1 by the Air1/2 proteins creates an interesting link between nuclear RNA surveillance 
and Hmt1 methylation. Therefore, understanding how the Air1/2 proteins function to 
regulate Hmt1 activity will not only yield valuable information regarding PRMT regulatory 
mechanisms, but given the role of Hmt1 in facilitating mRNA export, regulation by the Air 
proteins which have an established role in RNA surveillance hints at a functional role for 
Hmt1 in the RNA regulation of S. cerevisiae.  
 In order to understand Hmt1 regulation by the Air1/2 proteins, I have worked in 
collaboration with the Johnson lab (Utah State University) whose main research focus is 
the TRAMP complex, to express and purify recombinant Air1 and Air2 for 
methyltransferase inhibition studies. Several constructs of both Air1 and Air2 were created 
to map the areas of interaction with Hmt1, and to determine the minimal region necessary 
for Hmt1 inhibition. The solubility and stability of the Air proteins proved to be the limiting 
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FIGURE 4-3. Air1 and Air2 sequence alignment. Both Air1 and Air2 contain five zinc 
knuckle motifs within their core region. These are flanked by N-terminal and C-terminal 
sequences predicted to be primarily unstructured.  
 
factor for these studies, and therefore a full characterization of the mode of inhibition could 
not be attained. However, attempts to determine the molecular level details of the 
interaction between Hmt1 and the Air proteins via co-crystallization have shown 
significant promise and will be the focus of future efforts.  
  
EXPERIMENTAL PROCEDURES 
Materials— AdoMet was purchased from Sigma as a chloride salt (≥80%, from 
yeast).  [3H]AdoMet (83.1 Ci/mmol) was purchased from Perkin Elmer. ZipTip®C4/C18 
pipette tips were purchased from Millipore. The R3 (acGGRGGFGGRGGFGGRGGRG), 
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JMH1W (KGGFGGRGGFGGKW), and RKK (GGRGGFGGKGGFGGKW) peptides 
were synthesized by the Keck Institute (Yale  
University) and purified to ≥ 95%.  
Expression and Purification of Hmt1— E. coli BL21 cells expressing His6-tagged 
Hmt1 were grown in Luria Broth media at 37° C to OD600 reached 0.6, followed by 
induction with 0.5mM IPTG at 22° C for 20 hours. Cell pellets were resuspended in two 
times cell volume lysis buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 20 mM 
imidazole) and lysed using sonication. The cell lysate was clarified via centrifugation and 
incubated with Nickel resin (GoldBio) in a 1:1 cell mass: resin ratio for 1-2 hours at 4° C. 
The resin was washed eight times with eight column volumes of lysis buffer modified to 
contain 500 mM NaCl, followed by three washes with eight column volumes of wash 
buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 70 mM imidazole). The protein 
was then eluted off the resin five times with two column volumes of elution buffer (50 mM 
sodium phosphate pH 7.5, 100 mM NaCl, 250 mM imidazole). Elutions were pooled and 
dialyzed into 50 mM Hepes pH 7.5, 10% glycerol. The protein was then concentrated, 
aliquoted, and flash frozen in liquid nitrogen prior to storage at -80° C.  
Expression and Purification of Air Proteins (Done by Johnson lab)— Air1 and 
Air2 constructs were created, expressed, and purified in the Johnson Lab as previously 
described (33). In brief, His6-tagged and His6_TEV_FLAG-tagged (HTFlag) codon 
optimized Air1 and Air2 constructs were created. Expression constructs were transformed 
into in BL21 (DE3) codon+ RIL E. coli cells (Agilent Technologies). Overnight starter 
cultures were grown at 37° C in 30 ml LB media supplemented with 250 µM ZnSO4 and 
appropriate antibiotics. Approximately 5 ml starter culture was used to inoculate each 500 
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ml LB growth flask that had also been supplemented with 250 µM ZnSO4 and appropriate 
antibiotics. The cell growths were incubated at 37° C until OD600 reached 0.6-0.8, at which 
point protein expression was induced with the addition of 0.3 mM IPTG. The cultures were 
then incubated at room temperature for 16 hours, harvested by centrifugation, and dry cell 
pellets were stored at -80° C until used.  
 To purify the Air1/2 protein constructs, cells were resuspended in lysis buffer (50 
mM Hepes pH 7.5, 500 mM NaCl, 2 mM β-mercaptoethanol, 200 µM ZnSO4, 10% 
glycerol, 10 mM imidazole, 1 µg/ml aprotinin, 1.4 µg/ml pepstatin, 1 µg/ml leupeptin, and 
0.2 mg/ml lysozyme), using 3 ml of buffer for every gram of cells.  Cells were lyzed by 
sonication and cleared lysate was incubated with 5 ml GoldBio or GE Nickel affinity resin 
for 1 hour at 4° C. The Nickel resin was then washed with 700 ml lysis buffer (without 
protease inhibitors or lysozyme), followed by 200 ml of high salt buffer (50 mM Hepes pH 
7.5, 1 M NaCl, 2 mM β-mercaptoethanol, 200 µM ZnSO4, 10% glycerol) and then low salt 
buffer (100 ml of 50 mM Hepes pH 7.5, 150 mM NaCl, 2 mM β-mercaptoethanol, 200 µM 
ZnSO4, 10% glycerol). The protein was then eluted from the resin three times with 20 ml 
of 50 mM Hepes pH 7.5, 150 mM NaCl, 2 mM β-mercaptoethanol, 200 µM ZnSO4, 10% 
glycerol, 500 mM imidazole, allowing the elution buffer to incubate with the resin for 5 
minutes prior to elution. The three Nickel elutions were then polled and loaded onto a 5 ml 
Heparin column (GE), which was then run using a 100 ml gradient from 0 to 100% low 
salt to high salt buffer as used in the Nickel step, except without ZnSO4 present. For 
inhibition studies, the protein peaks were then collected, concentrated and buffer 
exchanged in a 10kDa cutoff concentrator (Millipore) to the low salt buffer. The 
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concentrated to protein (~ 0.5 mg/ml) were then be aliquoted and flash frozen in liquid 
nitrogen prior to storage at -80° C.    
 For the constructs Air2 N-ZnK5, Air2 N-ZnK3, and Air1 ZnK4-5, the proteins were 
purified on Nickel resin as noted above, but then loaded onto a 5 ml MonoQ column (GE) 
instead of Heparin. The contaminants would bind to the column while these constructs 
would not. Therefore, the flow through would be collected, concentrated, buffer 
exchanged, and frozen as described above.  
 It should also be noted that all Air1/2 inhibition data shown in this chapter 
corresponds to His6-tagged Air1/2 constructs. HTFlag constructs were used for binding 
studies and were also tested for inhibition but no effect was detected with any HTFlag Air1 
constructs, indicating this longer tag was somehow able disrupt the Air1 inhibition of 
Hmt1. 
Expression and Purification of Npl3— His6-tagged full length Npl3 (pAM436) 
was a generous gift from Dr.  Ann McBride (Bowdoin University). E. coli BL21 NiCo21 
(DE3) cells expressing His6-Npl3 protein were grown in Luria Broth media at 37° C until 
OD600 reached 0.6, followed by induction with 0.5 mM IPTG at 22° C for 20 hours. Cell 
pellets were resuspended in two times cell volume lysis buffer (50 mM sodium phosphate 
pH 7.5, 500 mM NaCl, 20 mM imidazole) and lysed by sonication. The cell lysate was 
clarified via centrifugation and incubated with Nickel resin (GoldBio) in a 2:1 cell mass to 
resin ratio for 1-2 hours at 4° C. The resin was washed eight times with eight column 
volumes of lysis buffer, followed by three washes with eight column volumes of wash 
buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 70 mM imidazole). The protein 
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was then eluted off the resin five times with two column volumes of elution buffer (50 mM 
sodium phosphate pH 7.5, 100 mM NaCl, 500 mM imidazole). Elutions were pooled, 
filtered and further purified using MonoQ and Heparin columns (GE) in tandem. Fractions 
containing Npl3 were pooled and dialyzed into 50 mM Hepes pH 7.5, 10% glycerol. The 
protein was then concentrated to ≥ 1mg/ml, beaded in liquid nitrogen, and stored at -80° 
C.    
Methyltransferase Activity Assay— A quantitative methylation assay using 
ZipTipC4/C18 pipette tips was used in testing the enzymatic activity under steady-state 
conditions (34). Briefly, methyltransferase activity was tested with 100 nM Hmt1, 2 μM 
AdoMet (1 μM [3H]AdoMet), 380 nM BSA, and 10 nM MTAN (5'-methylthioadenosine 
/S-adenosylhomocysteine nucleosidase) in 50 mM sodium phosphate (pH 8.0), initiated 
with 500 nM Npl3 protein substrate at 30° C. When present, 500 nM Air1/2 (various 
constructs) was added to the reaction mixture and allowed to incubate for 10 minutes on 
ice prior to initiation with substrate. When used, EDTA was present at a 1 mM final 
concentration and RNAse at 15 µg/ml.  At different time points, 5 µl samples were removed 
from reactions, quenched to stop the reaction, and processed with ZipTipC4/C18 pipette tips 
to separate the unreacted [3H]AdoMet from the radiolabeled product. 
Co-expression and Purification of His6 Air2 and N22+2 Hmt1— A pETDuet 
construct containing codon optimized Air2 N-ZnK5 in cloning site 1 (His6-tag) and 
untagged Hmt1K13S in cloning site 2 was obtained from the Johnson lab. The Hmt1K13S 
protein was removed from cloning site 2 using the NdeI and XhoI restriction sites. A 
N22+2 Hmt1 construct was received from Dr. Anne McBride (Bowdoin University) and 
was used as a template for PCR amplification with primers containing a 5’ NdeI site and a 
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3’ XhoI site. This PCR product was ligated into the pETDuet cloning site 2 to create a 
pETDuet vector which co-expressed His6-Air2 N-ZnK5 and untagged N22+2Hmt1.  
The Air2-Hmt1 construct was transformed into BL21 (DE3) codon+ RIL E.coli 
cells. A single colony from a fresh transformation plate was used to inoculate a 50 ml LB 
overnight culture supplemented with 250 μM ZnSO4 and antibiotics (ampicillin and 
chloramphenicol). Approximately 5 ml of the starter culture was used to inoculate each of 
six 500 mL cultures of LB media (also containing 250 μM ZnSO4) in 2.5 L baffled flasks. 
The cell cultures were incubated at 37° C at 300 rpm until an OD600 of 0.3 was reached. 
Protein expression was induced by adding 0.05 mM IPTG. The cultures were then moved 
to a room temperature shaker and adjusted to 200 rpm for 20 hours. The cells were then 
harvested by centrifugation and stored at -80° C until used.  
About 21 g of cells were resuspended in 63 ml of lysis buffer containing 50 mM 
Tris pH 7.5, 50 mM NaCl, 200 µM ZnSO4, 1 µg/ml aprotinin, 1.4 µg/ml pepstatin, 1 µg/ml 
leupeptin, and 0.2 mg/ml lysozyme. The cells were lysed by sonicating at 6/80 four times 
for 20 pulses with 30 second rest on ice in between. The cleared lysate was incubated with 
12 ml Nickel resin in six 15 ml conical tubes (GoldBio) which had been previously 
equilibrated with buffer 1 (50 mM Tris pH 7.5, 50 mM NaCl, 200 µM ZnSO4) for 1 hour 
at 4° C. The resin was then washed fourteen times with 7 ml buffer 1 per tube. Two washes 
were done with 5 ml per tube of 50 mM Tris pH 7.5, 150 mM NaCl, 200 µM ZnSO4, 5 
mM imidazole. The protein complex was finally eluted with 3 ml per tube of elution buffer 
(50 mM Tris pH 7.5, 50 mM NaCl, 200 µM ZnSO4, 250 mM imidazole, 5 mM β-
mercaptoethanol). The elutions were filtered and loaded onto a 5 ml Heparin column (GE) 
at 3 ml/min. Although some Air2 protein stuck to the Heparin column, the complex was 
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found in the unbound fraction which was concentrated down to 5 ml total volume using a 
30 kDa cutoff concentrator (Millipore). The 5 ml of concentrated Air2/Hmt1 complex 
was loaded onto a 120 ml size exclusion column (HiLoadTM 16/60 SuperdexTM 75 prep 
grade (Amersham)) equilibrated with 50 mM Tris pH 7.5, 50 mM NaCl, 200 µM ZnSO4, 
5 mM β-mercaptoethanol, 10% glycerol and run at 1 ml/min for 270 minutes while 
collecting 3 ml fractions.  Fractions 18, 17, and a combination of 14-16 and 19-20 were 
each separately concentrated to ≥ 20 mg/ml (F17 seemed to have a 2:1 Hmt1 to Air2 ratio; 
F18 had an approximately 1:1 ratio). Final concentrations were: F17 = 27.44 mg/ml, F18 
= 23.7 mg/ml, and the mixed fractions = 22.3 mg/ml. Each was used to set up crystal trays 
immediately upon concentrating and the leftover protein was flash frozen in 200 µl aliquots 
and stored at -80° C. Attempts to optimize crystallization conditions used frozen protein 
from each batch. No significant difference was observed in the ability to form crystals 
between the three batches of protein. Prior freezing of the protein complex also did not 
seem to deter crystal formation or crystal quality.  
Crystallization, Crystal Optimization, and Data Collection of Air2/Hmt1 
Complex— Concentrated Air2 (N-ZnK5) and N22+2 Hmt1 described above was used 
for sitting-drop vapor diffusion crystallization screening trials using an Art Robbins 
Gryphon LCP Crystallization Robot (Art Robbins Instruments) located in the Johnson lab. 
Intelli-plate 96-well crystallization plates (Art Robbins Instruments) were used for 
crystallization trials. Five different crystallizations screens each containing 96 individual 
crystallization solutions were used to set up five 96-well crystallization plates for each 
concentrated complex fraction. The crystallizations screens used were the MCSG suite 
(Microlytic) which consist of four different screens (MCSG 1-4), and the Index screen 
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(Hampton Research). Crystallization plates were incubated at 4° C. After one week protein 
crystals were observed in many crystallization conditions and the best looking crystals 
were analyzed for diffraction quality using a home-source X-ray generator (MicroMax-
007HF) and detector (Rigaku R-Axis IV++), as well as being subjected to washing with 
crystallization solution, run on an SDS-PAGE gel and stained with SYPRO Ruby (Sigma) 
to determine the presence of both proteins in the crystal. Several analyzed crystals were 
salt, but the majority were poor diffracting (> 15 Å) protein crystals. One condition from 
the Index screen, position H7 (0.15 M D, L-Malic Acid pH 7.0, 20% PEG3350) showed 
the best diffraction quality (~ 10 Å) and contained both proteins as shown by gel analysis.  
Additional 24-well hanging drop trays were set up to screen around this condition: 
(D, L Malic Acid pH 7.0 was varied from 0.1 M to 0.225 M; the pH was also varied to 6.5, 
7.5, and 8.2; PEG 3350 concentrations were varied from 19% to 20.5%). In addition, two 
hanging drop hand trays were set up with the original Index H7 condition to test the effect 
of additives. Using the F18 protein complex in a 1:3 and 2:2 protein to well solution ratio 
with a total drop volume of 4.5 µl which included 0.5 µl of additive from the Hampton 
Research Additive Screen (HR2-428), four drops were set up per well containing 500 µl of 
0.15 M D, L-Malic Acid pH 7.0, 20% PEG 3350. These trays were placed at 4° C and 
crystals were noted after two days. Two additive conditions in the 1:3 ratio tray produced 
large crystals which were analyzed for diffraction quality. The addition of 1 M tri sodium 
citrate yielded crystals diffracting to 8 Å, while the addition of 1 M NDSB-256 improved 
diffraction to ~5 Å. Another hanging drop vapor diffusion tray was set up using 0.15 M D, 
L-Malic Acid pH 7.0, 20% PEG 3350 as the well solution with both 1 M tri sodium citrate 
and 1 M NDSB-256 additives in varying ratios, along with different drop ratios and 
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different well solution volumes. Since most of these conditions produced crystals, the best 
from each were flash frozen in a cryo buffer supplemented with 7.5% glycerol and were 
sent to the Stanford Synchrotron Radiation Lightsource (SSRL) for data collection. 
Ultimately, a 3.2 Å resolution dataset was collected from a crystal grown for 2 days at 4° 
C in a 4.5 µl drop containing 1 µl protein complex (F18 fraction), 3 µl 0.15 M D, L-Malic 
Acid pH 7.0, 20% PEG 3350, and 0.5 µl 2 M NDSB-256 additive. Additionally, an X-ray 
excitation scan was conducted on this crystal at SSRL which detected the presence zinc 
ions, suggesting that the crystal contained Air2 zinc knuckles. Molecular replacement was 
performed using Phaser (35) from the Phenix program suite (36). The search model used 
was N22+2 Hmt1 hexamer (Protein Data Bank entry 1G6Q). 
 
RESULTS  
Air1 and Air2 Interact With Hmt1— The only report of the interaction between 
the Air1/2 proteins and Hmt1 found that Air1 binds directly with Hmt1 and at least the first 
56 amino acids of Hmt1 are essential for the binding of Air1 (20). However, the regions of 
Air1 necessary for binding Hmt1 were not indicated. Additionally, although it was 
suggested that Air2 would likely function in a manner similar to Air1, Hmt1 inhibition or 
binding by the Air2 protein was never proven. Therefore, a partnership was established 
with the Johnson lab at Utah State University in order to identify the regions of Air1, and 
possibly Air2, required for Hmt1 binding. Using the few predicted structural features of 
Air1/2 as a guide (ZnK), several truncated Air1 and Air2 constructs were created and tested 
for their ability to complex with Hmt1 (Figure 4-4-A). It was first established that without 
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the extended C-terminal region, both Air1 and Air2 are able to form a stable complex with 
Hmt1. The Johnson lab was able to perform in vitro pull-down experiments to show that 
truncated Air1 constructs are able to bind Hmt1 (Figure 4-4-B). Notably, the Air1 protein 
region spanning zinc knuckles 4 through 5 is enough to form a stable complex with Hmt1, 
although this does not discount binding by other regions of Air1. Size exclusion 
chromatography studies further established that an Air2 N-ZnK3 construct is sufficient to 
form a stable complex with Hmt1 in vitro (Figure 4-4-C), indicating that while Air2 region 
spanning zinc knuckles 4 through 5 may interact with Hmt1, this region is not necessary 
for stable complex formation. Due to protein availability, it has not been possible to 
determine whether this region alone is able to bind Hmt1. Future studies should attempt to 
clarify whether Air1 and Air2 indeed utilize the same regions for Hmt1 binding. 
Additionally, isolating minimal binding regions of the Air1/2 proteins would facilitate 
quantitative analyses of the binding interactions (as well as potentially enable further 
characterization of the mechanism of Hmt1 inhibition), and may prove promising for use 
in crystallization trials to determine exactly how Air1/2 and Hmt1 interact at the molecular 
level.    
Characterization of the Differential Effects of Air1 and Air2 on Hmt1 Activity— 
Although full length Air1 was previously confirmed to inhibit Hmt1 methylation of Npl3 
both in vitro and in vivo (20), the suggested regulatory role of Air2 on methyltransferase 
activity was never verified. C-terminal truncated constructs of Air1 and Air2 generated by 
the Johnson lab were used in conjunction with an in vitro methyltransferase assay 
developed in the Hevel lab to test their effect on the Hmt1 methylation of Npl3. As depicted 
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FIGURE 4-4. Air1 and Air2 truncated constructs used to test binding to Hmt1 and 
the ability to inhibit Hmt1 activity. (A) Air1 and Air2 truncated constructs are shown. 
All were made with both His6 and His6-TEV-FLAG tags. (B) FLAG-tagged Air 1 N-ZnK5 
and Air1 ZnK4-5 pull down Hmt1 on FLAG resin. Samples were run on SDS-PAGE and 
visualized by anti-His antibody. (C) Purified Hmt1 and Air2 N-ZnK3 co-elute on a size 
exclusion column, forming a complex with apparent 1:1 stoichiometry.  
 
in Figure 4-5, we were able to shown to that Air1 N-ZnK5, even without the C-terminal 
region is able to inhibit Npl3 methylation by Hmt1. In contrast, the Air2 N-ZnK5 construct 
has no significant effect on the ability of Hmt1 to methylate Npl3 (Figure 4-5). This result 
highlights a clear functional difference between the Air proteins.  
Characterization of Air1 Inhibition of Hmt1 Activity— Once Air1 regulation of 
Hmt1 was confirmed, the next step was to characterize what features of Air1 are needed 
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for inhibition of Hmt1. Air1 has no predicted secondary structure, other than the five zinc 
knuckle motifs which are thought to primarily enable Air1 to bind RNA (37,38). Zinc 
knuckles 4 and 5 of Air2 have also been shown to participate in protein-protein binding 
interactions with Trf4, and are believed to also mediate Air1 interactions with Trf5 (32). 
We therefore set out to determine whether RNA-binding or zinc-binding by the Air1 
protein are necessary for Hmt1 inhibition. Our preliminary results (Figure 4-6) show that 
treatment with RNAse has no significant effect on the regulation of Hmt1 activity by Air1. 
However, treatment with EDTA to remove the zinc coordinated by the zinc knuckle motifs 
completely abolished the ability of the Air1 protein to inhibit methyltransferase activity 
(Figure 4-6). Therefore, we conclude that while RNA binding is not important for Air1 
regulatory function, intact zinc knuckle motifs are required for Air1 to inhibit Hmt1 
methylation of Npl3.     
Given the significance of the Air1 zinc knuckle motifs for the regulation of Hmt1, 
we next set out to determine which zinc knuckles are necessary for this effect. Air1 
constructs containing Air1 N-ZnK3 were unable to affect Hmt1 activity, while Air1 N-
ZnK5 and, importantly, Air1 ZnK4-5 constructs were able to inhibit methylation of Npl3 
(Figure 4-7). These results indicate that the minimal region of Air1 required for Hmt1 
regulation lies within the ~60 amino acid region between zinc knuckles 4 and 5. 
Significantly, this is the same region known to regulate the interaction of Air2 with Trf4 
(32). In vivo, Air1 and Air2 are predicted to be the limiting components of the TRAMP 
complex (39). Therefore, the revelation that the same region of Air1 necessary to inhibit 
Hmt1 activity is seemingly required for interaction with Trf5 are puzzling, especially with  
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FIGURE 4-5. Effect of Air2 and Air1 on the methylation of Npl3 by Hmt1. The rate 
of Hmt1 activity on Npl3 was normalized to 100%.  The addition of Air2 N-ZnK5 slightly 
enhanced the rate of Npl3 methylation, but only as typically observed upon the addition of 
more total protein (same as BSA addition, data not shown). The addition of Air1 N-ZnK5 
inhibited activity of Hmt1 on Npl3. Data shown is average of minimum two replicates.  
 
no known evidence that either Air1 or Air2 may exist independently of Trf5 or Trf4 in the 
cell. The potential puzzle aside, the results discovered here may provide an opportunity to 
further narrow the regions of Air1 required for Hmt1 inhibition. Since Air2 does not inhibit 
Hmt1, the residues between zinc knuckles 4 and 5 of Air1 that are not conserved in Air2 
and that are not Trf4/5 binding residues are likely to be the ones responsible for the 
inhibition of Hmt1 (Figure 4-8). Future studies should target these residues. Through either 
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alanine scanning, or the construction of chimeric Air1/2 proteins, it should be possible to 
define the sequences required for Hmt1 inhibition.  
 
 
FIGURE 4-6. Air1 zinc binding is required for inhibitory effect on Hmt1. The percent 
inhibition by Air1 N-ZnK5 on Hmt1 activity is unchanged by the addition of 15 µg RNAse. 
The addition of 1 mM EDTA chelates the zinc from the Air1 protein and abolishes 
inhibition of Hmt1 activity. Single activity measurements shown for the addition of RNAse 





FIGURE 4-7. Air1 zinc knuckles 4 and 5 are required for Hmt1 inhibition. An Air1 
construct missing zinc knuckles 4 and 5 (Air1 N-ZnK3) is unable to inhibit Hmt1 activity, 




FIGURE 4-8. Sequence alignment of Air2 and Air1 zinc knuckles 4 through 5. Strictly 
conserved residues are colored in blue while semi-conserved residues are in light blue. 
Dark blue triangles above indicate Air2 residues shown to interact with Trf4 (PDB: 3NYB). 
Red arrows indicate residues that are not conserved between Air1 and Air2, or required for 




Characterization of the Hmt1-Air Interaction Through Crystallography— A 
crystallographic approach was also pursued to determine the molecular details of the 
interaction between the Air proteins and Hmt1. The Hmt1 protein has been previously 
crystallized with an N-terminal truncation shown to improve crystal formation and 
diffraction (40). The Johnson lab created several constructs for the co-expression of Air2 
and full-length Hmt1 and were successful in obtaining crystals of the complex. However, 
these crystals had poor diffraction quality and could not be used to solve a structure of the 
complex (33). Using the Johnson lab constructs, purification strategy, and crystallization 
conditions as a guide, I attempted to improve upon their efforts by using the N-terminally 
truncated Hmt1 construct that had been previously crystallized in order to enhance crystal 
diffraction.  
 A His6-tagged Air2 N-ZnK5 construct was co-expressed with the N22+2 Hmt1 
construct that had been previously crystallized. Following the Johnson lab optimized 
purification strategy as a guide, ≥ 95% clean Air2-Hmt1 complex was purified and used 
for crystallization trials. Hundreds of new conditions were screened for their ability to 
crystallize this complex, and while several resulted in protein crystals, none provided 
usable X-ray diffraction. We then turned to the crystallization condition previously used 
by the Johnson lab to generate 7 Å diffraction patterns and were able to get crystals that 
contained both proteins (Figure 4-9-A) and that diffracted out to about 10 Å (Figure 4-9-
B).  We then set out to optimize this condition to improve the diffraction quality. Ratios of 
reagents were varied without much improvement. Through the use of an additive screen 
(Hampton Research) we were finally able to produce crystals that diffracted at our home 
X-ray source out to 5 Å (condition: 1 µl Air2/Hmt1 complex, + 3µl well solution (0.15 
101 
M D, L-Malic Acid pH 7.0, 20% PEG 3350) + 0.5 µl additive (1 M NDBS-256)). Several 
crystals grown under these optimized conditions were then sent to the Stanford 
Synchrotron Radiation Lightsource (SSRL) where we were able to collect usable 
diffraction data out to 3.2 Å (Figure 4-9-C).  
 We have been able to solve a partial structure using molecular replacement to place 
six N22+2 Hmt1 molecules into an electron density map. The previously solved 
N22+2 Hmt1 structure was also a hexamer (40). As it stands, no Air2 has yet been built 
into the structure, but there are many areas of open density remaining where Air2 may be 
built. Of slight concern is the fact that the majority of the remaining density appears to have 
secondary structural features not expected to occur in Air2 (Figure 4-10). However, an X-
ray excitation scan was conducted on the crystal at SSRL which detected the presence of 
zinc ions within the crystal. This, along with the previous detection of both Air2 and Hmt1 
in a crystal under this condition (Figure 4-9-A), suggests that Air2 is present. Further work 
will be done to build Air2 into the existing electron density and finally decipher how Air2 
interacts with Hmt1 at the molecular level.  
 Additional work currently underway in the Hevel lab will focus on using a similar 
strategy to solve the structure of Air1 N-Znk5 or Air1 ZnK4-5 in complex with N22+2 
Hmt1. Such a structure will represent the first depiction of how Hmt1 is able to interact 





FIGURE 4-9. Air2 N-ZnK5 and N22+2 Hmt1 complex crystals and diffraction 
patterns. (A) SDS-PAGE analysis of crystal composition shows that both proteins are 
present in the crystals which are shown below. (B) Initial ~10 Å diffraction observed prior 
to optimization of crystallization conditions. (C) Typical diffraction image from 3.2 Å 
dataset collected after crystal optimization.  
 
 
FIGURE 4-10. Initial Air2-Hmt1 electron density map created after molecular 
replacement using N22+2 Hmt1 hexamer as search model. Hmt1 hexamer is shown 
in yellow and symmetry molecules are shown in pink. Empty density will be examined and 
used to build the Air2 structure.  
 
103 
Table 4-1. Data collection statistics for Air2-Hmt1 crystal 
Data Collection  
Space Group C121 
Cell dimensions  
     a, b, c  (Å) 239.4, 103.3, 118.1 
     α, β, γ  (deg) 90.0, 91.97, 90 
Resolution (Å) 50-3.45 (3.6-3.45)a 
Rsym 0.224 (0.987) 
I / σI 6.64 (2.03) 
Completeness (%) 99.8 (99.9) 
Redundancy 6.5 (6.4) 
a Values in parenthesis are for highest-resolution shell.  
 
DISCUSSION 
 This collaborative work has begun to examine the regulation of Hmt1 by the Air1/2 
proteins. We have been able to determine the first functional difference between the Air 
proteins by showing that Air2 is unable to regulate the methylation of Npl3 by Hmt1 
(Figure 4-5). It should be noted that regulation of Hmt1 by Air2 cannot be discounted since 
no other substrates have been tested. One approach to search for Hmt1 substrates that that 
are methylated under the influence Air2 control is to use hypomethylated yeast cell extracts 
from an Air2-null background to test for Hmt1 activity in the absence and presence of Air2 
in order to test whether Air2 may be a substrate-dependent Hmt1 regulator. Additionally, 
it was recently reported that Air2 is an Hmt1 substrate and can be methylated at two 
arginines on the C-terminal tail (41). Arginine methylation of the Air2 C-terminal tail was 
shown to increase the interaction between Air2 and Npl3 (41), indicating that this region, 
which was not included in any of the constructs tested in this work is important and should 
be retained in any future attempts to determine whether Air2 is able to regulate Hmt1.  
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 We have been able to corroborate that Air1 regulates Hmt1 and have identified the 
region between zinc knuckles 4 and 5 as responsible for this regulatory effect (Figure 4-7). 
Although unable to fulfill the initial goal of characterizing the mechanism of inhibition 
(competitive vs. noncompetitive) due to limitations obtaining clean Air1 protein, we were 
able to narrow down the region responsible for inhibition to a ~60 amino acid stretch of 
Air1. Analysis of this region has allowed us to identify specific residues for targeted 
mutagenesis to learn their effect on Hmt1 activity. Additionally, smaller constructs (for 
example, Air1 ZnK4+linker4 and Air1 linker4+ZnK5) should be created to hone in on the 
minimal Air1 region required for Hmt1 regulation. Depending on the length of a minimal 
construct, peptides can be ordered and used to characterize the mechanism of inhibition if 
protein production continues to be an issue.  
 We confirmed that Air1 regulates the methylation of Npl3 (20). Only one additional 
protein substrate, histone H4, was tested in this work.  H4 methylation was also inhibited 
by the presence of Air1 (data not shown). The methylation of all peptide substrates tested 
(JMH1W, R3, and RKK peptides) was also inhibited by Air1 (data not shown). However, 
as is the case with Air2, methyltransferase reactions should be performed on 
hypomethylated yeast cell extracts in the absence or presence of Air1 in order to fully 
assess if Air1 is a broad spectrum Hmt1 regulator of if the effects are substrate dependent. 
 A continuation of work started by the Johnson lab (33) has recently produced 
exciting results in the form of a full 3.2 Å X-ray diffraction dataset which will be used to 
solve the structure of an Air2/Hmt1 complex (Table 4-1). A similar strategy has also 
been recently initiated to solve the crystal structure of an Air1/Hmt1 complex. This 
would be the first structure of Air1, and the first structure detailing how Hmt1 interacts 
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with a regulatory protein. Obtaining the crystal structure of an Air1/Hmt1 complex 
would be a significant addition to the black-box that is PRMT regulation.   
 It is often the case that preliminary results, such as those here presented, are unable 
to answer many specific questions. However, there is immense value in the new questions 
which arise from data such as these. Since it has been shown that Air1 ZnK4 has a role in 
promoting RNA target recognition in the context of the TRAMP complex (42), and we 
have now shown that Air1 ZnK4-5 are implicated in regulating Hmt1 activity, we are left 
with the intriguing question of whether Hmt1 binding to the Air proteins may modulate 
their RNA binding ability or selectivity. It is also interesting to wonder since the TRAMP 
helicase Mtr4 has recently been shown to interact with Hmt1 (43), an interesting question 
is whether  TRAMP has a role in inhibiting Hmt1. Other important questions include: What 
may be the bigger implication of Air1 regulation given the important role of Hmt1 in the 
regulation of mRNA export? Does the human homolog of Air1 (ZCCHC7) regulate human 
PRMT1 activity? There is clearly much work that still needs to be done and a vast extent 
that remains to be learned about the activity and regulation of the PRMTs.  
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INVESTIGATING THE EFFECTS OF PHOSPHORYLATION 
ON HMT1 ACTIVITY 
  
ABSTRACT 
 Protein arginine methyltransferases (PRMTs) are a family of enzymes that can 
methylate arginine residues in substrate proteins. This posttranslational methylation can 
alter the interactome of the modified substrate protein, thereby extending the range of its 
functions. Given that dysregulation or loss of arginine methyltransferase activity has severe 
biological effects, proper regulation of the arginine methyltransferases is of paramount 
importance. It was recently reported that regulation of Hmt1, the major type I PRMT in 
yeast, through posttranslational phosphorylation is necessary for fine tuning cell-cycle 
progression to environmental conditions. Phosphorylation at Serine 9 of Hmt1 resulted in 
an increase in the in vivo methylation of the RNA binding protein Npl3.  Additionally, the 
in vivo effects observed could be mimicked using a glutamate residue at position 9 of 
Hmt1. However, because in vitro studies were not performed, it remains unclear if 
phosphorylation affects the intrinsic activity of Hmt1, or if phosphorylation results in the 
recruitment of another factor, leading to increased activity. Herein, we aimed to 
characterize how phosphorylation affects the methyltransferase activity of Hmt1 in vitro 
through the use of the S9E phosphomimetic and S9A nonphosphorylatable Hmt1 variants. 
We have been unable to obtain clear results and can therefore neither confirm nor negate 
the claim that phosphorylation of Hmt1 is necessary for activation. Our results, however, 
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do indicate that assay conditions, and even the protein tags used can greatly influence the 
rate of Hmt1 activity and should be taken into account for future work.  
 
INTRODUCTION 
Protein arginine methyltransferases (PRMTs) catalyze the addition of one or two 
methyl groups to protein substrates at arginine residues, thereby altering their function. 
Arginine methylation has been shown to mediate protein-RNA, protein-DNA, and protein-
protein interactions (1). In Saccharomyces cerevisiae the methylation of arginine residues 
by the major yeast methyltransferase Hmt1 is associated with several biological functions 
such as nucleocytoplasmic shuttling (2), mRNA and rRNA processing (3), splicing (4), 
translation (5), and transcription through both histone and non-histone proteins (5,6).   
However, despite the lack of a known demethylase and of the magnitude of processes 
affected by arginine methylation, little is known about how arginine methyltransferases are 
regulated.  
The only current report of Hmt1 regulation via a posttranslational modification 
showed that Hmt1 could be phosphorylated at serine 9 in the Hmt1 N-terminal region. In 
a 2013 Cell paper, Messier et al. reported that Hmt1 activity and oligomerization are 
dependent on phosphorylation (7). In this study they generated phosphomimetic (S9E 
Hmt1) and nonphosphorylatable (S9A Hmt1) variants and performed methylation assays 
with immunoprecipitated TAP-S9EHmt1 or TAP-S9AHmt1 from yeast cells. They showed 
that Npl3 was methylated by yeast-purified S9E Hmt1 in vitro, while yeast-purified S9A 
Hmt1 was unable methylate Npl3. This led to the conclusion that Hmt1 phosphorylation at 
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serine 9 is required for activity. They also concluded from immunoprecipitation 
experiments that phosphorylation is necessary for Hmt1 oligomerization. However, 
immunoprecipitation of Hmt1 also comes with the possibility that other protein factors 
were co-immunoprecipitated, a possibility that was never addressed in the paper. Since the 
authors of this report elegantly demonstrated that the phosphorylation effects could be 
mimicked using a glutamate substitution at position 9, we set out to investigate, in vitro, 
the mechanism by which phosphorylation affects Hmt1 activity. S9E Hmt1 
(phosphomimetic) and S9A Hmt1 (nonphosphorylatable) constructs were expressed, 
purified, and their activities measured in order to corroborate the in vivo published results. 
However, it has been impossible to validate the in vivo results with our in vitro quantitative 
methylation assay (8). This discrepancy hints at the possibility that the published results 
were a result of recruitment of an unknown factor, rather than solely due to the 
phosphorylation event. We end with a discussion of the methods that can be used to finally 
ascertain whether Hmt1 phosphorylation causes an intrinsic effect on methyltransferase 
activity, or if this posttranslational modification affects a change through interactions with 
an unknown regulatory factor.  
 
EXPERIMENTAL PROCEDURES 
Materials— AdoMet was purchased from Sigma as a chloride salt (≥ 80%, from 
yeast). [3H]AdoMet (83.1 Ci/mmol) was purchased from Perkin Elmer. The R3 peptide 
(acGGRGGFGGRGGFGGRGGRG) was synthesized by the Keck Institute (Yale  
University) and purified to ≥ 95%. The lyophilized peptide was dissolved in water and its  
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concentration was determined by mass or by UV spectroscopy (ɛ280 nm = 5,690 M-1cm-
1). ZipTip®C4/C18 pipette tips were purchased from Millipore. 
 Plasmid Generation—A His6-tagged full length wild type Hmt1 plasmid 
(pPS1319) was received from Dr. Anne McBride (Bowdoin University) (9). Constructs 
containing a His6-TEV-T7 (HTT7) tag were created in the Hevel Lab as described in 
chapter 3. Briefly, a pET24b+ vector was used to insert a NdeI_His6-TEV-T7 
(HTT7)_BamHI_Npl3_SacI construct into the NdeI and SacI sites. The Npl3 construct was 
cut out using the BamHI and SacI restriction sites, and a full length wild type Hmt1 
construct was inserted using the same restriction sites. Hmt1 phosphorylation variant 
proteins were generated using the QuikChange® Site-Directed Mutagenesis kit 
(Stratagene) with sets of complementary oligonucleotide primers spanning the desired site 
of mutation.  For each PCR reaction, the pPS1319 vector (from Dr. Anne McBride), or the 
pET24b+HTT7 vector, containing the gene that codes for full length Hmt1 (pET15b-Hmt1 
and pET24b+HTT7-Hmt1, respectively) (9) was used as a template.  Desired mutations 
(S9A and S9E) were confirmed through DNA sequencing.   
Expression and Purification of Hmt1 Constructs— E. coli BL21 cells expressing 
either His6-tagged Hmt1 (WT, S9A, or S9E), His6-TEV-T7 (HTT7) Hmt1 (WT, S9A, or 
S9E), or tagless Hmt1 (WT, S9A, S9E) were grown in Luria Broth media at 37° C to OD600 
reached 0.6, followed by induction with 0.5 mM IPTG at 22° C for 20 hours. Cell pellets 
were resuspended in two times cell volume lysis buffer (50 mM sodium phosphate pH 7.5, 
100 mM NaCl, 20 mM imidazole, or 5 mM imidazole when purifying tagless constructs) 
and lysed using sonication. The cell lysate was clarified via centrifugation and incubated 
with Nickel resin (GoldBio) in a 1:1 cell mass: resin ratio for 1-2 hours at 4° C. The resin 
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was washed eight times with eight times column volume of lysis buffer, followed by three 
washes with eight times column volume of wash buffer (50 mM sodium phosphate pH 7.5, 
100 mM NaCl, 70 mM imidazole). The protein was then eluted off the resin five times with 
two column volumes of elution buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 
250 mM imidazole). Elutions were pooled and dialyzed into 50 mM sodium phosphate pH 
7.5, 100 mM NaCl, 10% glycerol. For samples in which the His tag was cleaved from the 
HTT7 tag, 1 mg of each protein was dialyzed into storage buffer (50 mM sodium phosphate 
pH 7.5, 100 mM NaCl, 10% glycerol) for 1 hour, then into TEV cleavage buffer (50 mM 
sodium phosphate pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM β-
mercaptoethanol) for 1 hour prior to the addition of 0.2 mg TEV protease. The protease 
was added and allowed to work overnight at 4° C in a new bucket of TEV cleavage buffer. 
After 12 hours, the proteins were dialyzed back into storage buffer for 1 hour. The TEV 
cleaved proteins were then loaded onto a 1 ml HisTrap column (GE) which bound the 
cleaved tag and the TEV protein, while the cleaved Hmt1 constructs were collected in the 
unbound fraction.  The protein was then concentrated to ≥ 1 mg/ml, beaded in liquid 
nitrogen, and stored at -80° C.    
Expression and Purification of Npl3 Protein— E. coli BL21 Ni-Co (DE3) cells 
expressing His-TEV-T7 tagged full length Npl3 protein were grown in Luria Broth media 
at 37° C to OD600 reached 0.6, followed by induction with 0.5 mM IPTG at 22° C for 20 
hours. Cell pellets were resuspended in two times cell volume lysis buffer (50 mM sodium 
phosphate pH 7.5, 100 mM NaCl, 20 mM imidazole) and lysed using sonication. The cell 
lysate was clarified via centrifugation and incubated with Nickel resin (GoldBio) in a 2:1 
cell mass: resin ratio for 1-2 hours at 4° C. The resin was washed eight times with eight 
115 
times column volume of lysis buffer, followed by three washes with eight times column 
volume of wash buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 70 mM 
imidazole). The protein was then eluted off the resin five times with two column volumes 
of elution buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 500 mM imidazole). 
Elutions were pooled, filtered and further purified using MonoQ and Heparin columns 
(GE) in tandem. Fractions containing Npl3 were pooled and dialyzed into 50 mM sodium 
phosphate pH 7.5, 100 mM NaCl, 10% glycerol. The protein was then concentrated to ≥ 
1mg/ml, beaded in liquid nitrogen, and stored at -80° C.    
Methyltransferase Activity Assays—  Hmt1 methylation rates were 
measured according to an established methyltransferase activity assay (8) with the 
following modifications. 100 nM Hmt1 (WT, S9A, or S9E) was incubated with 10 nM 
AdoHcy nucleosidase (MTAN), 0.38 µM BSA, 1 µM (or 10 µM) AdoMet (Sigma), and 1 
µM [3H]-AdoMet (Perkin Elmer, specific activity 83.1 Ci/mmol) in 50 mM sodium 
phosphate buffer pH 8.0 at 4° C for 10 minutes prior to initiation with substrate and 
incubation at 30° C. Substrates used were 200 µM R3 peptide or Npl3 (0.1 µM to 1 µM).  
 
RESULTS  
 Initial Activity Measurements of Hmt1 Phosphorylation Variants— In order to 
investigate the effects of phosphorylation on Hmt1 activity, His6-tagged wild type (WT 
Hmt1), phosphomimetic (S9E Hmt1), and nonphosphorylatable (S9A Hmt1) constructs 
were recombinantly expressed and purified from E. coli cells. Using an established 
quantitative methyltransferase activity assay (8), the ability of each Hmt1 construct to 
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methylate recombinant Npl3 was measured. An in vitro confirmation of the previously 
published results should show weak to zero activity from non-phosphorylated WT Hmt1 
and S9A Hmt1, while the phosphomimetic S9E Hmt1 construct would be expected to have 
robust methyltransferase activity on the Npl3 substrate, as was shown in vivo (7). However, 
our initial findings did not yield these results. Instead, we observed the opposite of these 
predictions (Figure 5-1). The nonphosphorylatable (S9A Hmt1) variant showed robust 
methyltransferase activity, while WT Hmt1 and S9E Hmt1 proteins methylated Npl3, at a 
much lower rate. We were surprised by these results, prompting us to re-sequence the 
plasmids, re-express, purify, and again measure Npl3 methylation by these proteins, but 
the second set of results were very similar to the first (see error bars in Figure 5-1), 
indicating that an error was not committed on our part.  
 AdoMet Concentrations Affect Activity of Hmt1 S9A— The typical steady-state 
methyltransferase assay conditions used in the Hevel lab employ saturating concentrations 
of arginine-containing  substrate, but only use 2 µM AdoMet (SAM) which is below the 
reported KM for PRMT1 of 6 ± 1 µM (10). While the concentration of AdoMet used in the 
Cell paper was not reported, 2 µM [AdoMet] is fairly standard.  To examine a potential 
influence of AdoMet concentration on PRMT1 activity, the rates of Npl3 methylation by 
the Hmt1 phosphorylation variants at both 2 µM and 11 µM AdoMet ([AdoMet] used in 
Figure 5-1) were compared. At 2 µM AdoMet, the extreme difference in the methylation 
rates between the various Hmt1 constructs was not observed. Instead, the S9E Hmt1 and 
S9A Hmt1 rates become comparable.  
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FIGURE 5-1. Methylation of Npl3 by Hmt1 phosphorylation variants. The reactions 
were carried out with 100 nM Hmt1 (WT, S9E, or S9A), 10 µM AdoMet + 1 µM 
[3H]AdoMet, and 1 µM Npl3 substrate in 50 mM sodium phosphate buffer pH 8.0 at 30° 





FIGURE 5-2. Activity of Hmt1 phosphorylation variants at two AdoMet 
concentrations. The average rate of methyl group transferred is shown for each Hmt1 
phosphorylation variant in the presence of 1 µM Npl3 and either 2 µM or 11 µM AdoMet. 
Error bars shown represent the standard deviation between two biological replicated.   
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 Further attempts to replicate the conditions used in the reactions with yeast purified 
TAP-Hmt1 constructs focused on varying the concentration of the Npl3 substrate, since the 
original report used 700 nM Npl3 and our conditions used 1 µM. However, the S9A Hmt1 
construct that was unable methylate 700 nM Npl3 when purified from yeast cells, 
efficiently methylated 700 nM Npl3 in vitro (Figure 5-3-A). It must be noted that the data 
in Figure 5-3-A represents the measurement of only one rate for each Npl3 concentration 
per Hmt1 construct and therefore no attempts were made to fit the data to a Michaelis-
Menten equation. Since no clear distinction in the rate of methyl transfer was observed for 
the Hmt1 phosphorylation variants using the Npl3 protein substrate, the rates of 
methylation of R3 peptide substrate (ac-GGRGGFGGRGGFGGRGGFGG) were also 
measured (Figure 5-3-B). Again, no significant difference in the overall methylation rates 
was observed.  
Effect of N-terminal Tag on the Activity of Hmt1 Phosphorylation Variants— 
Although TAP-Hmt1 constructs tested by Messier et al. have not been used in the Hevel 
lab, the activity of TAP-tagged WT Hmt1 is known to be consistently very poor 
(conversations with Dr. Michael Yu), while the activity of recombinant WT Hmt1 (with a 
Histidine tag) in the Hevel lab has typically been robust. Therefore, the Hmt1 
phosphorylation variants were expressed with different affinity tags to determine if N-
terminal tags can affect the activity of the Hmt1 phosphorylation variants. The N-terminal 
Histidine tag that we employed does seem to have a direct effect on the overall activity of 
all of our constructs (Figure 5-4). The highest level of activity is shown by the constructs 
with the longest tag (HTT7 tag is 40 amino acids long, cleaved HTT7 (cHTT7) is 12 amino 
acids long, while the His6 tag is 6 amino acids long). Interestingly, the HTT7-tagged Hmt1 
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phosphorylation variants were able to methylate 1 µM Npl3 in a parallel to the results of 
Messier et al. (S9A Hmt1 significantly more impaired than S9E Hmt1). The TAP-Hmt1 
constructs used to immunoprecipitate the Hmt1 phosphorylation variants from yeast cells 
code for ProteinA-TEV-CBP-Hmt1, meaning that after TEV cleavage, the constructs used 
for methyltransferase assay by Messier et al. retained a 26 amino acid calmodulin binding 
protein (CBP) tag on the N-terminus of Hmt1. Our results, while only single data points, 
suggest that perhaps the observations made by Messier et al. could have been influenced 
by the use of a purification tag.   
 
 
FIGURE 5-3. Activity of Hmt1 phosphorylation variants with varying [Npl3], or with 
R3 peptide. The rates of methyl group transfer are shown for each Hmt1 phosphorylation 
variant with varied substrate concentration at 2 µM AdoMet. Error bars, when shown, 




FIGURE 5-4. Effect of N-terminal tags on Npl3 methylation by Hmt1 
phosphorylation variants. Single rate measurements are shown for the various Hmt1 
phosphorylation variants with one of the following N-terminal tags: His6 tag, His6-TEV-
T7 (HTT7) tag, or TEV-cleaved HTT7 tag. The methyltransferase activity of these 
constructs was measured in the presence of 1 µM Npl3, and 2 µM AdoMet.  
 
DISCUSSION 
The proper regulation of PRMT1 activity is critical for organismal well-being. 
Regulation of protein activity can be achieved many ways, including posttranslational 
phosphorylation which regulates many proteins, including several PRMT isoforms (11-
13). Recently, the yeast PRMT1 homolog, Hmt1, was reported to be activated in vivo 
through phosphorylation on an N-terminal serine residue (7). In this report, it was also 
shown that a phosphomimetic Hmt1 variant (S9E) immunoprecipitated from yeast cells 
could mimic the activity and oligomerization of phosphorylated Hmt1, while a 
nonphosphorylatable yeast-purified S9A Hmt1 variant had no activity.  However, there is 
precedent for the need to corroborate results observed in vivo with in vitro methods. One 
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well known example was the misclassification of PRMT7 as a type II PRMT due to 
contamination of immunoprecipitated type III PRMT7 with the type II PRMT5 (14). Since 
the report by Messier et al. did not address the possibility that their results may have been 
affected by the co-immunoprecipitation of an unknown factor with Hmt1, we determined 
to characterize the activity of recombinant Hmt1 phosphorylation variants (S9E and S9A) 
using a quantitative in vitro methyltransferase assay developed in our lab (8). We were 
unable to replicate the in vivo observations and find that the N-terminal tags used to purify 
Hmt1 may affect the measurement of Hmt1 activity. Tag-free constructs of the Hmt1 
phosphorylation variants should be used to be sure that our inability to reproduce the in 
vivo results is not a result of the tags attached to the protein.  
A possible experiment to ascertain whether phosphorylation at serine 9 of Hmt1 
has an intrinsic effect on Hmt1 activity, or affects activity through the recruitment of an 
unknown factor is to determine the activity of tag-free, recombinantly expressed 
phosphomimetic S9E Hmt1 and nonphosphorylatable S9A Hmt1 with and without an 
Hmt1-null yeast cell lysate. If an unknown yeast factor binds to and activates 
phosphorylated Hmt1, a stark difference should be noted between the methylation of S9E 
Hmt1 in the presence or absence of yeast lysate, whereas no significant difference would 
indicate an intrinsic effect on Hmt1 activity from phosphorylation. 
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REDOX CONTROL OF PROTEIN ARGININE METHYLTRANSFERASE 1 
 (PRMT1) ACTIVITY1 
 
ABSTRACT 
Elevated levels of asymmetric dimethylarginine (ADMA) correlate with risk 
factors for cardiovascular disease. ADMA is generated by the catabolism of proteins 
methylated on arginine residues by protein arginine methyltransferases (PRMTs), and is 
degraded by dimethylarginine dimethylaminohydrolase (DDAH). Reports have shown that 
DDAH activity is down regulated and PRMT1 protein expression is upregulated under 
oxidative stress conditions, leading many to conclude that ADMA accumulation occurs via 
increased synthesis by PRMTs and decreased degradation. However, we now report that 
the methyltransferase activity of PRMT1, the major PRMT isoform in humans, is impaired 
under oxidative conditions.  Oxidized PRMT1 displays decreased activity, which can be 
rescued by reduction. This oxidation event involves one or more cysteine residues that 
become oxidized to sulfenic acid (-SOH). We demonstrate a hydrogen peroxide 
concentration-dependent inhibition of PRMT1 activity that is readily reversed under 
physiological H2O2 concentrations. Our results challenge the unilateral view that increased 
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Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. The Journal of 
biological chemistry 290, 14915-14926 
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PRMT1 expression necessarily results in increased ADMA synthesis, but rather 
demonstrate that enzymatic activity can be regulated in a redox-sensitive manner. 
 
INTRODUCTION 
 Endothelial dysfunction plays a major role in cardiovascular disease, the leading 
cause of death in the United States (1).  Several factors have been suggested to contribute 
to endothelial dysfunction such as decreased activity and/or expression of endothelial nitric 
oxide synthase (eNOS) and/or increased vascular formation of oxygen-derived free 
radicals (2,3). Asymmetric dimethylarginine (ADMA) is an endogenously synthesized 
inhibitor of NOS that has been gaining increased attention in the cardiovascular field (2,4-
9). In the heart, ADMA and other NOS inhibitors cause reduced heart rate and cardiac 
output (10,11).  Interestingly, in addition to decreasing levels of nitric oxide, evidence 
suggests that ADMA may also uncouple NOS (conditions under which NOS generates 
superoxide anion), thus increasing oxidative stress and inducing additional endothelial 
dysfunction (7,12).  Furthermore, ADMA was shown to increase endothelial oxidative 
stress and up-regulate expression of redox-sensitive genes that encode endothelial adhesion 
molecules (13), increasing propensity for plaque buildup. Taken together, the available 
data indicates that ADMA levels represent a risk factor for the development of endothelial 
dysfunction. 
ADMA is generated through the degradation of cellular proteins containing 
asymmetrically dimethylated arginine residues (Fig. 6-1). Arginine residues in certain 
proteins can be modified by the addition of one or two methyl groups; this modification is 
catalyzed by the protein arginine methyltransferase (PRMT) family of enzymes. Nine 
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human PRMT isoforms can be subdivided into three types determined by their final 
methylation products. Type 1 PRMTs (such as PRMT1) form monomethylarginine 
(MMA) and/or ADMA and represent the majority of identified PRMTs. Type 2 PRMTs 
form MMA and/or symmetric dimethylarginine (SDMA), and type 3 PRMTs produce only 
MMA (14). Each of the methylated arginine products (MMA, ADMA, and SDMA) can 
induce different biological responses in the cell; however, only MMA and ADMA are 
inhibitors of NOS activity (9,14). ADMA in the body is metabolized by dimethylarginine 
dimethylaminohydrolase (DDAH) to citrulline and dimethylamine (15).  Thus, the amount 




FIGURE 6-1. ADMA formation and degradation. Protein arginine methyltransferases 
(PRMTs) transfer a methyl group from donor AdoMet to arginine residues in substrate 
proteins. Type 1 PRMTs can transfer one or two methyl groups to the same terminal 
guanidino nitrogen producing monomethyl arginine (MMA) or asymmetric 
dimethylarginine (ADMA), respectively. Upon degradation of the methylated proteins, 
free MMA and ADMA inhibit NO synthesis by acting as competitive inhibitors of nitric 
oxide synthase. Free ADMA is catabolized by dimethylarginine dimethylaminohydrolase 
(DDAH) to citrulline and dimethylamine, or excreted in urine. 
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Evidence has shown that under oxidative stress, a condition linked to a variety of 
disease states, free ADMA levels are increased.  In many instances these studies also 
showed that PRMT1 RNA or protein expression is increased and DDAH activity is 
decreased (11,16-20).  This has led many to conclude that the increased expression of 
PRMT1 protein results in increased protein methylation, giving rise to a larger pool of the 
precursors for free ADMA (6,18,21).  While it is clear that elevated ADMA levels are 
connected to oxidative stress, the assumption that increased levels of PRMT1 protein 
expression are directly responsible for increased free ADMA production has not been 
validated. In fact, a recent report showed a significant reduction in the production of 
ADMA-containing polypeptides in both replicative and H2O2-induced premature senescent 
cells (22). In order to clarify the role of PRMT1 in free ADMA accumulation under 
oxidative stress conditions, we set out to investigate if oxidative conditions affect PRMT1 
catalytic activity.  
Here we report that PRMT1, the major human PRMT isoform, is susceptible to 
oxidation. Oxidized rat PRMT1, which differs from human PRMT1 at just one residue, is 
characterized by impaired enzymatic activity that can be rescued by reduction. We 
demonstrate a reversible, concentration-dependent inhibition of PRMT1 activity by H2O2. 
Furthermore, we show that this oxidation event involves at least two cysteines which are 
oxidized to sulfenic acid (-SOH). Our results provide the first direct evidence that PRMT1 





Materials— AdoMet was purchased from Sigma as a chloride salt (≥ 80 %, from 
yeast).  [3H]AdoMet (83.1 Ci/mmol) was purchased from Perkin Elmer. R3 peptide 
(acGGRGGFGGRGGFGGRGGRG) was synthesized by the Keck Institute (Yale 
University) and purified to ≥ 95%. The lyophilized peptide was dissolved in water and its 
concentration was determined by mass or by UV spectroscopy (ɛ280 nm= 5,690 M
-1cm-1). 
Bulk histones from calf thymus were purchased from Sigma. Histone 4 protein was 
purchased from New England Biolabs. ZipTip®C4/C18 pipette tips were purchased from 
Millipore. DCP-Rho1 sulfenic acid probe was purchased from Kerafast and 5IAF thiol-
specific probe was purchased from Life Technologies.  
Plasmid Generation— The His6-ratPRMT1 plasmid (HisPRMT1) was previously 
generated (23). To create a construct with a cleavable His6-tag, a DNA segment coding for 
a tobacco etch virus (TEV) cleavage site was designed with both N- and C-terminal NdeI 
restriction sites. The NdeI restriction enzyme was used to cut open the vector at an NdeI 
site between the His6-tag and the enzyme coding sequence, and the designed TEV insert 
ligated using the Quick LigationTM kit (New England Biolabs) to form the His6-TEV-
ratPRMT1 plasmid (HisTevPRMT1). The C101S, C342S, C254S, C208S, C101S/C208S 
variants were generated using the HisTevPRMT1 plasmid (or confirmed HisTevPRMT1 
C101S plasmid for C101S/C208S) as a PCR template for site directed mutagenesis using 
the QuikChange Lightning Kit (Stratagene) and sets of complementary oligonucleotide 
primers spanning the desired site of mutation. To replace all 11 cysteine residues of 
PRMT1 with serines and create HisTevPRMT1 cys (or cys-), properly coded DNA with 
N-terminal NdeI and C-terminal BamHI restriction sites was ordered from GenScript. The 
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PRMT1 sequence in His6-TEV-PRMT1 was excised with NdeI/BamH1 and replaced with 
the synthetic PRMT1 cys insert. The cysteine-less with C101 reintroduced (cys-C101), 
cysteine-less with C208 reintroduced (cys-C208), and cysteine-less with both C101 and 
C208 reintroduced (cys-C101C208) variants were generated using the HisTevPRMT1 cys 
plasmid as a PCR template for site directed mutagenesis using the QuikChange Lightning 
Kit (Stratagene) and sets of complementary oligonucleotide primers spanning the desired 
site of mutation. All plasmids were transformed using the E.coli DH5α cell line. Plasmids 
were purified (Qiagen Plasmid Mini Kit) and sequenced to confirm the correctness of the 
open reading frame prior to protein expression. 
Recombinant Protein Expression and Purification— Full-length His-tagged 
PRMT1 (residues 1-353) was expressed and purified as described previously (23). Briefly, 
E. coli BL21 cells were transformed with the above constructs and grown on Luria Broth 
medium / kanamycin agar plates. Selected colonies were grown in Luria Broth to A600 = 
0.6 and induced with 0.5 mM IPTG for 24 hours at 25⁰ C. Cell pellets were resuspended 
in lysis/wash buffer (50 mM sodium phosphate [pH 7.6], and 20 mM imidazole), sonicated, 
and centrifuged at 47,000 x g for 20 minutes at 4⁰ C. The clarified supernatant was 
incubated with Nickel Sepharose 6 Fast Flow resin (Qiagen) rotating for 2 hours at 4° C. 
The binding reaction was pelleted at 700 x g, the supernatant discarded, and the resin 
washed 4 times with lysis/wash buffer, 7 times with wash buffer containing 70 mM 
imidazole, and then eluted in 6 washes with 250 mM imidazole buffer. The elutions were 
pooled and dialyzed into storage buffer (50 mM sodium phosphate [pH 7.6], and 10 % 
glycerol), concentrated to greater than 1 mg/mL, and beaded in liquid nitrogen for storage 
at -80° C. To generate cleaved constructs, half of the His6-TEV enzymes were put into 
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cleavage buffer (50 mM sodium phosphate, 1 mM DTT, 2 mM EDTA, and 5 % glycerol); 
the TEV enzyme added and allowed to cleave overnight. The cleaved enzyme was dialyzed 
into storage buffer, re-incubated with nickel resin (removal of TEV and remaining His6-
tag), and the subsequent supernatant was dialyzed, concentrated, and stored the same as 
the His6-tagged elutions.  Enzyme cleavage and purity (> 90%) were assessed during and 
after purification using SDS-page. pET21a TbPRMT7 and pET28b human PRMT6 were 
purified as PRMT1. pET28a human PRMT3 (residues 211-531) was grown and purified 
as described in Wang et al. (24). Protein concentrations were determined by UV 
spectroscopy (PRMT1 ɛ280 nm= 54,945 M
-1cm-1, PRMT3 ɛ280 nm= 37735 M
-1cm-1, PRMT7 
ɛ280 nm= 37150 M
-1cm-1, PRMT6 ɛ280 nm= 59040 M
-1cm-1) and by the Bradford assay with 
bovine serum albumin as a standard. 
Kinetic Assays of PRMT1 Constructs— Conditions of methylation reactions were 
as published previously (23). Briefly, enzyme activity was assessed at 37° C in assays 
containing 100 nM PRMT1, 2 μM AdoMet (1 μM [3H]AdoMet), 0.38 µM bovine serum 
albumin, 100 nM AdoHcy nucleosidase (MTAN, purified as described in ref. (25)) and 
initiated with 200 μM peptide substrate or 2 μM protein substrate. Reactions in the presence 
of DTT were performed by pre-incubation of the reaction with 1 mM DTT for 10 minutes 
at 4⁰ C prior to initiation with substrate. At different time points, 5 µL samples were 
removed from reactions and quenched with 6 µL of 8 M guanidinium hydrochloride. 
Samples were processed with ZipTip®C4/C18 pipette tips (Millipore) (for protein or peptide 
substrates, respectively) to separate the unreacted [3H]AdoMet and the radiolabeled 
product (26). Time-dependent incorporation of radiolabel into substrates was quantified 
using a scintillation counter (Beckman Coulter). Methyltransferase activity for hPRMT3, 
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hPRMT6, and TbPRMT7 were performed as above, except 1 mM bulk histones (Sigma), 
and 1 mM Histone 4 protein (NEB) were used as substrates for hPRMT6 and TbPRMT7, 
respectively.  
Conditions for testing the effect of hydrogen peroxide on enzymatic activity were 
published previously (27) and were modified as follows. PRMT1was pre-reduced in 1mM 
DTT for 2 hours on ice then rapidly desalted on a 7 kDa ZebaTM Spin desalting column 
(Thermo Scientific). PRMT1 (2 µM final concentration) was oxidized with 0, 0.4 µM, 4 
µM, 40 µM, 200 µM, 400 µM, or 800 µM H2O2 for 10 minutes at 37⁰ C and then incubated 
with catalase (300 U/ml) for 1 minute at 37⁰ C. The mixture was then kept on ice and used 
for kinetic assays as above. Methyltransferase activity was unaffected by the addition of 
catalase (data not shown). In all cases, data reported is the average of at least three 
independent measurements.  
Size Exclusion Chromatography— Gel filtration chromatography was performed 
on a SuperdexTM 200 10/300GL column (GE Healthcare) in 50 mM sodium phosphate pH 
7.6, 150 mM NaCl, and 5 % glycerol at 0.4 ml/min flow rate. Freshly purified PRMT1 
variants were allowed to equilibrate overnight into gel filtration buffer, with or without the 
addition of 1 mM DTT, 2 mM EDTA prior to examination.  All constructs were analyzed 
by loading 300 µL of enzyme at a concentration of 10-20 µM and run at 0.4 mL/min for 
75 minutes.  
In Vitro DCP-Rho1 Labeling of Sulfenic Acid in Recombinant PRMT1—
 DCP-Rho1 labeling of purified PRMT1 was modified from the method described 
in Poole et al.(28). Briefly, 2.5 µM recombinantly expressed, air oxidized WT PRMT1, 
cysteine-less PRMT1, cysteine-lessC101, cysteine-lessC208, or cysteine-lessC101C208 
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enzymes were incubated with 1 mM DTT or with buffer in the presence of 6 M urea for 1 
hour at 22° C prior to addition of 10 µM DCP-Rho1 for 20 minutes at 22° C in a final 
reaction volume of 25 µl. The labeling reaction was quenched by addition of 4X SDS 
loading dye and boiling for 5 minutes. Labeled proteins were separated from unreacted 
label by 12 % SDS-PAGE, and band quantification was performed using the Image Lab 
software from BioRad and is reported as the average of three independent measurements.   
In Vitro 5IAF Labeling of Free Thiol Content in Recombinant PRMT1—
 5IAF labeling of purified PRMT1 was modified from the method described in Wu 
et al. (29) with optimization conditions aided by Hansen et al. (30). Briefly, 2.5 µM 
recombinantly expressed, air oxidized WT PRMT1, cysteine-less PRMT1, cysteine-
lessC101, cysteine-lessC208, or cysteine-lessC101C208 enzymes were incubated with 1 mM 
DTT or with buffer in the presence of 6 M urea for 1 hour at 22° C prior to addition of 2.5 
mM 5IAF  for 1 hour at 22° C in a final reaction volume of 25 µl. The labeling reaction 
was quenched by addition of 4X SDS loading dye and boiling for 5 minutes. Labeled 
proteins were separated from unreacted label by 12 % SDS-PAGE, and band quantification 
was performed using the Image Lab software from BioRad and is reported as the average 
of three independent measurements.   
  LC-MS/MS Analysis of Sulfenic Acid Content in Recombinant PRMT1—
 120 µg WT PRMT1 was treated with 5 mM dimedone in the presence of 6 M urea for 
2 hours at 22° C. The sample was then buffer exchanged twice into 50 mM ammonium 
bicarbonate to remove excess dimedone and all urea. After reduction and alkylation, the 
labeled sample was precipitated by stepwise addition of 6 volumes of cold acetone with 
continuous vortexing and then incubated overnight at -20° C. After centrifugation at 20,000 
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g for 30 minutes at 4° C, the supernatant was removed, and the pellet was allowed to air-
dry. Two consecutive digestions steps were employed for the on-pellet-digestion. In step 1 
(digestion-aided pellet dissolution), Tris buffer (50 mM, pH 8.5) containing trypsin at an 
enzyme/substrate ratio of 1:40 (w/w) was added and incubated at 37° C for 6 hours with 
vortexing at 500 rpm in a ThermoMixer shaking incubator (Eppendorf); in step 2 (complete 
cleavage), another portion of trypsin solution was added at an enzyme/substrate ratio of 
1:40 (w/w) in a 50 µl final volume. The mixture was incubated at 37° C for 12 hours to 
achieve a complete digestion. The digestion was terminated by adding 1 % (v:v) formic 
acid and centrifuged at 20,000 g for 30 min at 4° C; the supernatant was used for LC-
MS/MS analysis.  
  Four µl of the digested solution was analyzed by nanospray LC-MS/MS, which 
constitutes an Orbitrap Fusion Tribrid mass spectrometer with ETD (Thermo Fisher 
Scientific, San Jose, CA) coupled to an ultra-high pressure Eksigent ekspert NanoLC 425 
system (Dublin, CA) with a autosampler of Eksigent NLC 400 (Made in the Netherlands). 
A nano-LC/nanospray setup was used to obtain a comprehensive separation of the complex 
peptide mixture and sensitive detection. Mobile phases A and B were 0.1 % formic acid in 
1 % acetonitrile and 0.1 % formic acid in 88 % acetonitrile, respectively. Samples were 
loaded onto a large ID trap (300 µm ID × 5 mm, packed with Zorbax 5 µm C18 material) 
with 1 % B at a flow rate of 10 µL/min for 3 min. A series of nanoflow gradients was used 
to back-flush the trapped samples onto the nano-LC column (75 µm ID × 100 cm, packed 
with Pepmap 3-µm C18 material). The column was heated at 52 °C to improve both 
chromatographic resolution and reproducibility. Gradient profile was as follows: i) a linear 
increase from 3 to 8% B over 5 min; ii) an increase from 8 to 27 % B over 117 min; iii) an 
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increase from 27 to 45 % B over 10 min; iv) an increase from 45 to 98 % B over 20 min; 
and v) isocratic at 98 % B for 20 min. 
  The mass spectrometry was operating under data-dependent product ion mode. A 
3 second scan cycle included an MS1 scan (Orbitrap) followed by MS2 scans (dual-cell 
ion trap) by alternating CID and ETD activation, was programed. The parameters used for 
MS and MS/MS data acquisition under the CID mode were: top speed mode with 3s cycle 
time; Orbitrap: scan range (m/z) = 400-1600; resolution = 120 K; AGC target = 5 × 105; 
maximum injection time (ms) = 50; Filter: precursor selection range = 400-1500; include 
charge state = 2-7; dynamic exclude after n times = 1, duration time 60 s; Decision: data 
dependent mode: top speed, precursor priority = most intense; for CID, isolation mode = 
quadrupole; isolation window = 1.6; collision energy (%) = 30; detection type: Ion trap; 
iontrap scan rate: Rapid; AGC target = 1 × 104; maximum injection time (ms) = 50; 
microscan = 1; and for ddMS2 (ETD), ETD reaction time (ms) 200; ETD reagent target 
1.0 x 106; Maximum ETD reagent injection time (ms): 200; AGC target = 1 × 104; 
maximum injection time (ms) = 50; microscan = 1. 
CID and ETD activation spectra were processed using Peaks 7. Briefly, raw files 
were searched against the sequence of PRMT1, with the precursor mass tolerance of 20 
ppm and peptide fragment mass tolerance of 1 Da. And the static side chain modifications 
of carbamidomethyl (57.021), and dynamic side chain modifications of oxidation (15.995) 





PRMT1 Activity is Reversibly Inhibited by Oxidation— The elevated levels of free 
ADMA that are observed under oxidative stress conditions (7) could arise from a few 
distinct mechanisms. Both proteosomal degradation and methyltransferase activities could 
affect the rate of free ADMA formation. Increased synthesis of ADMA-containing proteins 
(the precursors to free ADMA) could occur by increasing the expression of PRMT proteins 
while maintaining normal enzyme activity, or by increasing the methyltransferase activity 
of the current pool of PRMT proteins.  Since PRMT1 is responsible for ~85% of arginine 
methylation in cells and is the primary source of ADMA (31), altered expression and/or 
activity of this isoform would be expected to contribute greatly to altering levels of ADMA.  
In order to determine if oxidative conditions induce any changes in PRMT1 activity, we 
treated fully reduced recombinant PRMT1 with hydrogen peroxide, a common cellular 
oxidant, and measured the resulting methyltransferase activity. 
Recombinantly expressed PRMT1 was pre-reduced with dithiothreitol (DTT), and 
rapidly desalted to remove residual DTT. The reduced PRMT1 was then incubated with 
various concentrations of H2O2 (0.4—800 µM final concentration) followed by the addition 
of catalase to remove any remaining H2O2. Surprisingly, when the peroxide-treated 
PRMT1 was assayed, methyltransferase activity was found to be significantly inhibited by 
peroxide in a dose-dependent manner (Fig. 6-2A). At concentrations of hydrogen peroxide 
greater than 4 µM, PRMT1 activity was significantly impaired and could not be fully 
recovered (data not shown). However, at the physiologically relevant concentration of 0.4 
µM (physiological levels in mammals range from 0.001 µM to 0.7 µM)(32), hydrogen 
peroxide was also able to inhibit PRMT1 activity, and subsequent reduction with DTT 
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resulted in full recovery of activity (Fig. 6-2B). These experiments provide the first 
evidence that PRMT1 enzymatic activity is susceptible to reversible oxidative impairment 
under physiologically relevant oxidative conditions. 
 
 
FIGURE 6-2. PRMT1 activity is (A) inhibited by H2O2 in a concentration dependent 
manner and (B) activity lost can be recovered by reduction. In (A), reduced PRMT1 
was incubated with 0 (), 40 (), 200 (), 400 (), or 800 () µM H2O2 for 10 minutes 
at 37⁰ C, followed by the addition of catalase. Methyltransferase activity of the treated 
PRMT1 was measured with 200 µM R3 peptide as a substrate as described in Experimental 
Procedures.  In (B), reduced PRMT1 was treated with a physiologically-relevant 
concentration of hydrogen peroxide or phosphate-buffered saline (PBS) and subsequently 
treated with 1mM DTT or PBS prior to methyltransferase assays. 
 
PRMT1 Enzymatic Activity Increases After Reduction— In order to better 
understand the sensitivity of PRMT1 to oxidation, we purified recombinant PRMT1 in the 
absence of reductant and measured methyltransferase activity in the absence and presence 
of a reductant.  Pre-incubation with DTT increased methyltransferase activity by greater 
than 10-fold with the R3 peptide substrate (Fig. 6-3A). We examined the duration of this 
effect by rapidly desalting PRMT1 following the DTT pre-incubation step. The activity of 
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the desalted PRMT1 was increased only by 2-fold using the R3 peptide (Fig. 6-3A), 
indicating that the effect of DTT is transient and that PRMT1 oxidation occurs quickly in 
the absence of a reductant. We further studied the relationship between enzymatic activity 
and the concentration of DTT by comparing PRMT1 activity with varied concentrations of 
DTT ranging from 0.1 mM to 10 mM (Fig. 6-3B). Our results indicate that the effect of 
DTT is concentration-dependent, achieving a maximal rate enhancement at 1.5-2 mM DTT 
(Fig. 6-3B).  During the course of this study, more than 50 human and rat PRMT1 proteins 
were purified in the absence of reductant and showed anywhere from a 1.8-fold to 70-fold 
increase in methyltransferase activity when DTT was included in the reaction or the 
enzyme was pre-incubated with DTT (data not shown).  We note that in many cases, our 
purification protocol can be accomplished in as few as ~8 hours.  These results demonstrate 
that PRMT1 is sensitive to oxidation by not only hydrogen peroxide, but also cellular 
conditions and/or the mild conditions used for purification. 
Methylation of the sulfhydryl groups in DTT was previously observed with small 
molecule plant O-methyltransferases, where it acted as an intermediate acceptor molecule 
(33). Even though DTT methylation was not detected in our control reactions lacking 
peptide substrate (control Fig. 6-3A), we replaced DTT in our assay with an alternative 
thiol-free reductant, Tris(2-carboxyethyl)phosphine (TCEP). When 1 mM TCEP was used 
to reduce PRMT1, the rate enhancement with the R3 peptide was identical to that observed 
using 1 mM DTT (Fig. 6-3A). We conclude that the enhancement of HisPRMT1 




FIGURE 6-3. The effect of reducing agents on PRMT1 enzymatic activity. In (A) 
PRMT1 methyltransferase activity was measured without substrate (), or with 200 µM 
R3 peptide in the absence () and presence of DTT () or TCEP (), or after desalting 
following a 10 minute pre-incubation with DTT (). In (B), methyltransferase activity 
was measured as a function of DTT concentration.   
 
Several different affinity tags are used for PRMT1 purification and variable 
methylation rates have been observed (34-36). We questioned whether our His6-tag was 
influencing the observed rate changes upon reduction. To address this concern, we 
expressed a tag-less version of rat PRMT1. However, this version of PRMT1 was unstable 
and lost activity rapidly (data not shown). As an alternative strategy, we created a His6-
tagged, tobacco etch virus (TEV) cleavable, rat PRMT1 construct (HisTevPRMT1) which 
allowed us to cleave the tag after an initial purification step and then use the tag-free version 
(tag-freePRMT1) for kinetic assays. Both tagged and tag-free versions of PRMT1 
exhibited rate enhancement upon reduction, although the tag-free version was markedly 
more active than the tagged version even without DTT in the assay (Fig. 6-4). This 
observation is easily explained when the method for acquiring tag-free protein is taken into 
consideration. The protocol for TEV cleavage includes an overnight dialysis step in a 
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buffer containing 1 mM DTT and 2 mM EDTA and therefore the resulting tag-free enzyme 
used in the activity assays is already somewhat pre-reduced. To confirm this theory, we 
again purified the cleavable (HisTevPRMT1) enzyme by nickel chromatography.  Purified 
enzyme was divided into two separate dialysis bags.  TEV was added to one, and the other 
was left uncleaved; however, both tagged and cleaved samples were dialyzed overnight in 
the same 1 mM DTT, 2 mM EDTA containing buffer. Methyltransferase activity of these 
newly purified tagged and tag-free PRMT1 enzymes revealed no significant rate 
enhancement upon addition of DTT (Fig. 6-4). The addition of only EDTA had no 
significant effect on methyltransferase activity (Fig. 6-4). These results confirm that it is 
not the tag, but rather the reducing treatment of the tag-free enzyme which enhanced the 
enzymatic activity of PRMT1. 
Reduction Alters the Oligomeric State of PRMT1— It has been shown that 
PRMT1 forms at least a homo dimer in order to be catalytically active (36-38). Feng et al. 
introduced the idea that changing the oligomeric state of PRMT1 affects its enzymatic 
activity (34).  Since reduction of PRMT1 results in increased activity, we wondered if 
reduction had an effect on the oligomeric state of the enzyme. Size exclusion 
chromatography experiments in the presence or absence of DTT were carried out to 
determine the oligomeric state of PRMT1 under different redox environments (Fig. 6-5). 
Unreduced PRMT1 migrates over a broad range of oligomeric states, with the majority of 
the protein existing in oligomers that migrate at molecular weights above 660 kDa. As a 
reference, PRMT1 is thought to be active as an 80 kDa dimer (although a dimer form has 
not been observed on size exclusion chromatography) (36,39). Overnight incubation with 
1 mM DTT and 2 mM EDTA results in a shift towards a homogeneous oligomeric state 
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migrating between 200 and 450 kDa (Fig. 6-5). Analytical ultracentrifugation, a more 
sensitive technique for determining molecular weights, showed the same shift towards a 
smaller oligomeric species upon reduction as was observed using size exclusion 
chromatography (data not shown). In conclusion, oxidized PRMT1 forms a large molecular 
weight functional aggregate, while reduction of PRMT1 causes a shift towards a smaller, 
more uniform, oligomeric state that correlated with an increase in enzymatic activity. 
 
 
FIGURE 6-4. The enhancing effect of DTT on PRMT1 methyltransferase activity is 
independent of the His6-tag. Enzymatic activity of HisTevPRMT1 (), cleaved PRMT1 
(), and dialyzed HisTevPRMT1 () measured with 200 µM R3 peptide in the absence 
(open) and presence (closed symbols) of DTT respectively, as well as HisTevPRMT1 
treated with EDTA only as a control (). 
 
Reduction Alters the Oligomeric State of PRMT1— It has been shown that 
PRMT1 forms at least a homo dimer in order to be catalytically active (36-38). Feng et al. 
introduced the idea that changing the oligomeric state of PRMT1 affects its enzymatic 
activity (34).  Since reduction of PRMT1 results in increased activity, we wondered if 
reduction had an effect on the oligomeric state of the enzyme. Size exclusion 
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chromatography experiments in the presence or absence of DTT were carried out to 
determine the oligomeric state of PRMT1 under different redox environments (Fig. 6-5). 
Unreduced PRMT1 migrates over a broad range of oligomeric states, with the majority of 
the protein existing in oligomers that migrate at molecular weights above 660 kDa. As a 
reference, PRMT1 is thought to be active as an 80 kDa dimer (although a dimer form has 
not been observed on size exclusion chromatography) (36,39). Overnight incubation with 
1 mM DTT and 2 mM EDTA results in a shift towards a homogeneous oligomeric state 
migrating between 200 and 450 kDa (Fig. 6-5). Analytical ultracentrifugation, a more 
sensitive technique for determining molecular weights, showed the same shift towards a 
smaller oligomeric species upon reduction as was observed using size exclusion 
chromatography (data not shown). In conclusion, oxidized PRMT1 forms a large molecular 
weight functional aggregate, while reduction of PRMT1 causes a shift towards a smaller, 
more uniform, oligomeric state that correlated with an increase in enzymatic activity.  
The Oxidation-Dependent Effects on PRMT1 Activity Require a Cysteine(s) 
Residue— One of the most common mechanisms for oxidative damage is the oxidation of 
cysteine residues (40-43). We took a broad approach to evaluate whether any cysteine 
residues were responsible for the effects of oxidation/reduction by creating a PRMT1 
variant where all eleven rat PRMT1 cysteine residues were mutated to serine 
(HisTevPRMT1cys or cys-). Interestingly, the cysteine-less PRMT1 showed no 
enhancement in methyltransferase activity upon pre-incubation with DTT (Fig. 6-6). In 
addition to activity measurements, the oligomeric state of the cysteine-less PRMT1 variant 
was assessed by size-exclusion chromatography (Fig. 6-5). The cysteine-less PRMT1  
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FIGURE 6-5. Oligomeric state of PRMT1 proteins assessed by size exclusion 
chromatography.  PRMT1 without DTT treatment (top) or incubated overnight with 1 
mM DTT and 2 mM EDTA (middle), compared to Cysteine-less PRMT1 which migrates 
at the same position regardless of treatment with DTT or EDTA.  Reduction of PRMT1 or 
removal of all cysteine residues results in a shift towards a smaller oligomeric state.   
 
enzyme exhibited a migration pattern similar to that of the maximally active, reduced 
PRMT1, regardless of its treatment (data not shown).We conclude from these observations 
that indeed one (or more) cysteine(s) are responsible for the redox switching of PRMT1 
activity. 
C101, C342, C254, and C208 are not Individually Responsible for Reductive 
Effects— We examined the rat PRMT1 crystal structures (36) for cysteine residues capable 
of undergoing oxidation and found that out of the eleven cysteines present in rat PRMT1, 
cysteines 101, 208, 232, 254, and 342, are all solvent accessible (Fig. 6-8). Cysteines 9 and 
15 are not visible in the crystal structure and were not considered in this study since a 
human PRMT1 variant lacking the first 27 amino acids exhibits enhanced activity after 
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reduction (data not shown). A recent quantitative reactivity profiling study identified C101 
as hyper-reactive with 4-hydroxyl-2-nonenal (HNE) (44), indicating that C101 may be 
susceptible to oxidation. Cysteine 101 is situated on the far edge of the AdoMet binding 
pocket and directly interacts with the adenine ring structure of AdoMet (see Fig. 6-8), and 
thus, seemed like an excellent target to control enzymatic activity depending on its redox 
state.  Mutation of C101 to serine results in a construct mimicking wild type 
methyltransferase activity, including the response to DTT (Fig. 6-6). Closer evaluation of 
our rat PRMT1 M48L crystal structure (23) showed additional electron density around 
cysteine 342, suggesting possible oxidation of the thiolate moiety to a reducible sulfenic 
acid moiety. Although this residue is relatively removed from the active site, it has been 
suggested that residues distant from the active site can regulate PRMT substrate specificity 
(45). However, the C342S variant also mimicked wild type enzymatic activity, including 
the DTT enhancement (Fig. 6-6). The PRMT1 crystal structure (36) also shows that C254 
forms an intermolecular disulfide bond with another PRMT1 dimer, and was therefore also 
mutated to determine if reduction of this disulfide caused the increase in activity and the 
corresponding shift towards a smaller oligomeric state. However, as we saw with the other 
two individual cysteine variants, C254S activity was still enhanced upon reduction with 
DTT (Figure 6-6). The C254S PRMT1 variant also behaved as WT PRMT1 when run on 
size exclusion chromatography (data not shown)(36).   
As previously mentioned, it is believed that PRMT1 dimerization is necessary for 
catalytic activity. In fact, all currently available Type 1 and Type 2 PRMT structures reveal 
a conserved mode of dimerization between catalytic subunits (36-38,46,47). Each subunit 
contains a dimerization helix-turn-helix dimerization arm (blue in Fig. 6-8) that extends  
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FIGURE 6-6. Methyltransferase activity of PRMT1 cysteine variants in the absence 
or presence of DTT. WT PRMT1, Cysteine-less PRMT1, C101S PRMT1, C342S 
PRMT1, C254S PRMT1, C208S PRMT1, and C101S/C208S PRMT1 methylated 200 µM 
R3 peptide in the absence (light gray/purple) or presence (dark gray/purple) of DTT. 
Results shown correspond to the average of at least two biological replicates. Removing 
all cysteine residues from PRMT1, or making C101 and C208 unavailable for oxidation 
resulted in abolished redox control over PRMT1 catalytic activity.  
 
 from the C-terminal 𝛽-barrel (dark gray in Fig. 6-8) and rests upon the N-terminal AdoMet 
binding domain (light gray in Fig. 6-8) of the other subunit; coming together to form an 
active dimer with a central cavity and two opposing active sites (Fig. 6-8).  
Zhang, X. et al. reported that removal of the helix-turn-helix dimerization arm of 
PRMT1 not only eliminated homodimerization, but also AdoMet binding and 
methyltransferase activity. It was thus suggested that the dimer interaction is required to 
engage the residues on the other side of the structural elements to interact with AdoMet 
properly (36). In the analysis of another type 1 PRMT structure, Cheng, Y. et al. computed 
the atomic position fluctuations (APFs) of the monomer and dimer to determine the impact 
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of dimerization of the motion of atPRMT10, also a type 1 PRMT. They found two regions 
to have lower APFs in dimeric form than in monomeric form: the αγ-loop-αZ (40-68 in 
atPRMT10) (orange in Fig. 6-8) and the dimerization arm (187-235 in atPRMT10) (blue 
in Fig. 6-8), suggesting that these regions are stabilized upon dimer formation. The αγ-
loop-αZ region is directly involved in AdoMet binding and the formation of the substrate 
binding groove I (36). It was also suggested that stabilization of this region by dimerization 
likely improves the binding of AdoMet and substrate proteins (37). Additionally, 
Higashimoto et al. demonstrated that in PRMT4 (CARM1), phosphorylation of S229, 
located on the outer face of the AdoMet binding domain, compromised dimerization, 
negatively regulated methyltransferase activity, and lowered AdoMet binding (48). The 
presence of a charged functional group adjacent to the hydrophobic dimerization arm 
binding surface likely destabilizes dimerization interactions.  Cysteine 208 of PRMT1 is 
located on the PRMT1 dimer interface (Fig. 6-8). Given the importance of dimerization for 
PRMT activity and the predicted susceptibility to oxidation, this residue was also deemed 
likely to be culpable for the effect of oxidation in impairing methyltransferase activity. 
Additionally, use of the Cysteine Oxidation Prediction Algorithm (COPA) which uses 
distance to the nearest cysteine sulfur, solvent accessibility, and pKa as parameters for thiol 
oxidation susceptibility, suggested Cysteine 208 is susceptible to oxidation by exposure 
(49). However, measurement of the enzymatic activity of the individual C208S variant 
revealed this construct was also enhanced by DTT (Fig. 6-6).  
If PRMT1 dimerization is indeed stabilizing substrate binding, we rationalized that 
oxidation of C208 in the dimerization arm in conjunction with C101 in the AdoMet binding 
pocket could be responsible for the diminished methyltransferase activity observed under 
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oxidizing conditions. In order to explore this hypothesis, a C101S/C208S variant of 
PRMT1 was created, and methyltransferase activity was measured in the presence and 
absence of DTT. Remarkably, methyltransferase activity of the double variant was the 
same under both oxidizing and reducing conditions (Fig. 6-6). We note that the activity of 
the double variant (C101S/C208S) is lower than the activity of reduced wild type enzyme, 
suggesting that these residues may have an additional role in PRMT1 activity. Surprisingly, 
when both C101 and C208 are unavailable for oxidation, the protein does not completely 
shift to a smaller oligomeric state as the cysteine-less construct (data not shown). In 
conclusion, making C101 and C208 unavailable for oxidation resulted in abolished redox 
control over PRMT1 catalytic activity.  
Sulfenic Acid Formation at C101 and C208 In Vitro— In order to further analyze the 
oxidation events occurring at C101 and C208, we used the sulfenic acid-specific probe 
DCP-Rho1, which contains a rhodamine attached to the functional core of dimedone. To 
detect sulfenic acids, air oxidized wild type PRMT1 (WT), cysteine-less with C101 
reintroduced (cys-C101), cysteine-less with C208 reintroduced (cys-C208), and cysteine-less 
with both C101 and C208 reintroduced (cys-C101C208) were incubated with DCP-Rho1 or 
DMSO as a negative control in the presence or absence of reductant under denaturing 
conditions.  Cysteine-less PRMT1 (cys-) was also subjected to labeling as a negative 
control. Analysis of the fluorescent label incorporation (Fig. 6-7-A and B) clearly shows 
the presence of sulfenic acid at cysteine 101 and 208 of PRMT1. Interestingly, while both 
cysteine 101 and 208 are necessary for oxidative impairment of C101, we consistently 
observed more sulfenic acid formation at C208, suggesting either that C101 is less 
susceptible to oxidation than C208, or that the sulfenic acid form of C101 is transient and 
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can be further oxidized to sulfinic or sulfonic acid. The possibility that these two cysteine 
residues may somehow be involved in a disulfide linkage was ruled out using Native PAGE 
analysis (data not shown).  Free thiol content analysis using the 5IAF probe (Fig. 6-7-C 
and D) and performed in parallel with the DCP-Rho1 labeling, shows similar free thiol 
content for cys-C101 and cys-C208. When analyzed together, these results are consistent with 
a higher propensity for irreversible oxidation at C101.In addition to the fluorescent probes, 
WT PRMT1 treated with sulfenic-acid-specific dimedone was subjected to LC-MS/MS 
analysis to further confirm sulfenic acid formation. Using this method, dimedone 
incorporation was observed at both C101 and C208 (Figure 6-7-E and F), confirming the 
fluorescent probe results. In conclusion, the reversible activity impairment observed under 




Elevated ADMA concentrations have been proposed to predict cardiovascular 
mortality in patients with chronic renal insufficiency (50) and acute coronary events (8). 
Additionally, ADMA is not only a marker, but also a mediator of oxidative stress within 
vascular tissue (7). Given that PRMT1 is the primary source of ADMA in eukaryotes, it is 
of the utmost importance to understand how PRMT1 activity and ADMA synthesis are 
regulated under oxidative stress conditions. Here, we have shown that PRMT1 activity is 
decreased in vitro under physiologically relevant oxidative conditions, an effect which is 
readily reversed upon reduction and is associated with cysteine oxidation to sulfenic acid.   
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FIGURE 6-7. Sulfenic acid detection and free thiol content in PRMT1.  In (A), (B), 
(C), and (D) Air oxidized wild type PRMT1 (WT), cysteine-less (cys-), cysteine-less with 
C101 reintroduced (cys-C101), cysteine-less with C208 reintroduced (cys-C208), and 
cysteine-less with both C101 and C208 reintroduced (cys-C101C208) were denatured in 6M 
urea and incubated with 1 mM DTT or buffer prior to addition of 10 µM DCP-Rho1 or 2.5 
mM 5IAF. Labeled samples were resolved by SDS-PAGE.  (A) shows a representative 
image of the rhodamine fluorescence signal and the corresponding coomassie bands. (B) 
graphical representation of triplicate gel analysis. Normalized percent DCP-Rho1 
fluorescence represents the percentage of fluorescent signal divided by the amount of 
protein observed in the coomassie bands which is interpreted as the relative amount of 
sulfenic acid present. (C) shows a representative image of the 5IAF fluorescence signal 
and the corresponding coomassie bands. (D) graphical representation of triplicate 5IAF gel 
analysis, interpreted as relative amount of free thiols present. (E) and (F) show a 
representative MS/MS fragmentation spectra for peptides containing dimedone-modified 
sulfenic acids in PRMT1. In (E), the CID fragments of peptide IECSSISDYAVK labeled 
with dimedone at C101. (F) ETD fragments of peptide MCSIKDVAIK labeled with 
dimedone at C208. The mass shift by the modification is 138.068 (exact number), as 




FIGURE 6-8. Cysteine residues in rPRMT1. PRMT1 dimer (1OR8) colored as 
described in text (AdoMet binding domain in light gray, β-barrel domain in dark gray, 
dimerization arm in blue, αγ-loop-αZ in orange, AdoHcy in green, and cysteine residues in 
red. Residues 26-39 were modeled based on the position of this helix in the PRMT3 
structure (1F3L).  (A) PRMT1 dimer (B) Surface representation showing close active site 
interactions between AdoHcy, C101 and F36. (C) Top view of dimerization arm in one 
monomer interacting with AdoMet binding site in other monomer. (D) Back view showing 
packing of C208 in one monomer with alpha helix in AdoMet binding domain of other 
monomer.  
 
Our results complicate the view that the increased PRMT1 protein expression observed 
under oxidative stress conditions is responsible for increased ADMA levels, by supporting 
a model in which PRMT1 activity can be regulated in a redox-sensitive manner. While it 
has long been known that DDAH breakdown of ADMA is under redox control, we provide 
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the first evidence that the activity of enzymes involved in the formation of ADMA 
precursors are regulated in a redox-sensitive fashion.  
Removal of two cysteine residues implicated in PRMT1 dimerization and cofactor 
binding eliminates the redox-dependent control over PRMT1 methyltransferase activity. 
Dimerization is strictly conserved in all known PRMTs and seems necessary for 
methyltransferase activity (36-38). One of the pathways proposed for signal 
communication between the dimer interface and the catalytic center uses the mainly 
hydrophobic dimer interactions between the αγ-loop-αZ (orange in Fig. 6-8) of one 
monomer and the  helix-turn-helix dimerization arm of another (blue in Fig.6-8) (36,37,46). 
It has been proposed that this dimer interaction is required to engage residues into proper 
conformation for interaction with the AdoMet cofactor (36). It is feasible that oxidation of 
residues involved in this cooperative effort could disrupt PRMT1 methyltransferase 
activity by affecting AdoMet binding. Interestingly, cysteine 208 is conserved in PRMT3 
and PRMT6, while both cysteine 101 and 208 are conserved in PRMT8. Remarkably, the 
type III PRMT7 from Trypanosoma brucei, which contains only three cysteine residues 
that do not align with any cysteines in PRMT1, but does contain a cysteine at a different 
location in its dimerization arm, also shows increased activity upon reduction.  Activity 
measurements using human PRMT3, human PRMT6, and TbPRMT7 demonstrate that 
these type 1 and type 3 PRMTs are also under redox control (Figure 6-9). Ongoing studies 
will help provide insight as to how these residues affect AdoMet interactions and PRMT 




FIGURE 6-9. Redox control is conserved among PRMT family members. Human 
PRMT3 (residues 211-531), human PRMT6, and TbPRMT7 activities were tested with R3 
peptide, bulk histones, or Histone 4 respectively in the absence or presence of DTT. The 
average of three activity measurements are shown as relative percent activity for each 
isoform with its corresponding substrate.  
 
While the active form of PRMT1 is expected to be a dimer, size exclusion 
chromatography analysis, as well as dynamic light scattering, have shown the enzyme 
typically migrates as a high molecular weight oligomer (34,36,38,51,52). Feng et al. 
suggested that PRMT1 multi-oligomerization (i.e., greater than a dimer) is concentration 
dependent in the range of 0-0.5 µM and that the final PRMT1 multi-oligomeric complex is 
the most active form (34). It is important to note that the Feng study was done with fully 
reduced PRMT1 and at significantly lower enzyme concentrations than those used in this 
study.  Our results show that oxidized PRMT1, which displays less activity, shifts from a 
large oligomeric species to a smaller, but still large oligomeric state under reducing 
conditions. While our results seem to be at odds with the Feng study, they only serve to 
highlight the high degree of complexity that exists in relating PRMT1 oligomerization and 
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activity. Interestingly, while cysteine-less PRMT1 remains a smaller oligomer under both 
reducing and oxidizing conditions, the C101S/C208S PRMT1 variant presents as a mix of 
both large and smaller oligomers under reducing conditions (data not shown). It is difficult 
to assess what may be causing PRMT1 to form such large oligomeric aggregates, and the 
link between PRMT1 cysteine oxidation and protein oligomerization remains to be 
determined. While our results add to the larger story, much remains to be discovered on 
the impact of oligomeric state on PRMT1 activity.  
It is also important to point out that much of the work in the PRMT field is carried 
out exclusively under reducing conditions. Our work emphasizes the importance of 
PRMT1 as a redox-sensitive enzyme and the need for careful control of its redox 
environment. Since PRMT1 activity is under redox control, it is possible that experiment 
conditions might inadvertently alter activity and/or interaction partners. In the future, it 
will be highly important to take into account the redox environment of experiments before 
reaching conclusions. Additionally, while the different affinity tags that were used in this 
study did not change the increase in activity observed upon PRMT1 reduction, the overall 
methyltransferase activity was generally lower for HisTevPRMT1 constructs than for 
HisPRMT1 constructs. Since the tags are located on the N-terminal end of the enzyme, this 
observation may hint at the importance of the N-terminal PRMT1 sequence in controlling 
enzymatic activity.  
In addition to providing ADMA precursor pools, growing evidence supports the 
involvement of PRMT1 in the cellular oxidative stress response as a modifier of signal 
transduction. PRMT1 has recently been reported to be involved in the transcriptional 
regulation of the human ferritin gene, up-regulation of which is an important cellular 
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defense response to oxidative stress (53). It was also recently reported that PRMT1 
methylation is involved in the transcriptional repression of HIFα (54), a protein needed to 
activate the cellular adaptive response to hypoxia, another condition linked to high levels 
oxidative stress. Finally, we note that oxidative stress in HEK293 cells was reported to 
enhance PRMT1-mediated methylation of FOXO1 in the nucleus (55). The observed 
increase in FOXO1 methylation seems contradictory to our results and highlights the 
importance of further investigating the effect of oxidation in vivo on PRMT1 substrate 
specificity, and/or cellular localization. In future studies, it will also be interesting to 
determine how redox regulation affects the role of PRMT1 in signal transduction. 
In summary, this work has demonstrated that PRMT1 is a redox-responsive 
enzyme. Oxidation at two cysteine residues potentially destabilizes dimerization leading to 
diminished methyltransferase activity, while reduction readily reverses the effects of 
oxidation under physiologically relevant conditions, consistent with sulfenic acid 
formation observed at both cysteine residues. Our results provide the first direct evidence 
that PRMT1 enzymatic activity can be regulated in a redox-sensitive manner and raise the 
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SUMMARY AND FUTURE DIRECTIONS 
 
The protein arginine methyltransferases catalyze the post-translational 
modification of proteins implicated in a variety of fundamental cellular pathways, and 
unsurprisingly, their dysregulation has been linked to may human diseases (reviewed in 
Chapter 2). As the predominant PRMT in cells (31), PRMT1 methylation must be tightly 
regulated in order to respond adequately to specific cellular needs. However, despite the 
critical need for proper PRMT1 regulation, very little is actually known about the factors 
that influence PRMT1 substrate selection, product made (MMA vs. ADMA), and overall 
methyltransferase activity. The work presented here has combined structural and kinetic 
approaches to better understand how PRMT1 binds its substrates, and how overall 
methyltransferase activity can be regulated. A summary of each project and future 
directions along with existing preliminary data are described below. 
Investigation of the In Vivo Effects of Oxidation on PRMT1— We discovered 
that PRMT1 (as well as PRMT3, PRMT6, and PRMT7) methyltransferase activity can be 
regulated by the redox environment in vitro. To determine whether this regulatory 
mechanism is relevant in cells, we have collaborated with the lab of Dr. Michael Yu (State 
University of New York, Buffalo) to test the methyltransferase activity of PRMT1 after 
treating cells with increasing amount of oxidants. The Yu lab grew human embryonic 
kidney (HEK293 that had been transfected to over express FLAG-tagged PRMT1) cells to 
about 85% confluency prior to treatment with hydrogen peroxide (0, 0.6 mM, or 1.2 mM 
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H2O2) for 1 hour at 37° C to mimic increasing cellular oxidative stress conditions. They 
then used magnetic beads containing anti-FLAG antibody to immunoprecipitate FLAG-
tagged PRMT1 from these cells. The immunoprecipitated PRMT1 (IP PRMT1) was then 
sent to our lab where we used a gel-based methyltransferase assay to determine the effect 
of cellular oxidative stress on the ability of PRMT1 to methylate histone H4. As shown in 
Figure 7-1-A and B, the methyltransferase activity of PRMT1 decreases with increasing 
levels of cellular oxidative stress. Additionally, the immunoprecipitated PRMT1 samples 
were also probed for sulfenic acid content using the same sulfenic acid-specific fluorescent 
probe (DCP-Rho1) used in our in vitro studies. As depicted in Figure 7-2, increasing 
cellular oxidative stress is associated with increasing sulfenic acid formation on PRMT1, 
suggesting that the redox regulatory mechanism described in vitro (discussed in chapter 6) 
also occurs in vivo. The in vivo significance of PRMT1 redox regulation remains to be 
determined. Newly emerging Bioorthogonal Profiling of Protein Methylation (BPPM) 
approaches (56), may be used for PRMT1 in cells with and without oxidative stress 
treatment to determine whether substrate preference is affected by the redox state and 
provide an indication of what specific pathways may be affected by this regulatory 
mechanism. A more targeted avenue of investigation would be to characterize the effect of 
PRMT1 redox regulation on pathways that have already linked PRMT1 to the cellular 
oxidative stress response. Such pathways include the PRMT1-dependent transcriptional 
regulation of HIFα or of the human ferritin gene, which are needed for the cellular adaptive 




FIGURE 7-1. PRMT1 methyltransferase activity is impaired by oxidation in vivo. In 
(A), immunoprecipitated PRMT1 from HEK293 cells treated with 0, 0.6, or 1.2 mM H2O2 
was used to methylate 1 µM histone H4 protein using 2 µM [3H]AdoMet as the methyl 
group donor in 50 mM sodium phosphate pH 8.0 at 30° C. At the noted time points, 10 µl 
was removed from each reaction, quenched in SDS sample buffer and boiled for 5 minutes 
prior to running on a 12% SDS-PAGE gel. The proteins were transferred to a PVDF 
membrane which was dried and exposed to a Tritium imaging screen (BioRad) for 96 
hours. After exposure the amount of PRMT1 present in each lane was detected using an 
anti-PRMT1 antibody (Bethyl). In (B) a graphical representation of (A) is shown, with the 
activity normalized based on the levels of PRMT1 present.  
 
Impact of Redox Regulation of PRMT1 on Substrate Binding— While we have 
clearly determined that PRMT1 oxidation at two critical cysteine residues leads to a 
decrease in the PRMT1 enzymatic activity, the mechanism through which oxidation 
impacts activity remains undetermined. Methods such as fluorescence quenching, 
isothermal titration calorimetry (ITC), or fluorescence anisotropy could be used to 
determine the effect that oxidation on the indicated cysteine residues may have on the 





FIGURE 7-2. Sulfenic acid levels in PRMT1 increase with increasing cellular 
oxidative stress. The sulfenic acid-specific DCP-Rho1 fluorescent probe was used as 
described in chapter 6 to quantify the sulfenic acid levels in PRMT1 immunoprecipitated 
from HEK293 cells treated with 0, 0.6, or 1.2 mM H2O2.  
 
Mechanism of PRMT6 Redox Regulation— Sequence conservation analysis of the 
PRMT1 cysteines necessary for redox control of PRMT1 activity led us to identify 
PRMT3, PRMT6, PRMT7, and PRMT8 as additional PRMT isoforms that may be 
regulated by oxidative stress since at least one of the two cysteines were conserved in these 
isoforms (57). As described in chapter 6, we were able to confirm the redox regulation of 
PRMT3, PRMT6, and PRMT7. While our redox regulation manuscript was under review, 
the structure of the mouse PRMT6 was solved in both an oxidized and reduced form (58). 
Although the two structures (PDB ID: 4C03 reduced, 4C05 oxidized) crystallized in 
different space groups (P21212 and I41, respectively), the monomers of each form overlap 
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with an rmsd of 0.59. The main difference between the two structures occurs in the 
positioning of the N-terminal helix αX (orange in Figure 7-3) which is properly folded in 
the reduced structure (Figure 7-3-B) and unfolded in the oxidized structure (Figure 7-3-A). 
The oxidized form of the PRMT6 structure shows the presence of a disulfide bond bridging 
helix αX in the AdoMet binding domain of one monomer to the dimerization arm of the 
other monomer (disulfide bond links C53 and C232 of two mouse PRMT6 monomers), 
resulting in a covalent dimer with an unfolded αX helix (58). As discussed in chapter 2, it 
has long been known that the helix αX is essential for the activity of all PRMTs. In mouse 
PRMT6, proper folding of the αX helix locks and buries the cofactor in place for catalysis. 
Additionally, the Y50 and Y54 residues position the double-E-loop E167 in an active 
conformation for catalysis (Figure 7-4). Therefore, indicating that proper folding of the αX 
helix is necessary for catalysis, but not for initial cofactor binding.  
 The determination of this structure in differing conformations that depend on the 
redox state 1) validates our determination that PRMT6 is under redox control, 2) indicates 
that PRMT6 likely has a mechanism of redox control that is different from PRMT1 since 
there is no cysteine present on the PRMT1 αX helix, and 3) serves as a guide for us to begin 
work to determine the mechanism of PRMT6 redox control.  
  I have initiated construction of several human PRMT6 cysteine to serine variant 
constructs (ie. cysteine-less PRMT6) which can be used to determine the mechanism of 
redox control of PRMT 6 activity. These can be used much like the PRMT1 constructs 
were to identify the specific cysteines necessary for redox regulation. It will be interesting 
to determine if only the presence of the two cysteines found to form a disulfide bond are 
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FIGURE 7-3. PRMT6 structures in (A) oxidized and (B) reduced forms. In (A) and 
(B) the structures of oxidized (PDB: 4C05) and reduced (PDB: 4C03) PRMT6 are shown. 
The N-terminal helix αX has been colored in orange in both forms. (A) Helix αX is 
disordered in the oxidized (light green) structure and mouse PRMT6 cysteine 53 (red) 
forms a disulfide bond with cysteine 232 (blue) of the adjacent monomer. (B) The αX helix 
of PRMT6 is properly folded over the cofactor and substrate binding pockets in the reduced 
(light blue) PRMT6 structure. 
 
 
FIGURE 7-4. Position of PRMT6 active site E167 in (A) oxidized and (B) reduced 
forms. Active site comparison of (A) oxidized and (B) reduced PRMT6, colored as in 7-3. 
Residue E167 of the double-E loop has been colored in magenta in both. In the reduced 
structure, residues Y50 and Y54 of the N-terminal helix αX help position E167 in the 
position required for catalysis.  
166 
required, since neither of those are conserved in any other PRMT isoform, or if additional 
cysteines play a role in the redox regulation of PRMT6 activity.  
 Interestingly, the PRMT6 structure suggests that the redox state of this enzyme may 
affect substrate binding and catalysis but have no effect on cofactor binding (58). As 
suggested for PRMT1, fluorescence quenching, isothermal titration calorimetry (ITC), or 
fluorescence anisotropy should be used to determine the specific effects of oxidation on 
the on the ability of PRMT1 to bind AdoMet and peptide substrates in both the 
unmethylated and monomethylated forms. 
Redox Regulation of PRMT1 Product Formation— Another interesting discovery 
that has emerged since we reported the redox regulation of PRMT1 activity is that the 
PRMT1 redox state may influence the product formation of the PRMT1 enzyme. Using an 
HPLC-based PRMT product detection assay (59), my lab mate Tamar Caceres found that 
reduced PRMT1 forms primarily MMA, while oxidized PRMT1 makes both MMA and 
ADMA when methylating the R3 peptide (Figure 7-5). I attempted to determine whether 
oxidized PRMT1 makes more ADMA than reduced PRMT1 when methylating a different 
substrate, histone H4 protein. Initial results indicate that reduced PRMT1 catalyzed more 
ADMA on the H4 protein than the oxidized enzyme (data not shown). Although these 
results are preliminary and will be tested again to confirm these observations, they hint at 
the possibility that redox regulation of PRMT1 activity may affect the processivity of the 
enzyme in a substrate dependent manner. This subject will continue to be investigated in 
the Hevel lab. Similar studies should also assess whether reduction/oxidation affects the 
processivity of PRMT6.  
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FIGURE 7-5. PRMT1 product formation on the R3 peptide depends on the redox 
state. Reverse HPLC analysis of the methylation products of the R3 peptide indicate that 
(A) the presence of a reducing agent impedes ADMA formation, while (B) ADMA 
formation can be catalyzed in the absence of reducing agent. 
SUMMARY 
 This dissertation provides new insights into regulatory mechanisms that control 
PRMT methyltransferase activity. New insights into the workings of previously reported 
PRMT1 regulators, along with the discovery of a novel regulatory mechanism for several 
members of the PRMT family, provide a strong foundation for future research that will 
help unravel mechanisms that control PRMT activity.  
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